

Publication number:

0 372 445 B1

FUROPEAN PATENT SPECIFICATION

- (6) Date of publication of patent specification: 09.03.94 (61) Int. Cl.5: C07D 233/64, C07D 233/70,
- (21) Application number: 89122302.6
- Date of filing: 03.12.89

C07D 233/84, C07D 233/88. C07D 491/044, C07D 491/056, C07D 405/14, C07D 409/14, A61K 31/415, //(C07D405/14, 307:00,307:00,233:00), (C07D409/14,333:00,333:00, 233:00)

- Imidazoles for the treatment of atherosclerosis.
- Priority: 05.12.88 US 279981 10.10.89 US 416606
- Date of publication of application: 13.06.90 Bulletin 90/24
- (48) Publication of the grant of the patent: 09.03.94 Bulletin 94/10
- (a) Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE
- (56) References cited:
 - EP-A- 0 043 788 EP-A- 0 130 526 EP-A- 0 236 628 DE-A- 3 504 677 DF-A- 3 504 680 US-A- 4 137 234 US-A- 4 198 421
- (73) Proprietor: THE DU PONT MERCK PHARMA-CEUTICAL COMPANY Barley Mill Plaza,

Building 25 Wilmington, Delaware 19880-0025(US)

(2) Inventor: Billheimer, Jeffrey Thomas

- 1618 E. Lafayette Drive West Chester Pennsylvania 19382(US) Inventor: Gillies, Peter John 55 Quail Hollow Drive Hockessin Delaware 19707(US) Inventor: Wexler, Ruth Richmond 2205 Patwynn Road Wilmington Delaware 19810(US) Inventor: Higley, C. Anne 17 Ballad Drive Newark Delaware 19702(US) Inventor: Maduskuje, Thomas Peter Jr. 613 Foulkstone Road
- Wilmington Delaware 19810(US)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Representative: von Kreisler, Alek, Dipl.-Chem. et al Patentanwälte von Kreisler-Selting-Werner Postlach 10 22 41 D-50462 Kölin (DE)

Description

Field of the Invention

This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), processes for their preparation, and their use as antihypercholesterolemic agents.

US-A-4 137 234 describes in Examples 21, 22 and 53 certain N-methyl-N'-[(3-(2-imidazolylthio)propyl]urea compounds which are disclaimed herein.

10 Background of the Invention

Hyporcholesterolomia is an established risk factor in the development of atherosclerosis. Therapoutic agents which control the level of serum cholesterol have proven to be effective in the treatment of coronary artery disease. While agents exist that can modulate circulating levels of cholesterol. Dietary cholesterol carrying lipoproteins, 1s these agents have little or no effect on the intestinal absorption of cholesterol. Dietary cholesterol can increase the level of serum cholesterol to levels which place an individual at increased risk for the development or exacerbation of atherosclerosis. Since much of the free or unesterified cholesterol that is absorbed by intestinal mucosal cells must first be esterfied by ACAT prior to its incorporation and secretion to the bloodstream in large lipoprotein particles called chylomicrons, inhibition of ACAT can reduce the absorption of dietary cholesterol. In addition, the accumulation and storage of cholestery lesters in the arterial wall is associated with increased activity of ACAT. Inhibition of the enzyme is expected to inhibit the formation or progression of atherosclerotic lesions in mammals.

There are a limited number of patents in the literature disclosing compounds which are useful as ACAT inhibitors in particular and antiatheroscipacitic agents in general. For example, U.S. Patent No. 4,823,682,25 issued to De Vries on November 18, 1986, discloses ureas and thioureas as ACAT inhibitors useful for reducing the cholesterol ester content of an arterial wall, inhibiting atterosciencis lesson development, and/or treatment of mammalian hyperlipidemia. U.S. Patent No. 4,722,927, issued to Holmes on February 2, 1988, discloses disubstituted pyrimidinesmides of oleic and linoleic acids as ACAT inhibitors useful for inhibiting interesting also proposed in the patent of the

U.S. Patent No, 4,460,598, issued to Lautenschläger et al. on July 17, 1984, discloses compounds of the formula:

R

R

$$R^3$$
 R^6
 R^6

whorein

50

30

R¹, R², R³, R³, R³ and R⁵ independently are H, F, Cl, Br, I, alkyl, alkoxy, or CF₃, with the proviso that one or several of R¹ and R², R³ and R⁴, or R² and R⁵ taken together represent methylenedioxy.

R⁷ is H, alkali metal ion, alkyl of 1 to 6 carbon atoms, or benzyl; and is 0 to 10

The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory and/or atherosclerotic diseases is disclosed.

U.S. Patent No. 4,654,358, issued to Lautenschläger et al. on March 31, 1987, discloses compounds of the formula:

wherein

5

10

15

20

30

35

40

45

k is 0, 1, or 2,

R1, R2 and R3 independently are H, F, Cl, CH3, CH3O, or CF3;

R⁴ is H, Na, K, CH₃, CH₃CH₂, (CH₃)₂CH, CH₃(CH₂)₂, or butyl; A is C(CH₃)₂, CH(CH₂)_mCH₃, (CH₂)_n, or (CH₂)_{n-2}(CH(CH₃);

m is 0 to 8; and

n is 2 to 10.

The synthesis and the use of these compounds in the treatment of inflammatory diseases, diseases of lipid metabolism, and/or hyperlipidemic diseases is disclosed.

German Laid Open Application No. DE 3504679, Lautenschläger et al., published August 14, 1986, discloses compounds of the formula:

$$\begin{array}{c|c} R^1 & & R^4 \\ & & \\ N & & \\ R^2 & & \\ R_3 & & \\ R_5 & & \\ \end{array}$$

wherein

R1, R2 and R3

independently are H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 1 to 6 carbon atoms, or

50 R⁴ and R⁵ R⁶ and R⁷ independently are H, C_6H_5 , or alkyl of 1 to 9 carbon atoms; independently are H, OH, saturated or unsaturated alkyl, cycloalkyl, or hydroxyalkyl of 1 to 10 carbon atoms.

$$(CH_2)_p$$
 R^{10}
 $HC-CH_2$
 R^{11}
 R^{12}
 R^{12}
 R^{13}

B8, B9, B10, B11, B12 and B13

independently are H, F, Cl, Br, NO2, CH3CONH, OH, alkyl of 1 to 3 carbon atoms, CF3, and alkoxy of 1 to 3 carbon atoms, with the proviso that R8 and R9, R10 and R11, or R12 and R13 taken together represent methylenedioxy:

B14

15

20

25

30

40

45

50

is alkyl of 1 to 2 carbon atoms;

taken together represent a whole number from 0 to 9; m and n

is 0 to 2: р

is 0 to 2; and s

is 0 or 2.

The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory, atherosclerotic, and lipid metabolism diseases in general is disclosed.

German Laid Open Application No. DE 3504680, Lautenschläger et al., published August 4, 1986. discloses compounds of the formula:

$$\begin{array}{c|c}
R^1 & & & R^4 \\
& & & \\
R_2 & & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\
& & & \\$$

wherein

R1, R2 and R3

independently are H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 1 to 6 carbon atoms, or

R4 and R5 B6

R1 and R2 can be taken together with the carbon atoms in the 4 and 5 position of the imidazole ring to represent a carbocyclic five- or six-membered aromatic or partially hydrogenated ring which may be substituted by R8 or R9;

independently are H, C₆H₅, or alkyl of 1 to 9 carbon atoms;

is alkyl, cycloalkyl, or hydroxyalkyl of 1 to 20 carbon atoms, H, alkali metal if X is -COO-, 1-phenethyl, or

is H, OH if X is -CONR7-, or alkyl of 1 to 4 carbon atoms;

R8, R9, R10 and R11 are independently H, Cl, F, Br, NO2, CH3CONH, OH, alkyl of 1 to 3 carbon atoms, CF3, or alkoxy of 1 to 3 carbons, or R8 and R9 or R10 and R11 taken

together represent methylenedioxy;

¥ is a bond, O, OC(=0)O, C(=0)O, CONR7, OC(=0), or OC(=0)NR7;

m and n taken together represent a whole number from 0 to 9:

is 0 to 2; р s is 0 to 2: and

5

is 0 or 2. 10 The synthesis and the use of these compounds in the treatment of thromboembolic, inflammatory, atherosclerotic, and lipid metabolism diseases in general is disclosed.

There are no known literature references disclosing the imidazoles of this invention, their use as ACAT inhibitors, or their use in the treatment of atherosclerosis.

The compounds of this invention are very potent ACAT inhibitors. As shown by the data presented 15 below in Table 6, the compounds of this invention inhibit ACAT activity in vitro with at least ten times the potency of any ACAT inhibitors described in the current literature. As shown by the data presented below in Table 8, the compounds of this invention cause a reduction in the serum cholesterol level in cholesterol-fed hamsters. The compounds of this invention are thus expected to be useful in pharmaceutical formulations for the treatment of atherosclerosis. The compounds of this invention have been shown to lower serum 20 cholesterol, and this invention should not be construed as limited to any particular antihypercholesterolemic mechanism of action.

Summary of the Invention

The present invention provides novel compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing such imidazoles, and therapeutic methods for their use as antihypercholesterolemic agents.

This invention provides compounds of Formula (I):

wherein

B1 and B2 are selected independently from H. C₁-C₈ alkyl, provided that when R¹ is H. then R² cannot be H and when R1 is C1-C8 alkyl, then R2 cannot be C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl, 2-, 3- or 4-pyridinyl, 2thlenyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C1-C4 alkoxy, C1-C4 alkyl, C3-C8 branched alkyl, CH3S(O), NO2, CF3, or NR7R8; or

R1 and R2 can also be taken together as

50

30

35

an

45



where L or O, O(CH₂)_{m+1}O, or (CH₂)_m where m is 0-4;

R3 is H, C₁-C₆ alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH₃, CH₃O, or CF₃:

R⁴ is straight chain C₁-C₂ alkyl optionally substituted with F: C₁-C₂ branched alkyl, C₂-C₇ cycloalkyl, C₄-C₁ cycloalkylalkyl, C₇-C₁, araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C₁-C₂ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₂ carboalkoxy, NR⁷R³, or NCOR⁷; C₃-C₂ alkenyl or alkynyl, C₁-C₂ carboalkoxy, NR⁷R³, or NCOR⁷; C₃-C₃ alkenyl or alkynyl, C₁-C₂ alkyl, C₁-C₃ alkoxyl, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₃ carboalkoxy, NR⁷R³ or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₃ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₃ carboalkoxy, C₁-C₃ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₃ carboalkoxy

NR⁷R⁸, or NCOR⁷; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

R⁵ is H, C₁-C₆ alkyl, or benzyl;

R⁶ is H, C₁-C₆ alkyl, C₂-C₆ branched alkyl, C₂-C₇ cycloalkyl, C₂-C₈ alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, Ch, CC₂-C, Carbolakoxy, NR²R³, or NCOR²; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR²R³, or NCOR².

R⁷ and R⁸ are selected independently from H or C₁-C₄ alkyl;

35 X is S(O)_r, O, NR⁵, CH₂;

A is C₂-C₁₀ alkvl, C₃-C₁₀ branched alkvl, C₃-C₁₀ alkenvl, or C₃-C₁₀ alkvnvl;

Y is O, S, H₂;

Z is NHR⁴, OR⁴, or R⁴;

r is 0-2.

or a pharmaceutically acceptable salt thereof.

Preferred are compounds of Formula (I) wherein:

R¹ and R² are selected independently from C₁-C₂ alkyl, provided that when R¹ is C₁-C₂ alkyl, then R² cannot be C₁-C₂ alkyl, C₃-C₂ branched alkyl, C₃-C₂ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₂-C₂

C₁₄ araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH, Cr-C₄ alkoxy, Cr-C₄ alkyl, C₃-C₆ branched alkyl,

CH₂S(O), NO₂, CF₃, or NR⁷R⁸; or

R1 and R2 can also be taken together as

55

45

50

5

10

20

75 where L is O, O(CH₂)_{m+1}O, or (CH₂)_m where m is 0-4. More preferred are compounds of Formula (I) wherein:

R3 is H, CH3, phenyl;

5

10

20

25

35

40

45

50

55

R⁶ is H, C1-C₂ alkyl, C₂-C₆ branched alkyl, C₃-C₇ cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Br, CI, NH₂, OH, CN, CO₂H, CF₃, or di(G₁-C₄)alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₂O, F, Br, CI, NH₂, OH, CN, CO₂H, CF₃, or di(G₁-C₄)alkylamino;


X is S(O)r, CH₂;

is C₂-C₁₀ alkyl, C₄-C₉ branched alkyl.

More specifically preferred because of their biological activity are compounds of Formula (I) wherein:

R¹ and R² are selected independently from C₁-C₂ alkly, provided that when R¹ is C₁-C₂ alkly, then R² is C₁-C₂ alkly, t

CF₃, or di(C₁-C₄)alkylamino; or 30 R¹ and R² can also be taken together as



where L is O or OCH₂O:

D3 ie I

R⁴ is C₁-C₈ alkyl, C₃-C₆ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ araalkyl, phenyl substituted with 1 to 3 groups selected from CH₃, F, Cl, CH₃O, CN; or

benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, CI, or CN; is C₁-C₈ alkyl or phenyl optionally substituted with 1 to 3 groups selected from CH₃,

CH₂O. F. Cl. or CN:

A is C₄-C₉ alkyl;

X is $S(O)_r$;

Y is O. H₂.

Specifically preferred are:

N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-phenylurea

5

10

15

20

25

30

35

40

45

50

```
N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea
    N-butyl-N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea
    N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
    N-[5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea
    N'-(2.4-diffuorophenyl)-N-[5-[4.5-diphenyl)-1H-imidazol-2-vl)sulfonyl]pentyl]-N-heptylurea
    N-[5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylthiourea
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea
    N'-(2,4-difluorophenyl)-N-heptyl-N-[5-(4-phenyl-1H-imidazol-2-ylthio)pentyl]urea
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(2,4,6-trifluorophenyl)thiourea
    N'-(2,6-dichlorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
    N-[5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyl]-N-hentyl-N'-(1-methylethyl)urea
    N-15-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyll-2.4-difluoro-N-heptylbenzeneacetamide
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylthiourea
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-octylurea
    N'-cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
    N'-(2.4-difluorophenyl)-N-[5-(4.5-diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurea
    N'-(2,4-difluorophenyl)-N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-N-heptylurea
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide
    N-[5-(4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
    N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
    N'-(2.4-difluorophenyl)-N-[5-(4.5-dipropyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
    N-I5-I4.5-bis(4-fluorophenyl)-1H-imidazol-2-vlthiolpentyl]-N'-(2.4-difluorophenyl)-N-heptylurea
    N-[5-(1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
    N-[5-[4,5-bis(2-thienyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
    N-[5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyl]-N-heptylpentanamide
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl[1,1'-biphenyl]-4-acetamide
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(2,4,6-trifluorophenyl)urea
    N-[5-[4,5-bis(2-pyridinyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl]-N-heptylurea
    N'-(2.4-difluorophenyl)-N-[6-(4.5-diphenyl)-1H-imidazol-2-vl)hexyl]-N-heptylurea
    N-[5-[4.5-bis(4-methylphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2.4-difluorophenyl)-N-heptylurea
    N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylbutanamide
    N-[5-[4,5-bis(4-hydroxyphenyl)-1H-imidazol-2-vlthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
    N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide
    N-[5-[4,5-bis(3-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-diffuorophenyl)-N-heptylurea
    N-I5-I4.5-bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
    N'-[1,1'-biphenyl)-4-yl]-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
    N-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octylurea
    Propvl [5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyl]heptylcarbamate
    (Phenylmethyl) [5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
    Phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
    (2-Methylpropyl) [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
    Ethyl [5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyl]heptylcarbamate
    Octyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
    N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea
    N-(5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-diffuorophenyl)-N-heptylurea)
    (4-fluorophenyl)[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate
    N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea
    N-[5-(1H,9H-dibenz[4,5:8,9][1,3]dioxonino[6,7-d]imidazol-2-ylthio)-pentyl-N'-(2,4-difluorophenyl)-N-
heptylurea
    N'-(4-cyanophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
    N-(2.4-difluorophenyl)-N'-[5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]urea
    N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-vlthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide
    Phenyl [5-[4,5-bis(4-dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbamate
    or pharmaceutically acceptable salts thereof.
```

Detailed Description of the Invention

Synthesis

35

40

45

50

55

The novel compounds of Formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic synthesis that the functionality present on the imidazole and other portions of the molecule must be compatible with the reagents and reaction conditions proposed. Not all compounds of Formula (I) falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily appoarent to one skilled in the art and alternative methods described must then be used.

The compounds of Formula (I) wherein X is O, S, CH2 or NH can be prepared by the route shown in Scheme 1. The esters of Formula (3) wherein X is O or S can be prepared by converting the requisite 4-15 imidazolin-2-one (1) where X is O, or 4-imidazolin-2-thione (1) where X is S, into the corresponding alkali metal salt by addition of a base such as sodium hydride, and the salt is alkylated with a compound of the formula M-(A')CO₂R, wherein R is CH₃ or C₂H₅, M is a halogen or a tosylate group, and A' is a moiety having one less methylene group than A, in a polar solvent such as N,N-dimethylformamide. Alternatively, the esters of Formula (3) where X is S may be prepared by direct alkylation of the requisite 4-imidazolin-2-20 thione with M-(A')CO2R, without the addition of a suitable base, in a polar solvent such as N.Ndimethylformamide at a temperature from ambient temperature to the reflux temperature of the solvent. The esters of Formula (3) wherein X is NH can be prepared by the reaction of the requisite 2-aminoimidazole of Formula (2) with a compound of the formula M-(A')CO₂R wherein R. M. and A' are as defined above, in a suitable solvent such as N,N-dimethylformamide. Compounds of Formula (2) wherein R3 is H are preferen-25 tially alkylated at a ring nitrogen atom. Therefore, in order to prepare compounds of Formula (I) wherein X is NH and R3 is H, it is usually necessary to protect the ring nitrogen atom. The protecting group is preferably stable under basic conditions and easily removed under acidic conditions, e.g., a silyl or trityl group. The protected 2-aminoimidazole can then be used to prepare esters of Formula (3) wherein R3 is a protecting group. The protecting group can be removed at any suitable stage in the synthetic sequence for the preparation of the compounds of Formula (I) wherein X is NH and R3 is H.

Scheme 1

The esters of Formula (3) are hydrolyzed to the corresponding carboxylic acids of formula (4) by methods which are well known in the chemical literature. For example, the hydrolysis can be accomplished by reaction with an alkali metal hydroxide in aqueous or organic solvents such as water, alcohols, ethers or mixtures thereof, followed by acidification with a mineral acid. The methods used to prepare compounds of formula (4) are substantially similar to the methods described in U.S. 468-4369, U.S. 4460;989 and in U.S. 490.0744. Compounds of Formula (4) wherein R¹ and R² are phenyl or substituted phenyl, R³ is H, X is S, A¹ is (CH₂)—; and n is 8 to 21 are claimed as antihypercholesterolemic compounds in U.S. 4900,744.

The amides of Formula (5) are prepared by coupling the carboxylic acids of Formula (4) with a primary amine by amide bond forming reactions which are well known in the chemical literature. One method of 10 amide bond formation is to use a coupling reagent which generates a reactive intermediate such as a mixed anhydride or active ester. Examples of such coupling agents are disubstituted carbodilmides, N,N-carbonydilmidazole, diphenylphesphoryl zaide, and the like. For example, the coupling can be carried out with a disubstituted carbodilmide such as dicyclohexylcarbodilmide in an appropriate solvent such as methylene chloride, acetonitrile, toluene, or N,N-dimethylformamide. Nucleophilic hydroxy compounds such as 1-hydroxy-11-benzoritazole, which form highly active seters, may be added to catalyze the reaction.

There are several alternate approaches to the proparation of the amides of Formula (5). For example, the boron trifluoride etherate catalyzed reaction of the carboxylic acids of Formula (4) with a primary amine, with azeotropic removal of water, affords the amides of Formula (5). Another approach is to convert the carboxylic acids of Formula (4) to the corresponding acid chloride using thionyl chloride, oxalyl chloride or 20 the like and then to react the acid chloride with a primary amine in the presence of a base such as trieftly/amine to afford the amides of Formula (5). Alternatively, the esters of Formula (3) can be directly converted to the amides of Formula (5) by ester aminolysis in the presence of strong alkali metal catalysts such as sodium amide, sodium hydride, sodium methoxide, Grignard reagents or butyllithum, or in the presence of milder catalysts such as 2-projetone, boron tribromide, or dimethylaluminum amides.

The amines of Formula (8) can be prepared by reduction of the corresponding amides of Formula (5) by a variety of methods well known to those skilled in the art. For example, reagents such as lithium aluminum hydride, diborane, sodium bis[2-methoxyethoxy)aluminum hydride (Red-A19), and dilsebutylaluminum hydride can be used to reduce an amide to an amine. Such reactions are typically conducted in an appropriate antrydrous aprofic solvent such as either, toluene or tetrahydrofuran at a semerature from room temperature to the boiling point of the solvent for a period of 2-48 hours.

Alternatively amines of Formula (6), wherein X is NH can be prepared by the route shown in Scheme 2. The primary amines (9) can be prepared by reacting 2-bromoimidazoles of Formula (8) with an appropriately elaborated diamine under neat, thermal conditions or in appropriate solvent such as N,N-dimethylformamide, foluene, acetonitrile or tetrahydrofuran, at or below the boiling point of the solvent.

35

40

45

50

Scheme 2

5

10

15

20

25

an

45

50

55

The secondary amines of Formula (6) wherein X is NH can be prepared by direct alkylation of the primary amines of Formula (9) with an appropriately substituted alkyl halide. Or, the secondary amines (6) are prepared by acylation of the primary amines of Formula (9) with an acid chloride or activated carboxylic so acid derivative to give the amide of Formula (10) and reduction of the amide (10) to the amines (6) by well known methods previously described.

The compounds of Formula (7) where Y is O and Z is NR¹, OR¹ R¹ are prepared by the reaction of the secondary amines (6) with the requisite isocyanates, chloroformates, acid chlorides or activated carboxylic acid derivatives in an appropriate solvent such as hexane, toluene, diethyl ether, methylene chloride or tetrahydrofuran at a temperature at or below the boiling point of the solvent.

The amines of Formula (7), wherein Y is H_2 are prepared by reaction of the corresponding ureas or amides of Formula (7) wherein Y is O, with a reducing agent such as lithium aluminum hydride or other such reagents in an appropriate anhydrous aprotic solvent such as hexane, toluene, diethylether or tetrahydrofuran at temperatures at or below the boiling point of the solvent.

As shown in Scheme 3, the thioureas of Formula (12) wherein X is S, O or NH and Z is NHR¹ can be prepared in an analogous manner by the reaction of the secondary amines of Formula (6) with the requisite isothiocyanate. Alternatively, the thioureas or thioamides where Z is R¹ of Formula (12) can be prepared from the ureas or amides of Formula (7) by the reaction with Lawesson's reagent or diphosphorus pontasulfide in an appropriate solvent such as toluene.

Scheme 3

5

10

15

20

30

As shown in Scheme 4, alternatively the amides of Formula (5) can be prepared by the alkylation of (1) 5 or (2) with compounds of the formula M-(A')CONHR⁶ wherein M is a halogen or tosylate group, as, described for compounds of Formula (3), Scheme 1.

Scheme 4

Alternatively, compounds of Formula (7), where X is O, S, or NH can be prepared by the route shown in Scheme 5. The compounds of Formula (13) can be prepared from a lactone or an hydroxyalkylcarboxylic ester and an appropriate amine, neat or in an inert solvent such as N,N-dimethylformamide at ambient or elevated temperatures. The amines of Formula (14) are prepared by reduction of the corresponding amid (5) are prepared by the reaction of the secondary amine (14) with the requisite isocyanates, chloroformates, acid chlorides or activated carboxylic acid derivatives as described for the preparation of compounds of Formula (7). Scheme 1.

The compound of Formula (18) can be prepared by conversion of the hydroxy group to a halogen moiety by a variety of well known methods. Examples of these methods are phosphorous tribromide, phosphorous oxychloride, thionyl chloride, or triphenylphosphine and carbon tetrabromide. Or, compounds of Formula (16) where M is a tosylate or similar functionality, can be prepared from toluene sulfonyl chloride sand triefthytamine, in an acronoraite acrotic solvent such as methylene chloride. betafydrofuran or toluene.

The compounds of Formula (?) can be prepared by converting the requisite 4-imidazolin-2-one (1) where X is 0, or 4-imidazolin-2-thione (1) where X is S into the corresponding alkali metal salt by addition of a base such as sodium hydride, and alkylating with the compounds of Formula (16) in a polar aprotic

solvent such as N,N-dimethylformamide at an appropriate temperature.

5

10

15

20

25

30

50

55

Scheme 5

The compounds of Formula (7) wherein X is CH2 are prepared by the route shown in Scheme 6. The compounds of Formula (18) are prepared by converting the requisite imidazoles of Formula (17) where R3 is alkyl or an appropriate protecting group, into the corresponding alkali metal salt, by addition of a base such as n-butyl lithium, and alkylating with an appropriate alkyl halide in a solvent such as tetrahydrofuran under an inert atmosphere and reduced temperatures. The compounds of Formula (19) are prepared from 35 compounds of Formula (18) by reaction with an appropriately substituted amine, in an inert solvent such as toluene, acetonitrile, tetrahydrofuran or N.N-dimethylformamide, at a temperature at or below the boiling point of the solvent. The imidazole compounds of Formula (20) are prepared by the reaction of the secondary amines of Formula (19) with the requisite isocyanate, chloroformate, acid chloride or other activated carboxylic acid derivative as previously described. Or, the imidazole compounds of Formula (20) 40 can be prepared by reacting the alkali metal salt of compounds of Formula (17) with the elaborated compounds of Formula (16) in analogous conditions described above. The compounds of Formula (7) wherein X is CH2 and R3 is H, are prepared by deprotecting compounds of Formula (20), where R3 is a protecting group. For example, when R3 is a silv! protecting group, removal with tetrabutylammonium fluoride in tetrahydrofuran at reflux, affords compounds of Formula (7) where X is CH2.

Likewise, compounds of Formula (7) wherein X is O, S, NH or CH2 and Y is H2 may be prepared by reacting compounds similar to compounds of Formula (18) with an appropriately functionalized secondary amine, HNCH2 ZR6, in a solvent such as toluene, acetonitrile, tetrahydrofuran, or N,N-dimethylformamide at a temperature at or below the boiling point of the solvent.

Scheme 6

5

10

15

20

25

30

40

50

55

The linked phenyl compounds of Formula (224) are prepared as shown in Scheme 7. The linked bisbenzaldehyde compounds of Formula (21) are prepared by bis alkylation of an appropriately functionalized dihaloalkyl, with a substituted salisaldehyde, using an alkali base, such as sodium hydride in an innet solvent, such as N.N-dimethylformamide. The a-hydroxyketones of Formula (22) are prepared by standard literature benzoin forming reaction conditions, Walter S. Ide, Johannes S. Buck, Organic Reactions, Vol. IV, p. 289, utilizine potassium cvanide in ethanoltwater, at reflux.

The imidazoles of Formula (23) are prepared by methods well known in the literature, Klaus Hoffman, The Chemistry of Heterocyclic Compounds, Imidazoles, Part I, by condensing the a-hydroxyketone compounds of Formula (22) with thiourea, or ammonium thiocyanate, or an appropriately substituted thiourea in a suitable solvent such as N.N-dimethylformamide, ethanol or hexanol, at a temperature at or below the bolim point of the solvent.

The compounds of Formula (24) are prepared by alkylating the alkali metal salt of imidazole (23) with the compound of Formula (16), as described previously to give the compounds of Formula (24) directly or with compound of formula $M(A')CO_2R$ when R is CH_3 or C_2H_5 , M is halogen or a tosylate group and A' is a moiety having one less methylene group than A, as described in Scheme 1.

Scheme 7

5

10

15

20

25

30

The compounds of Formula (1), Scheme 8, wherein X is S are available from commercial sources or can be prepared by methods as described above.

Scheme 8

Alternatively, the compounds of Formula (1) where X is S, Scheme 8, can be prepared from the corresponding 4-imidazolin-2-ones of Formula (1) where X is O, Org. Syn. Coll., Vol. II, 231, by reaction with Lawesson's reagent or diphosphorus pentasulfide in a suitable solvent such as toluene.

As shown in Scheme 9, the 2-aminoimidazoles of Formula (2) can be prepared by the reaction of the appropriately substituted α -aminoketones of Formula (27) with cyanamide (28). Compounds of Formula (2)

can be used in the preparation of compounds of Formula (I) as previously described in Scheme 1.

Scheme 9

As shown in Scheme 10, the compounds of Formula (i) wherein X is S(0), and r is 1 or 2 can be prepared by the oxidation of the compounds of Formula (29) by methods which are well known in the chemical literature. For example, the oxidation of (29) with one equivalent of a peracid such as methoroperoxybenzoic acid in a suitable solvent such as methylene chloride at a low temperature affords primarily the sulfoxides of Formula (30), and the oxidation of (29) with an oxidant such as potassium hydrogen persulfate, or Oxone®, in a suitable solvent such as methanol affords the sulfones of Formula (31).

Scheme 10

Alternatively, compounds of Formula (7) where R³ is not H, Scheme 11, can be prepared by direct alkylation of compounds of Formula (7) when R is H, in the presence or absence of a base such as potassium carbonate, pyridine, sodium hydride, triethylamine, or potassium t-butoxide in an appropriate solvent such as N.N-dimethylformamide, glyme, tetrahydrofuran, pyridine or methylene chloride.

Scheme 11

Preparation of pharmaceutically suitable salts of Formula (f) can be carried out in accordance with well known techniques for forming salts. Physiologically acceptable salts include acid addition salts, e.g., hydrochloric, sulfuric, acetic, trifluoracetic, succinic, citric, and benzene sulfonic acid salts.

The compounds of this invention and their preparation can be further understood by the following 20 examples, which exemplify but do not constitute a limitation of the invention. In these examples, unless otherwise indicated, all temperatures are in degrees centigrade and parts and percentages are by weight.

EXAMPLE 1

5

10

15

30

35

4n

45

50

55

25 Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

Part A. To a solution of 4,5-diphenyl-2-imidazolethiol (25.2 g, 0.1 mol) in N,N-dimethylformamide (250 ml) was added, dropwise, a solution of ethyl 5-bromopentanoate (23.73 ml., 31.55 g, 0.15 mol) in N,N-dimethylformamide (80 ml.), and the reaction mixture was striend at reflux under nitrogen for 18 hours. The reaction mixture was cooled, poured into 5% sodium bicarbonate and ice, and then extracted with ethyl acetate. The combined organic extracts were washed sequentially with 5% sodium bicarbonate, water, saturated sodium chloride solution, dried over magnesium sulfate, and concentrated under vacuum. The residue was chromatographed with 7.3 hexane-ethyl acetate, and the resulting solid was recrystallized from acetonitie and triturated with hexane to give 54(4-51/phenyl-11-thindazol-2-ythtio)-pontanoic acid ethyl ester (25.95 g, 0.088 mol) as a white solid, mp 87-99 *. **H NMR (DMSO-6) 5 7.55-7.15(m.111h. 40/0.2H.) = 814:0. 29/1.2H.J. 29/1.2H.J. 29.16(ml.) 184:1. 21.3(2H.J.) = 814:0.

Additional esters which can be used as intermediates in the preparation of compounds of Formula (I) are prepared similarly as taught in U.S. 4,900,744.

Part B. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthiol)pentanoic acid ethyl ester (7.6 g, 0.02 mol) in ethanol (200 mL), was added dropwise a solution of soldum hydroxide (7.6 g) in water (200 mL), and the reaction mixture was stirred at reflux under nitrogen for 3 hours. The reaction mixture was concentrated to half the original volume and then extracted with ether. The ether extracts were discarded. The reaction mixture was acidified to pH I with I N hydrochloric acid and extracted with ether, and the combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The resulting solid was recrystallized from acetorities and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (3.88 g, 0.011 mol) as a white solid, mp 190-195*. ¹H NMR (DMSO-d₈) \$2 (16,9,1H), 7.6-1 (1m,10H), 3.3-3 (1m,2H), 2.2-2 (1m,3H), 1.8-1 (6,m,4H).

Additional acids which can be used as intermediates in the preparation of compounds of Formula (I) are prepared similarly and are claimed in U.S. 4,900,744.

Part C, Method 1. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentanoic acid (2.0 g, 0.0057 mol) in N,N-dimethyllformamide (25 mL) was added 1-hydroxybenzotriazole hydrate (0.93 g, 0.0069 mol) followed by a solution of heptylamine (1.10 mL, 0.88 g, 0.0074 mol) in N,N-dimethylformamide (10 mL). The reaction mixture was striend for 2 hours at 0° and then stirred for 48 hours at ambient temperature. The solids were filtered and washed with N,N-dimethylformamide. The filtrate was concentrated and the residue was chromatographed with 1:1 hexane-ethyl acetate. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide (2.21 g, 0.0049 mol) as a white solid, mp 104-106°. "It NMR (CDCls) 6

11.6(s,1H), 7.6-7.1(m,10H), 6.1-6.0(m,1H), 3.1-2.8(m,4H), 2.2(t,2H,J = 7Hz), 1.9-1.7(m,2H), 1.7-1.5(m,2H), 1.4-1.1(m.10H), 0.9(t.3H,J=8Hz),

Part C. Method 2. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-vlthio)pentanoic acid (2.0 g. 0.0057 mol) in toluene (35 ml) was added heptylamine (1.63 ml., 1.27 g, 0.011 mol) and then boron trifluoride etherate (1.35 mL., 1.56 g, 0.011 mol) and the reaction mixture was stirred at reflux for 120 hours using a Dean-Stark moisture trap. The reaction mixture was cooled, extracted with 0.1 N NaOH, 0.1 N HCl, and water, and the combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed and worked-up as described in Part C, Method 1, to give 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide (2.35 g, 0.005 mol) as a white solid.

Part D. To a solution of lithium aluminum hydride, (1.52 g. 0.04 mol) in dry tetrahydrofuran (50 mL) was added, dropwise, a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptylpentanamide(4.04 g, 0.009 mol) in tetrahydrofuran (25 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0*, quenched by the slow and careful sequential addition of water (1.52 mL), 15% sodium hydroxide (4.56 mL), and water (4.56 mL), and then stirred at 0° for 30 minutes. The solution was then dried over magnesium sulfate and concentrated under vacuum, and the residue was chromatographed with a gradient of 1:0 to 3:1 to 1:1 ethyl acetate-methanol. The resulting yellow oil was triturated with cold hexane to give N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine as a white solid. A solution of this amine (0.80 g, 0.0018 mol) in ether (20 mL) was treated with a sufficient amount of ethereal HCI (about 25 mL) to cause complete precipitation of the amine as the hydrochloride salt. The reaction mixture was stirred for 15 minutes, and the supernatant liquid was decanted to afford a gummy solid, which was triturated with hot acetonitrile and then with cold hexane to give N-[5-(4,5diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine hydrochloride (0.82 g, 0.0017 mol) as a white solid, mp 187-190*, ¹H NMR (CDCl₈) δ 9.3(s,2H), 7.7-7.3(m,10H), 3.7-3.5(m,2H), 3.0-2.7(m,4H), 2.0-1.2(m,16H), 0.9(t,3H,J=8Hz).

Part E. To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (1.0 g, 0.0024 mol) in hexane (50 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.296 mL, 0.388 g, 0.0025 mol) in hexane (25 mL), and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate to give the title compound (0.86 g, 0.0015 mol) as a white solid, mp 96-98*. 1H NMR (CDCl₃) δ 10.8(s,1H), 7.7-7.1(m,14H), 3.4(t,2H,J=7Hz), 3.2(t,2H,J=7Hz), 3.0(t,2H,J=7Hz), 1.9-1.4-(m, 16H), 0.9(t, 3H, J = 8Hz).

EXAMPLE 2

5

10

15

20

30

35 Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-phenylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanamine (1.0 g, 0.0024 mol) in hexane (50 mL) was added, dropwise, a solution of phenylisocyanate (0.27 mL, 0.298 g, 0.0025 mol) in hexane (25 mL) and the reaction mixture was stirred at ambient temperature for 4 hours. The reaction 40 mixture was concentrated under vacuum and the residue was chromatographed with 6:4 hexane-ethyl acetate to give the title compound (0.5 g, 0.009 mol) as a yellow amorphous solid. 1H NMR (CDCl₃) § 11.0-(s,1H), 7.7-6.9(m,14H), 6.4(s,1H), 3.4(t,2H,J=7Hz), 3.2(t,2H,J=7Hz), 3.0(t,2H,J=7Hz), 1.9-1.1(m,16H), 0.9-(t.3H.J = 8Hz).

45 EXAMPLE 3

50

55

Preparation of N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea

Part A. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-ylthio)octanoic acid (8.44 g, 0.02 mol) in methylene chloride (100 mL) at 0° was added, portionwise as a solid, dicyclohexylcarbodiimide (4.12 q, 0.02 mol). and the reaction mixture was stirred at 0° for 30 minutes. To this reaction mixture was added, dropwise, heptylamine (2.96 mL, 2.3 g, 0.02 mol) and the reaction mixture was stirred at reflux for 72 hours. The reaction mixture was cooled, and the solids were filtered and washed with chloroform. The filtrate was concentrated under vacuum and the residue was chromatographed with a gradient of 7:3 to 1:1 hexaneethyl acetate. The resulting solid was recrystallized from acetonitrile and triturated with hexane to give 8-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-heptyloctanamide (3.28 g, 0.0067 mol) as a white solid, mp 119-120°. ¹H NMR (DMSO-d₆) δ 12.5(s,1H), 7.8-7.1(m,10H), 3.2-2.9(m,4H), 2.0(t,2H,J=7Hz), 1.75-1.0-(m,21H), 1.0-0.8(m,3H).

Part B. To a solution of lithium aluminum hydride (0.96 g. 0.025 mol) in dry tetrahydrofuran (30 mL) was added, dropwise, a solution of 8-(4,5-diphenyl-1H-imidazol-2-ytlthio)-N-heptyloctanamide (2.82 g. 0.0057 mol) in tetrahydrofuran (15 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0°, quenched by the slow and careful sequential addition of water (0.96 mL), 15% sodium hydrovide (2.88 mL), and water (2.88 mL), and then stirred at 0° for 30 minutes. The solution was then dried over magnesium sulfate and concentrated, and the residue was chromatographed with 1:1 hexane:ethyl acetate-methanol to give 8-(4.5-diphenyl-1H-imidazol-2-ytlthio)-N-heptyl-1-octanamine (1.07 g. 0.0022 mol) as a white solid, mp 87-89°. 'IH NMR (CDCls) & 7.6-7.2(m,11H), 3.1(t,2H,J=7Hz), 2.7-2.5(m,2H), 1.8-1.1(m,25H), 0.9-(t,3H,J=8Hz).

Part C. To a solution of 8-(4,5-diphenyl-1H-imidazol-2-yithio)-N-heptyl-1-octanamine (0.5 g. 0.001 mol) in hexane (25 mL) was added, dropwise, a solution of 2,4-difluorophenylisocyanate (0.15 mL, 0.194 g, 0.00125 mol) in hexane (10 mL), and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed using 8-2 hexane-ethyl scateta to give a solid which was triturated with cold ethyl acetate and then hexane to give the title compound (0.18 g, 0.00028 mol) as a white solid, mp 89-91 · 1H MMR (DMSO-d₆) δ 12-5(s,1H)-7,9(s,1H), 2-7,7 (m.10H), 33-31 (m.5H), 13-2 (m.17H), 0.0(3.H) = 8H2.

EXAMPLE 4

5

10

15

25

30

35

an

45

50

55

Preparation of N-butyl-N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea

Part A. To a solution of 9-(4,5-diphenyl-1H-imidazot-2-ylthio)octanoic acid (4.4 g, 0.0125 mol) in methylene chloride (65 mL) at 0' was added, portoriwse as a solid, dicyclohexylcarbodimide (2.3 g, 0.011 mol) and the reaction mixture was stirred at 0' for 30 minutes. To this reaction mixture was added, dropwise, a solution of butylamine (1.24 mL, 0.92 g, 0.012 mol) in methylene chloride (15 mL) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled, and solids were filtered and washed with methylene chloride. The filtrate was concentrated under vacuum and the residue was chromatographed with a gradient of 7.3 to 1:1 hexane-ethyl accelate. The resulting solid was recrystallized from accelonitrile and triturated with hexane to give N-butyl-8-(4.5-diphenyl-1H-limidazot-2-ythho)cotamanide (1.43 g, 0.03 mol) as a white solid, mp 136-137* ' H-NMR (DMSC-4,5) 1.2.5(s,1H), 7.8-7.7(m,1H), 7.7-7.1(m,10H), 3.2-2.9(m,4H), 2.0((.2H,J=7Hz), 1.8-1.1(m,14H), 0.9((.3H,J=8Hz)). Part B. To a solution of lithium aluminum hydride (0.46 g, 0.012 and) in dry tetrahydroturan (15 mL) was added, dropwise, a solution of N-butyl-9-(4.5-diphenyl-1H-imidazot-2-ythho)cotamanide(1.22 g, 0.0027).

mol) in tetrahydrofruran (8 ml) and the reaction mixture was stirred at reflux for 18 hours. The reaction mixture was cooled to 0 °C and quenched by the slow and careful sequential addition of water (0.46 ml.). 15% sodium hydroxide (1.38 ml.), and water (1.38 ml.) and the reaction mixture was stirred at 1°5% solution mixture was stirred at 0° for 30 minutes. The solution was dried over magnesium sulfate and concentrated under vacuum, and the residue was chromatographed with 1:1 hexane-ethyl acetate and then with a gradient of 1.0 for 2.2 to 1:1 ethyl acetate-methanol. The resulting solid was triturated with hexane to give N-butyl-8-(4.5-diphenyl-1H-imidazol-2-yithio)octanamine (0.45 g., 0.001 mol) as a white solid, mn 75-78°. "If NMR (CDCI₃) 8 7.6-7.1 (m.10H), 3.1 (L2HJ = 71£), 2.5((2HJ = 71£), 7.1-1 (m.16H), 0.9((3HJ = 18±).

Part C. To a solution of N-butyl-B-(4,6-diphenyl-1H-imidazol-2-ylthio)octanamine (0.2 g. 0.00045 mol) in hexane (15 mL) was added, dropwise, a solution of 2,4-diffuorophenylisocyanate (0.065 m.l. 0.085 g. 0.00055 mol) in hexane (5 mL) and the reaction mixture was stirred at ambient temperature for 3 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7.3 hexane-ethyl acatelate and the resulting solid was recrystallized from accoloritie and riturated with hexane to give the title compound (0.138 g. 0.00023 mol) as a white solid, mp 114-115*. ¹H NMR (CDCl₅) δ 8.1-7.9(m,1H), 7.6-7.2(m,11H), 6.95-6.75(m,2H), 6.5-6.4(m,1H), 3.4-3.1(m,6H), 1.8-1.3(m,16H), 1.0-(13H.1=8H2).

EXAMPLE 5

Preparation of N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidzao-l2-ythio)pentylI-1-heptanamine (0.75 g, 0.0017 mol), prepared according to the procedure of Example 1, Part D, in hexane (40 mL) was added, dropwise, a solution of 2.4-dimethoxyphenylisocyanate (0.358 g, 0.002 mol) in hexane (20 mL) and the reaction mixture

was stirred at ambient temperature for 4.5 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 7:3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (0.83 g, 0.0014 mol) as a glassy solid. ¹H NMR (CDCb) 8 7.77-7. (m;10H), 6.8-6.1 (m;3H), 3.8(s,3H), 3.7(s,3H), 3.45(s,1H), 3.4-3.3 (m;2H), 3.2(t;2H,J=7Hz), 3.0(t;2H,J=7Hz), 1.8-1.1-5 (m;16H), 0.01;3H,J=8Hz).

EXAMPLE 6

10

Preparation of N'-(2,4-difluorophenyl)-N-heptyl-N-[5-(1-methyl-4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]urea

To a solution of potassium carbonate (0.056 g, 0.00042 mol) in dry tetrahydrofuran (10 mL) was added, portionwise as a solid, N*-(2,4-difluorophenyl)*-N*-[5-(4,5-diphenyl-1H-imidazol-2-yithio]pentyl]*-N-heptyltrata (0.25 g, 0.00042 mol) and the reaction mixture was stirred at ambient temperature for 10 minutes. To this reaction mixture was added, dropwise, methyl iodide (0.039 mL, 0.0895 g, 0.00063 mol) and the reaction mixture was stirred for 18 hours at ambient temperature. The reaction mixture was then treated with N.N-dimethylformamide (1.0 mL) and methyl iodide (0.1 mL) and the reaction mixture was stirred at reflux for an additional 24 hours. The reaction mixture was cooled, poured into water and extracted with eithyl acetate. The combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed with 3:7 hexane-ethyl acetate to give the title compound (0.13 g, 0.00022 and) as a yellow oil. ¹H NMR (CDCb) δ 8.1-8.0(m,1H), 7:5-7.1(m,10H), 6.9-6.7(m,2H), 6.4(s,1H), 3.5(s,3H), 34-3.2(m,9H), 1.9-12(m,17H), 0.9(3.4H). = 8Hz).

EXAMPLE 7

25 Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl-1-heptanamine (0.30 g, 0.0007 mol) in hexane (15 mL) was added methylisocyanate (0.06 mL, 0.057 g, 0.001 mol) and the reaction mixture was stirred at ambient temperature for 18 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed with 1:1 hexane-ethyl acetate. The resulting oil was triturated with hexane to give the title compound (0.23 g, 0.00047 mol) as a white solid, mp 93-96*. "H NMR (CDCl₃) 8 7.6-7.2-(m,11H), 4.52-2/(m,9H), 1.9-1.2(m,16H), 0.9((.3HJ,J=8HZ))

EXAMPLE 8

35

50

55

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea

To a solution of N-[5-(4,5-diphenyl-IH-midazol-2-ythio)pentyl-I-heptanamine (0.36 g, 0.0008 mol) in hexane (15 mL) was added propylisocyanate (0.094 mL, 0.085 g, 0.001 mol), and the reaction mixture was stirred at ambient temperature for 4 hours. The reaction mixture was then treated with additional propylisocyanate (0.094 mL, 0.085 g, 0.001 mol) and stirred at ambient temperature overnight and then at reflux for 72 hours. The reaction mixture was concentrated under vacuum and the residue was chromatographed using 2.8 hexane-ethyl acetate. The resulting oil was triturated with hexane to give the title compound (0.8 g, 0.00015 mol) as a white solid, mp 78-80: "IH NIMR (CDCls) § 7.6-7.2(m,10H), 4.4-40 (1.1H,J. = 7442), 34-2.9(m,8H), 1.9-1.1(m,19H), 1.0-0.75(m,9H).

EXAMPLE 9

Preparation of N'-(2,4-difluorophenyl)-N-[2-(4,5-diphenyl-1H-imidazol-2-ylthio)ethyl]-N-propylurea

Part A. To a solution of bromoscotylchloride (25.51 mL, 48.67 g, 0.31 mol) in methylene chloride (200 mL) at -15° was added, dropwise, a solution of propylamine (24.62 mL, 17.7 g, 0.3 mol) in methylene chloride (100 mL) and the reaction mixture was stirred at 0° for 30 minutes and then stirred at ambient temperature for 30 minutes. The reaction mixture was poured into water and then extracted with methylene chloride. The combined organic extracts were dried over magnesium sulfate and concentrated under vacuum. The residue was distilled to give bromo-N-propylacetamide as a clear liquid, bp 138-142. '!H NMR (CDCls) 57.1(s.1th.) 3.9(d.241.3-614t). 3.3(m.2th.) 1.6(m.2th.) 5.9(d.24t). 0.9(d.341.3-514.3).

Part B. A portion of sodium hydride. 60% in mineral oil (0.4 g. 0.01 mol), was washed twice with hexane (10 mL) and the hexane was replaced with N,N-dimethyfformamide (100 mL). To this solution was added, portionwise as a solid, sodium iodide (0.4 g. 0.003 mol) and then, dropwise, a solution of diphenylimidazole (2.52 g. 0.01 mol) in N,N-dimethyfformamide (10 mL) followed by the dropwise addition of a solution of brome-N-propylacetamide (1.80 g. 0.01 mol) in NN-dimethyfformamide (10 mL). The reaction mixture was stirred at reflux for 18 hours, then cooled and poured, carefully, into ice water, and then extracted with ethyl acetate. The combined organic extracts were backwashed with brine, dried over magnesium sulfate and concentrated under vacuum. The residue was chromatographed using 1:1 hexane-ethyl acetate and the resulting solid was recrystallized from acetonitrile to give 2-(4,5-diphenyl-HH-midazol-2-ythio)-Phropylacetamide as a white solid, mp 183-185: "IN NMR (0MSO-d.) 5 12-6 (s.1H), 8.3(s.1H), 7.5-7.1(m,10H), 3.8(s.2H), 3.0(g.PL), 1.4 (sexviet, 2H,1=9Hz), 0.8(g.3H,1=6Hz), Part D, in the propylacetamide, N-12-(4,5-diphenyl-HH-midazol-2-ythio)-phropylacetamide, N-12-

Part D. Employing the method of Example 1, Part E, but using N-[2-(4,5-diphenyl-1H-imidazol-2-yithio)-ethyl-1-proparamine, the title compound (0.20 g, 0.00045 mol) was obtained as a white solid, mp 189-190 · ' H NMR (CDCl_b) § 11.6-11.2(s,1H), 7.8-7.6(s,1H), 7.8-6.9(m,10H), 6.8-6.6(m,2H), 3.8(t,2H,J=7Hz), 3.4(t,2H,J=65Hz), 3.2(t,2H,J=6Hz), 1.8-1.8(m,4H), 1.0(t,3H,J=7.5Hz).

EXAMPLE 118

5

10

15

25

30

35

an

45

50

55

 $\begin{tabular}{lll} \hline Preparation & of & N-[5-(4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]-pentyl]-N'-(2,4-diffuorophenyl)-N-hep-tylurea & Preparation & Preparation$

Part A. A solution of ,-valerolactone (25.0 g., 0.249 mol) in toluene (50 mL) and n-heptylamine (35.96 g. 0.312 mol) was heated to reflux for 18 hours under a nitrogen atmosphere. The reaction mixture was allowed to cool to ambient temperature, diluted with ethyl acetate (300 mL), washed with 1 N aqueous HCI (50 mL), water, brine, dried over magnesium sulfate and concentrated to give a white solid. The product was crystallized from ethyl ether-thexane to give N-heptyl-5-hydroxypentanamide (4.18 g. 0.194 mol) as white plates, mp 55-6*. "H NMR (CDCl₉) & 6.06(bs,1H), 3.61(l₂H), 3.24(q₂H), 3.19(bs,1H), 2.19 (t₂H), 1.80-1.23m(1.4H), 0.896(t₃H).

Part B. To a solution of lithium aluminum hydride (6.7 g. 0.176 mol) in dry tetrahydrofuran (300 mL), a solution of N-heptyl-5-hydroxypentanamide (19.0 g, 0.088 mol) in dry tetrahydrofuran (100 mL) under a nitrogen atmosphere was added dropwise. The reaction mixture was heated to reflux for 18 hours, allowed to cool to room temperature and was poured slowly into a stirred mixture of 10% aqueous sodium sulfate (400 mL) and ice (200 mL). The resulting slurry was filtered through a bed of Celite® and the filtrate was extracted with ethyl acetate (2 x 500 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous vellow oil. The product was crystallized from hexane to give N-(5-hydroxypentyl)-N-heptylamine (15.2 g, 0.075 mol) as a white powder, mp 47-8*. 1H NMR (CDCl₃) § 3.63(t,2H), 2.63(q,4H), 2.39(bs,2H), 1.66-1.24(m,16H), 0.905(t,3H). Part C. To a solution of N-(5-hydroxypentyl)-N-heptylamine (11.65 g, 0.0578 mol) in methylene chloride (75 mL) under a nitrogen atmosphere cooled to 0*, 2,4-difluorophenylisocyanate (8.97 g, 0.0578 mol) was added slowly. The reaction mixture was stirred for 1 hour, poured into 1 N aqueous HCl (200 mL) and was extracted with ethyl acetate (300 mL). The combined organic layer was washed with water, brine, dried over magnesium sulfate and was concentrated to give N'-(2,4-difluorophenyl)-N-heptyl-N-5hydroxypentylurea as a pale yellow oil (20.0 q, 0.056 mol). ¹H NMR (CDCl₃) δ 8.03 (m,1H), 6.88-6.59-(m,2H), 6.45(bs,1H), 3.68(t,2H), 3.33(m,4H), 1.81-1.22(m,16H), 0.907(t,3H).

Part D. To a solution of N-(2.4-ciffulorophenyl)-N-heptyl-N-5-hydroxypentylurea (15.0 g. 0.04z mol) and carbon tetrabornide (16.75 g. 0.051 mol) in methylene chloride (350 m.l) under a nitrogen atmosphere at ambient temperature, a solution of triphenylphosphine (13.24 g. 0.051 mol) in methylene chloride (100 ml) was added slowly. The reaction mixture stirred for 3 hours and was concentrated in vacuo to give crude viscous oil. The product was purified by flash chromatography on slicita get (400 ml.) eluting with hexane:ethyl acetate (90:10 v.v) to give N-(5-bromopentyl)-N-(2.4-difluorophenyl)-N-heptylurea as a viscous colorless oil (17.5 g. 0.02 mol). "I NMR (CDCs) δ 8.14-8.00(m,1H), 6.92-6.79(m,2H), 6.35-(bs.1H), 3.49-3.25(m,6H), 1.99-1.26(m,16H), 0.915((3.H)).

Part E. To a suspension of sodium hydride (0.88 g, 60% mineral oil dispersion, 0.0022 mol) (washed free of mineral oil with hexane) in N,N-dimethylformamide (15 mL) under a nitrogen atmosphere, cooled to

0°, a solution of 4,5-fbis-(4-methoxyphenyl)-Hi-Imidazolly-2-thione (0.63 g. 0.002 mol) in N.N-dimethylfor-mamide (5 mL) was added slowly. The reaction mixture was stirred for 2 hours and then a solution of N.G-bromopentyl)-N°-(2,4-difluorophenyl)-N-Heptylurea (0.845 g. 0.002 mol) in N.N-dimethylformamide (3 mL) was added. The reaction mixture was allowed to warm to ambient temperature, stirred an additional 2 hours, poured into water (50 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic extracts were washed with water, brine, dried over magnesium sulfate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (100 mL) eluting with hexanecothyl acetate (7/30 v.v) to give the title compound as a pure yellow foam (0.98 g. 0.0015 mol). "H NMR (CDCls) § 10.15(bs.1H), 7.87-7.76(m.1H), 7.51(d.2H), 7.3(d.2H), 6.86-6.6(m.6H), 6.42(d.1H), 3.8(s. 6H), 3.4(d.2H), 3.6(d.2H), 2.94(d.2H), 1.84-1.25(m.16H), 0.98(d.3H).

EXAMPLE 191

10

15

20

30

Preparation of N-(2.4-difluorophenyl)-N'-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]urea

Part A. mixture of 5-(4,5-diphenyl-1H-imidazol-2-ythio)pentanoic acid (4.0 g. 0.011 mol) and urea (1.38 g. 0.023 mol) was heated to 179-180° for 5 hours. The cooled reaction mixture was partitioned in sodium carbonate (5%) and extracted with chloroform. The organic layers were washed with saturated sodium chloride solution then dried over magnesium suitless and concentrated under vacuum. The residue was chromatographed with 9.1 ethyl acetate-methanol to give 5-(4,5-ci)plenyl-1H-imidazol-2-ythio)-pentanamide (0.73 g. 0.002 mol) as a white solid, mp 136-138°. 'N NMR (CDCl₆) § 10.56(s,1H), 7.7-7.2-(m,10H), 5.9(g,1H), 5.4(s,1H), 5.0(g,2H) = 7.441g, 2.3(g,H) = 814tz, 2.0-16(m,4H).

Part B. Employing the method of Example 1, Part D, using 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-pentianamide (2.0 g, 0.0057 mol), 5-(4,5-diphenyl-1H-imidazol-2-ylthio)-1-pentianamine (0.32 g, 0.00055 mol) was obtained as a tan solid, mp 111-113°. ¹H NMR (DMSO-d₆) δ 7.5-7.2(m,12H), 3.1-(1,2H,J=72Hz), 2.5(1,2H,J=6,2Hz), 1.8-1.3(m,7H).

Part C. A solution of 5-(4.5-tijpheny-l1H-imidazol-2-yllthio)-1-pentanamine (0.34 g, 0.001 mol) and 2.4-diffuorophenylisocyanate (0.24 mL, 0.31 g, 0.002 mol) in toluene (10 mL) was stirred at ambient temperature for 120 hours. The solution was concentrated under vacuum to give a residue (0.53 g) which was chromatographed with 1:1 hexane-ethyl acetales. The resulting solid was triturated with cold acetonitrile to give the title compound (0.13 g, 0.0026 mol) as a white solid, mp 187-198°. *H NMR (DMSO-Cs) δ 12.5(s,1H), 8.2-8.0(m,2H), 7.5-7.1(m,11H), 7.0-6.9(m,1H), 6.6-6.5(m,1H), 3.2-3.0(m,4H), 1.8-1.3(m,8H).

35 EXAMPLE 207

Preparation of N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-ythhio)pentyl|benzeneamine (0.41 g, 0.001 mol) in toluene (25 mL) was added n-oclylisocyanate (0.23 g, 0.0015 mol). The reaction mixture was stirred at reflux for 18 hours and then the solvent was removed under vacuum. The residue (1.0 g) was chromatographed with 7:3 hexane-ethyl societae. The resulting solid was triturated with hexane to give the title compound (0.32 g, 0.00056 mol) as a white solid, mp 74-76*. 'IH MINH (DCDIs) a 11,8(s,11t), 77-80*. In (II-H), 17-80*. In (II-H), 18-80*. I

EXAMPLE 209

Preparation of N-[5-[4,5-bis(4-hydroxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N-(2,4-difluorophenyl)-N-heptylurea

To a stirred solution of N-[5-(4.5-bis(4-methoxypheny)-1H-imidazob-2-ythio)penyl-1H-or(2.4-difluoropheny)-N-heptylurea (0.78 g., 0.0012 mol) in methylene chloride (30 mL) cooled to -78° unitargen atmosphere, 1M boron tribromide in methylene chloride (3.6 mL) was added. The reaction mixture so stirred for 1 hour at 0°, was pound over ice (100 mL) and extracted with othyl acetate (2 x 50 mL). The combined organic layer was washed with 10% acqueous NaHCO, 50 mL), water, brine, dired over magnesium sulfate, and concentrated in vacuo to give the crude oil. The product was purified by flash chromatography on silica cell (100 mL) buting with hexanes/ethyl acetate (4/650 v.y) to give a white form

mp 110-12° (0.5 g, 0.00008 mol). ¹H NMR (DMSO-d₆) δ 12.22 (bs,1H), 9.55(bs,1H), 9.32(bs,1H), 7.45-6.6(m,11H), 3.24(m,4H), 3.06(t,2H), 1.77-1.17(m,16H), 0.88(t,3H).

EXAMPLE 211

5

10

15

20

25

30

35

an

46

Preparation of N-[5-(1H,9H-dibenz-[4,5:8,9][1,3]dioxonino-[6,7-d]imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea

Part A. To a suspension of sodium hydride (washed free of mineral oil with hexane) (2.45 g, 80% oil dispersion, 0.081 mol) in dry N,N-dimethylformamide (60 mL) under a nitrogen atmosphere, cooled to 0°, a solution of salisaldehyde (10.0 g, 81,9 mmol) in dry N,N-dimethylformamide (10 mL) was added slowly. The reaction mixture was stirred at 0° for 2 hours and dilodomethane (11.3 g, 0.041 mol) was added. The reaction mixture was allowed to warm to ambient temperature for 18 hours and then was warmed to 60° for 20 hours. The reaction was allowed to cool to ambient temperature, poured into 1 N aqueous HCI (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water, brins, dried over magnesium sulfate and concentrated to give a solid. The product was purified by flash chromatography on silica gel (300 mL) eluting with methylene chloride (100%) to give 2.2*(methylenedioxy)-bis-(2-benzaldehyde) as a white crystalline solid, mp 131 to 3° (5.1 g, 0.0199 mol). 11 MMR (COCb) à 10 47(5, 241), 78(241), 78(2421), 78(2

Part B. A mixture of 2.2-(methylenedioxy)-bis-(2-benzaldehyde) (5.0 g. 0.0195 mol), potassium cyanide (0.83 g. 0.0975 mol) in ethanol (75 ml.) and water (50 ml.) was heated to reflux for 8 hours. The reaction mixture was allowed to cool to ambient temperature, was concentrated in vacuo and the resultant acucous residue was partitioned between ethyl acetate and water. The organic Byer was washed with water, brine, dried over magnesium sultate and concentrated to give a viscous oil. The product was purified by flash chromatography on silica gel (250 ml.) eluting with hexanecethyl acetate (80:20 vv.) to give 13-hydroxy-dibenzo(4hj.11,3-dioxonino-12(13H)-one as a crystalline solid, mp 129-30* (25 g. 0.0975 mol). ¹H NMR (DMSO-d₆) 8 7.49(1,2H), 7.29-7.08(m,6H), 6.40(d,1H), 5.97(d,1H), 5.92(d,1H), 5.24(d,1H).

Part C. A solution of 13-hydroxy-dibenzo[d.h][1,3}-dioxonion-12(13H)-one (2.0 g. 0.0078 mol), thiourea (0.82 g. 0.018 mol) and hexanol (28 m.), equipped with a column of 4 × a sieves and a condenser, was heated to 160 ° for 20 hours under a nitrogen atmosphere. The reaction mixture was allowed to cool to ambient temperature and was diffuled with ethyl either (100 m.) to give a solid. The solid was washed with ethyl either and dried to give Nr(1H,9H-dibenz=(4,58,8)[1,3]dioxonio-[6,7-d]midracyl-zhitione as a white crystalline powder (1.6 g, 0.00539 mol), mp >250 °. ¹H NMR (DMSO-d₆) § 12.5(s,2H), 7.43-7.08 (m,8H), 6.2-5(0dc,2H).

Part D. Employing the method of Example 118, Part E, but using N-(1H,9H-dibenz-[4,58,9][1,3]-dioxonino-[6,7-d]imidazol)-2-thione, the title compound was isolated as a white foam, mp 65-70° (0.85 g, 0.00134 mol). ¹H NMR (CDCl₂) δ 10.35-10.10(bs,1H), 7.56(m,1H), 7.30-6.95(m,10H), 6.4(d,1H), 5.70-5.20-6.95(m,19m,4H), 3.086(.2H), 1.85-1.23(m,16H), 0.880(.3H).

EXAMPLE 212

Preparation of N'-[5-(1H-dibenz[2,3:6,7]oxedino[4,5-d]imidazol-2-ylthio)pentyl]-N-(2,4-diffuorophenyl)-N-hep-tylurea

Employing the method of Example 118, Part E, but using 1H-dibenz[2,3.6,7]oxedino[4,5-d]imidazol)-2-thione, the title compound was isolated as a white powder, mp 82-7* (0.36 g, 0.00059 mol). ¹H NMR (CDCl₂) 5 9.75-9.5(bs, 2H), 7.84-7.59(m,3H), 7.43-7.05(m,6H), 5.13-6.53(m,3H), 3.43-3.13(m,6H), 1.75-1.20-(m.16H), 0.88(3.3H).

50 Additional ureas, which are listed in Tables 1 and 2, were prepared or could be prepared analogously according to the procedures listed above.

S—(CH ₂) _n N—R ⁶ N H ³ O NHR ⁴	
. A. 7. 24.	

	Mp C	86-98	(CH ₂) ₆ CH ₃ amorphous solid	89-91	114-115	(CH ₂) ₆ CH ₃ glassy solid	oil	93-96	78-80	189-190			
	읾	(сн2) есн3	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃ 89-91	(CH2)3CH3 114-115	(сн2) есн3	(CH ₂) ₆ CH ₃ oil	5 (CH ₂) ₆ CH ₃ 93-96	(сн2)6сн3 78-80	2 (СН2)2СН3 189-190	10 (CH2)3CH3	5 СН2СН3	3 (СН2)8СН3
	디	2	2	80	80	2	2	2	2	2	10	2	က
	<u>R</u> 4	2,4-diFC ₆ H ₃	C ₆ H ₅	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diCH30C6H3	2,4-diFC ₆ H ₃	윤	n-C3H7	2,4-diFC ₆ H ₃			
	No. R ¹ R ² R ³	1 С6И5 С6И5 И	2 C6H5 C6H5 H	3 C6H5 C6H5 H	4 C6H5 C6H5 H	5 C6H5 C6H5 H	6 C6H5 C6H5 CH3	7 C6H5 C6H5 H	8 С6И5 С6И5 И	9 С6И5 С6И5 И	10 C6H5 C6H5 H	11 C6H5 C6H5 H	12 C6H5 C6H5 H
Ä	2				,		_		-		=	=	H

5			J dm								99-101												
10			Re	(CH ₂) ₁₀ CH ₃	(CH ₂) 10CH ₃	(CH2)3CH3	(CH ₂) ₆ CH ₃	(CH2)6CH3 99-101	(CH ₂) ₃ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH2) 6CH3	(сн2) есн3	(сн2) 6сн3	(СН2) 6СН3	(CH ₂) ₆ CH ₃	(CH2)3CH3						
10	ê		=	٣	2	8	2	2	2	ა	2	8	2	2	2	2	2	2	2	2	2	S	80
15	Table 1 (continued)		R4	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H3	2,4-diFC ₆ H3	2,4-diFC ₆ H3	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H3	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H3	2,4-diFC ₆ H3	2,4-diFC ₆ H3	2,4-diFC ₆ H3	2,4-diFC ₆ H ₃	2,4-diFC ₆ H3	3-FC6H4	2,4-diFC ₆ H ₃	2,4-diFC ₆ H3	2,4-diFC ₆ H ₃
20	ab le			2,1	2,4	2,4	2,4	2,4	2,4	2,4	2,4	2,4	2,4	2,4	2,4	2,4	2.4	2.4	2,4	3-	2,4	2,4	2,4
25	F		R ³	±	±	CH3	n-C3H7	n-C6H13	CH2CH=CH2	CH ₂ C ₆ H ₅	C6H5	C ₆ H ₅	4-FC6H4	4-CH3C6H4	C6H5 4-CH30C6H4	C6H5 4-CF3C6H4	C6H5 C6H5 4-C1C6H4	3-FC6H4	C6H5 2-FC6H4	C6H5 3-CH30C6H4	30 C6H5 C6H5 3-CH30C6H4	31 C6H5 C6H5 2-CF3C6H4	32 C6H5 C6H5 4-FC6H4
			ሬ	C ₆ H ₅	C6H5	C6H5	C6H5 1	C ₆ H ₅	C6H5	C ₆ H ₅	C6H5	C6H5	C6H5	C6H5 4	C6H5	26H5	26H5	C6H5	26H5	6H5	.6H5	26H5	.6H5
30			^[2]	C6H5	CeH5	CeH5		CeH5	C ₆ H ₅	CeH5	C6H5	CeH5	C6H5	CeH5)	C ₆ H ₅	C6H5 (C6H5 (C ₆ H ₅ (C6H5	C6H5	C6H5 (C6H5 (C6H5 (
		Ĕ.	<u>§</u>	13	14	12	16	17	18	19	20	21	22	23	24	52		27	28	53	30	31	32
35																							

Ĕ.							
<u>8</u>	RJ R	2	R3	R4	⊏I	9 <u>8</u>	J.du
33 C	CeH5 C6	£	C6H5 2-FC6H4	2,4-diFC6H3	æ	(CH ₂) ₃ CH ₃	
34 0	C6H5 C6	£.	C6H5 3-CH30C6H4	2,4-diFC6H3	œ	(CH ₂) ₃ CH ₃	
35 0	C6H5 C6	£,	C6H5 4-CH30C6H4	2,4-diFC ₆ H ₃	æ	(CH ₂) ₃ CH ₃	
36 (C ₆ H ₅ C ₆	托	C6H5 4-CH30C6H4	CeH5	2	(CH ₂) ₅ CH ₃	
37 (C6H5 C6	C ₆ H ₅	===	2-CF3C6H4	æ	(CH ₂) ₆ CH ₃	
38 (C ₆ H ₅ C ₆	휷	-	3-CF3C6H4	2	(CH ₂) ₆ CH ₃	
39 (C6H5 C6	C ₆ H ₅	-	4-CF3C6H4	2	(CH ₂) ₆ CH ₃	
40	C6H5 C6	C ₆ H5	=	2-CH3C6H4	2	(CH ₂) ₆ CH ₃	
41 (C6H5 C6	C ₆ H ₅	*	3-CH3C6H4	2	(сн2) есн3	
45 (CeHs C6	C ₆ H ₅	-	4-CH3C6H4	2	(CH ₂)6CH ₃	
43 (CeHs Ce	돐	_	3-C2H5C6H4	2	(CH ₂) ₆ CH ₃	
44	6. S. C.	C ₆ H ₅	=	3-(CH3)2CHC6H4	2	(CH ₂) ₆ CH ₃	
45 (6. S. C.	C6H5 F	=	2-BrC ₆ H4	2	(CH ₂) ₆ CH ₃	
20	50 C6H5 C6	C ₆ H ₅	=	3-BrC ₆ H4	2	(СН2) 6СН3	
21 (C ₆ H ₅ C ₆	CeHS	=	4-BrC ₆ H ₄	2	(CH ₂)6CH ₃	
25 (C ₆ H ₅ C ₆	C ₆ H ₅	_	2-FC ₆ H4	2	(CH ₂) ₆ CH ₃	
53	C ₆ H ₅ C ₆	C ₆ H ₅	-	3-FC ₆ H4	2	(CH ₂) ₆ CH ₃ 124-126	124-1
5.	C6H5 C6	C6H5	=	4-FC ₆ H4	2	(CH ₂) ₆ CH ₃	
22 (55 C ₆ H ₅ C ₆	C ₆ H ₅	_	3-C1C6H4	2	(CH ₂) ₆ CH ₃	
26 (56 C ₆ H ₅ C ₆ H ₅ H	£	=	4-n-C4H9C6H4	2	(CH2) 6CH3	

			J. du								90-92							78-80					
5			Ձ	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(сн2)есн3	(сн2) 6сн3	(сн2)есн3	(CH ₂) ₆ CH ₃												
10			디	2	2	2	2	2	2	2	2	2	2	2	2	2	2	5	Ŋ	2	S	2	2
15	ntinued)		R4	4-CH30C6H4	4-CH3CH202CC6H4	2,3-diCH ₃ C ₆ H ₃	2,5-diCH ₃ C ₆ H ₃	2,6-diCH ₃ C ₆ H ₃	2,4-diCH3C ₆ H3	2,3-diClC ₆ H ₃	2,6-diClC ₆ H3	2,4-diClC ₆ H ₃	2,5-diClC ₆ H ₃	2,3-diFC ₆ H ₃	2,5-diFC ₆ H ₃	2,4,6-triClC ₆ H2	2,4,5-triClC ₆ H ₂	2,4,6-triFC ₆ H2	2,4,5-triFC ₆ H ₂	3,4,5-triCH30C6H2	.,4,6-triCH3C6H2	4-C1,2-CH3C6H3	4-C1,2,5-diCH3C6H2
20	Table 1 (continued)			4-CH	4-CH	2,3-	2,5-	2,6-	2,4-	2,3-	2,6-	2,4-	2,5-	2,3-	2,5-	2,4,	2,4,	2,4,	2,4,	3,4,	2,4,	4-C1	4-C1
25																							
30			R1 R2 R3	C6H5 C6H5 H	C6H5 C6H5 H	C6H5 C6H5 H		C6H5 C6H5 H	CeH5 CeH5 H	CeHS CeHS H	C6H5 C6H5 H	£9	6H5	C6H5 C6H5 H	C6H5 C6H5 H	69 C6H5 C6H5 H	C6H5 C6H5 H	C6H5 C6H5 H	C6H5 C6H5 H	C6H5 C6H5 H	74 C6H5 C6H5 H	75 C6H5 C6H5 H	76 C6H5 C6H5 H
35		Ë	No.	57	28	59	09	61	9 62 (63	64 (9 69	99	19	89	69	70 0	11	72	73	74	75	76
40																							

		J. dw									68-70									95-97		
10		92	$(CH_2)_6CH_3$	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH2) 6CH3	(CH ₂) ₆ CH ₃ 68-70	$(CH_2)_6CH_3$	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH2) 6CH3	(CH ₂) ₆ CH ₃	$(CH_2)_6CH_3$	(CH ₂) ₆ CH ₃	(сн2)есн3 95-97	$(CH_2)_6CH_3$	(сн2) есн3			
		= 1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
15	(pa			C6H2			5												_			
20	[able 1 (continued)	R4	-C1,3-CF3C6H3	-C1,2,6-diCH3	-С1,4-СН3С6Н3	-C1,4-FC6H3	-с1,2-сн30с6	-C1,5-CF3C6H3	-F,2-СН3С6Н3	-NO ₂ C ₆ H ₄	-CNC ₆ H ₄	-NH2C6H4	4-CH3NHC6H4	-(CH3)2NC6H4	-носен4	-pyridinyl	-pyridinyl	-pyridinyl	,6-pyrimidinyl	C6H11	C5H9	n-C ₆ H ₁₃
25	Tab		4	4	m	3	2	2	4	4	4	4	4	4	4	2	e	4	7	S	٥	-
30		R ² R ³	C6H5 H		С645 И	C6H5 H	C6H5 H	C6H5 H	C6H5 H	C6H5 H	C6H5 H	C6H5 H	сен5 н	C6H5 H	C6H5 H	С645 н	C6H5 H	С645 и	C ₆ H ₅ H	C6H5 H	C6H5 H	сенз н
35	Ē.		77 C6H5	78 C ₆ H5	79 C ₆ H ₅	80 C ₆ H ₅	81 C ₆ H ₅	82 C ₆ H ₅	83 C ₆ H ₅	84 C6H5	85 C ₆ H ₅	86 C ₆ H5	87 C ₆ H ₅	88 C ₆ H5	89 C ₆ H5	90 C ₆ H ₅	91 C ₆ H ₅	92 C ₆ H ₅	93 C ₆ H ₅	94 C ₆ H ₅	95 C ₆ H ₅	96 C ₆ H ₅
40																						
45																						
50																						

5			mp°C	oi1(a)								84-86		oi1(b)			75-80				82-84		
10			શ્રી	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	$(CH_2)_6CH_3$	(CH ₂) ₆ CH ₃	$(CH_2)_6CH_3$	(CH ₂) ₆ CH ₃	(CH2)6CH3	$(CH_2)_6CH_3$	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH2)6CH3	(сн2)есн3	(сн2)есн3	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$	$(CH_2)_6CH_3$			
			디	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	8	œ
15	Table 1 (continued)		R4	n-C8H17	n-C3H7	CF ₃	сн2сн=снсн3	сн2сн=сн2	сн2сн=снсн2сн3	сн₂с≡ссн₃	n-C4H9	сн(сн3)2	CF2CF3	2,4-diFC ₆ H ₃	2,4-diFC6H3	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	n-C ₃ H ₇
	<u>၂</u>		<u>س</u>	=	=	=	=	=	±	Ŧ	×	=	Ŧ	Ŧ	Ŧ	Ŧ	=	Ŧ	=	=	=	Ŧ	=
25 30	Table		R2	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	2-pyridinyl	3-pyridinyl	4-pyridinyl	2-thienyl	Сен5СН2	C6H5(CH2)2	C6H5(CH2)5	4-FC ₆ H4	4-FC ₆ H4	4-FC6H4
35			<u>R</u> 1	, C ₆ H ₅	1 CeH5	· C ₆ H ₅	· C ₆ H ₅	. CeH5	; C ₆ H ₅	, C6H5	1 C6H5	i C ₆ H ₅	i C ₆ H ₅	2-pyridinyl	3-pyridinyl	109 4-pyridinyl	110 2-thienyl	C6H5CH2	; C6H5(CH2)2	, C ₆ H ₅ (CH ₂) ₅	1 4-FC6H4	115 4-FC ₆ H4	116 4-FC ₆ H4
40		Ex.	9	46	98	66	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116

Û

		υ
	•	5
	i	
		=
		-
	4	
	7	=
	¢	-
	Č	0
	Ċ	3
	•	-
	_	_
,	-	
,		
		_
	-	-
	7	5
	7	5
	7	-

Ģ

R6 mp°C	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃ 55-59	(CH ₂)6CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃ 63-65 ⁽¹	(CH ₂) ₆ CH ₃	(сн2) есн3	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₇ CH ₃	
=1	'n	'n	8	80	S	2	80	∞	40	80	'n	'n	'n	'n	2	œ	∞	2	4	
R4	2,4,6-triFC ₆ H ₂	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	n-C ₃ H ₇	2,4,6-triFC6H2	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	n-C3H7	2,4,6-triFC ₆ H ₂	CH ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diCH30C ₆ H3	2,4-diCH3C ₆ H3	2,4,6-triFC ₆ H ₂	4-FC6H4	2,4,6-triFC ₆ H ₂	
2	±	±	±	×	Ŧ	×	=	=	=	#	=	±	×	×	×	×	=	×	=	
땅	4-FC6H4	4-CH30C ₆ H4	4-CH30C6H4	4-CH30C ₆ H4	4-CH30C ₆ H4	4-CH3C6H4	4-CH3C6H4	4-CH3C6H4	4-CH3C6H4	4-(CH3)2NHC6H4	4-NO ₂ C ₆ H ₄	4-CH3SC6H4	4-CH3SOC6H4	4-CH3S02C6H4	4-C1C ₆ H ₄	4-BrC ₆ H4	4-FC6H4	4-CF3C6H4	2-C1C ₆ H4	
립	117 4-FC ₆ H4	18 4-CH ₃ 0C ₆ H ₄	119 4-CH ₃ 0C ₆ H ₄	120 4-CH ₃ 0C ₆ H ₄	121 4-CH ₃ 0C ₆ H ₄	122 4-CH ₃ C ₆ H ₄	123 4-CH ₃ C ₆ H ₄	124 4-CH3C6H4	125 4-CH3C ₆ H4	126 4-(CH3)2NC6H4	127 4-N0 ₂ C ₆ H¢	128 C ₆ H ₅	129 C ₆ H ₅	130 C ₆ H ₅	131 4-C1C6H4	132 4-BrC ₆ H ₄	133 C ₆ H ₅	134 4-CF3C6H4	135 2-C1C ₆ H4	
	R ³ R ⁴ n R ⁶	$rac{R^2}{4-FG644} = rac{R^3}{12} = rac{R^4}{45-triFG642} = rac{R^6}{(CH_2)_6CH_3}$	$\frac{R^2}{4 + Fc6H_4}$ $\frac{R^4}{1 + 2,4,6 - triFC6H_2}$ S $(CH_2)_6CH_3$ $6H_4$ $4 - CH_3OC_6H_4$ H $2,4 - diFC_6H_3$ S $(CH_2)_6CH_3$	R2 R3 R4 n R6 4-FC6H4 H 2,4,6-triFC6H2 5 (CH2)6CH3 6H4 4-CH3OC6H4 H 2,4-diFC6H3 5 (CH2)6CH3 6H4 4-CH3OC6H4 H 2,4-diFC6H3 8 (CH2)6CH3	R2 R3 R4 n R6 4-FC6H4 H 2,4,6-triFC6H2 5 (CH2)6CH3 6H4 4-CH30C6H4 H 2,4-diFC6H3 5 (CH2)6CH3 6H4 4-CH30C6H4 H 2,4-diFC6H3 8 (CH2)6CH3 6H4 4-CH30C6H4 H n-C3H 8 (CH2)6CH3	R2 R3 R4 n R6 4-FC6H4 H 2,4,6-triFC6H2 5 CP2)6CH3 6H4 4-CH30C6H4 H 2,4-diFC6H3 5 CP2)6CH3 6H4 4-CH30C6H4 H 2,4-diFC6H3 8 CP2)6CH3 6H4 4-CH30C6H4 H 2,4-diFC6H2 8 CP2)6CH3 6H4 4-CH30C6H4 H 2,4,6-triFC6H2 5 CP2)6CH3	R2 R3 R4 n R6 n R6 n R6 n L7,6-triFG _R 1 5 (CH2) _G CH3 4 CH2) _G CH3 4 CH2) _G CH3 4 CH2) _G CH3 4 CH2) _G CH3 8 CH2) _G CH3 8 CH2) _G CH3 4 CH2) _G CH3 4 CH2) _G CH3 4 CH3) _G CH3 7 CH3) _G CH3 6 CH3) _G CH3 7 CH3, _G CH3 7	R2 R3 R4 n R6 4-F644 H 2,4,6-triFGeH2 5 (CH2)6CH3 4-CH30C6H4 H 2,4-diFGeH3 5 (CH2)6CH3 4-CH30C6H4 H 2,4-diFGeH3 8 (CH2)6CH3 4-CH30C6H4 H 1-2,4-diFGeH3 8 (CH2)6CH3 4-CH30C6H4 H 2,4,6-triFGeH2 5 (CH2)6CH3 4-CH30C6H4 H 2,4-diFGeH3 5 (CH2)6CH3 4-CH3G6H4 H 2,4-diFGeH3 5 (CH2)6CH3 4-CH3G6H4 H 2,4-diFGeH3 6 (CH2)6CH3 4-CH3G6H4 H 2,4-diFGeH3 8 (CH2)6CH3	R2 R3 R4 n R6 4-FG644 H 2,4,6-triFG6H2 5 (CR2)GCH3 4-CH30C6H4 H 2,4-diFG6H3 5 (CR2)GCH3 4-CH30C6H4 H 2,4-diFG6H3 8 (CH2)GCH3 4-CH30C6H4 H 7.4-diFG6H3 8 (CH2)GCH3 4-CH30C6H4 H 2,4-diFG6H3 8 (CH2)GCH3 4-CH3-G6H4 H 2,4-diFG6H3 5 (CH2)GCH3 4-CH3-G6H4 H 2,4-diFG6H3 5 (CH2)GCH3 4-CH3-G6H4 H 2,4-diFG6H3 8 (CH2)GCH3 4-CH3-G6H4 H 2,4-diFG6H3 8 (CH2)GCH3 4-CH3-G6H4 H 1-diFG6H3 8 (CH2)GCH3	R2 R3 R4 n R6 4-FC6H4 H 2.4,6-triFGeH2 5 (CH2)6CH3 4-CH30C6H4 H 2.4-diFGeH3 5 (CH2)6CH3 4-CH30C6H4 H 2.4-diFGeH3 8 (CH2)6CH3 4-CH30C6H4 H 2.4-diFGeH3 8 (CH2)6CH3 4-CH30G6H4 H 2.4-diFGeH3 5 (CH2)6CH3 4-CH3-G6H4 H 2.4-diFGeH3 8 (CH2)6CH3 4-CH3-G6H4 H -C-3+GFGH3 8 (CH2)6CH3 4-CH3-G6H4 H -C-4-GFGH3 8 (CH2)6CH3 4-CH3-G6H4 H -C-4-GFGH3 8 (CH2)6CH3	R2 R3 R4 n R6 4-FC644 H 2.4.6-triFG6H2 5 (CR2)6CH3 4-CH30C6H4 H 2.4-diFC6H3 5 (CR2)6CH3 4-CH30C6H4 H 2.4-diFC6H3 8 (CR2)6CH3 4-CH30C6H4 H n-C3H7 8 (CR2)6CH3 4-CH30C6H4 H 2.4-diFC6H2 5 (CR2)6CH3 4-CH3C6H4 H 2.4-diFC6H3 5 (CR2)6CH3 4-CH3C6H4 H 2.4-diFC6H3 8 (CR2)6CH3 4-CH3C6H4 H 2.4-diFC6H3 8	R2 R3 R4 n R6 4-FC644 H 2.4,6-triFG6H2 5 (CR2)6CH3 4-CH3OC6H4 H 2.4-diFC6H3 5 (CR2)6CH3 4-CH3OC6H4 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3OC6H4 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3C6H4 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3C6H4 H -C-4-diFC6H3 5 (CR2)6CH3 4-CH3C6H4 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3C6H4 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3C6H4 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3C6H4 H -C-4-diFC6H2 5 (CR2)6CH3 4-CH3C6H3 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3C6H3 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3C6H4 H -C-4-diFC6H3 8 (CR2)6CH3 4-CH3CFCH4 H -C-4-diFC6H3	R2 R3 R4 n R6 n R6 n L7.6-trifceh2 5 (CH2)6CH3 4 CH2)6CH3 4 CH2)6CH3 4 CH3)6CH3 4 CH2)6CH3 CH2)6CH3	R2 R3 R4 n R6 4-F644 H 2.4,6-triFGeh2 5 (CR2)GCH3 4-CH30C6H4 H 2.4-diFGeh3 5 (CR2)GCH3 4-CH30C6H4 H 2.4-diFGeh3 5 (CR2)GCH3 4-CH30C6H4 H 2.4-diFGeh3 8 (CR2)GCH3 4-CH30C6H4 H 2.4-diFGeh3 8 (CR2)GCH3 4-CH3G6H4 H 2.4-diFGeh3 5 (CR2)GCH3 4-CH3G6H4 H 2.4-diFGeh3 5 (CR2)GCH3 4-CH3G6H4 H 2.4-diFGeh3 6 (CR2)GCH3 4-CH3GH4 H 2.4-diFGeh3 8 (CR2)GCH3 4-CH3Geh4 H 2.4-diFGeh3 8 (CR2)GCH3 4-CH3Geh4 H 2.4-diFGeh3 5 (CR2)GCH3 4-CH3C6H4 H 2.4-diFGeh3 5 (CR2)GCH3 4-CH3C6H4 H 2.4-diFGeh3 5 (CR2)GCH3 4-CH3C6H4 H 2.4-diFGeh3 5	R2 R3 R4 n R6 4-F644 H 2.4,6-triFGeh2 5 (CH2)6CH3 4-CH30C6H4 H 2.4-diFGeh3 5 (CH2)6CH3 4-CH30C6H4 H 2.4-diFGeh3 8 (CH2)6CH3 4-CH30Gh4 H 2.4-diFGeh3 8 (CH2)6CH3 4-CH30Gh4 H 2.4-diFGeh3 5 (CH2)6CH3 4-CH3Gh4 H 2.4-diFGeh3 5 (CH2)6CH3 4-CH3Geh4 H 2.4-diFGeh3 8 (CH2)6CH3 4-CH3Geh4 H 2.4-diFGeh3 8 (CH2)6CH3 4-CH3Geh4 H 2.4-diFGeh3 8 (CH2)6CH3 4-CH3Geh4 H 2.4-diFGeh3 5 (CH2)6CH3 4-CH3CGh4 H 2.4-diFGeh3 5 (CH2)6CH3 4-CH3CGh4 H 2.4-diFGeh3 5 (CH2)6CH3 4-CH3CGeh4 H 2.4-diFGeh3 5 (CH2)6CH3 4-CH3CGeh4 H 2.4-diFGeh3 5	R2 R3 R4 n R6 4-F644 H 2.4,6-triF66H2 5 (CH2)6CH3 4-CH30C6H4 H 2.4-diFG6H3 5 (CH2)6CH3 4-CH30C6H4 H 2.4-diFG6H3 5 (CH2)6CH3 4-CH30C6H4 H 7.4-diFG6H3 8 (CH2)6CH3 4-CH30C6H4 H 2.4-diFG6H3 5 (CH2)6CH3 4-CH3C6H4 H 2.4-diFG6H3 8 (CH2)6CH3 4-CH3C6H4 H 2.4-diFG6H3 5 (CH2)6CH3 4-CH3C6H4 H 2.4-diFG6H3 5 (CH2)6CH3 4-CH3SOC6H4 H 2.4-diFG6H3 5 (CH2)6CH3 4-CH3SOC6H4 H 2.4-diFG6H3 5 (CH2)6CH3 4-CH3SOC6H4 H 2.4-diFG6H3	R2 R3 R4 L R6 R7 R6 R7 </td <td>R2 R3 R4 R6 R6<</td> <td>R2 R3 R4 R6 R7 R6 R7 R6<</td> <td>R2 R3 R4 R6 R6<</td>	R2 R3 R4 R6 R6<	R2 R3 R4 R6 R7 R6 R7 R6<	R2 R3 R4 R6 R6<

		J.dm	25-57 (d)																			
		<u>R</u> 9	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(сн2) есн3	(CH ₂) ₆ CH ₃	(сн2) есн3	8 (CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₇ CH ₃	(CH ₂) ₆ CH ₃	(сн2) есн3	(сн2) есн3	(CH ₂) ₆ CH ₃	5 (CH ₂) ₇ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	8 (СН ₂) ₆ СН ₃	5 (CH ₂) ₆ CH ₃
			2	2	2	9	2	2	æ	8	2	9	4	2	2	2	2	9	Ŋ	2	æ	2
Table 1 (continued)			2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	CeH5	n-C3H7	C6H11	2,4-diFC ₆ H3	2,4-diFC ₆ H ₃	n-C ₃ H ₇	2,4,6-triFC ₆ H ₂	2,4,6-triFC ₆ H ₂	2,4-diFC ₆ H ₃	CeHs	2,4-diCH30C6H3	2,4-diFC6H3	CeH5	2,4-diCH3C6H3	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	CeH5	2,4-diFC ₆ H ₃
7		3	×	Ŧ	±	=	×	×	×	×	±	×	±	×	±	±	Ŧ	=	×	Ŧ	=	×
Tab		<u>R</u> 2	4-C1C6H4	3-C1C6H4	4-nC4H9C6H4	C6H5	3-pyridinyl	3-pyridinyl	3-pyridinyl	3-pyridinyl	3-pyridinyl	3-pyridinyl	2-thienyl	2-thienyl	2-thienyl	4-pyridinyl	4-pyridinyl	4-pyridinyl	2-pyridinyl	CeH5	4-FC6H4	C6H ₅
	Ex.	No. R1	137 4-C1C6H4	138 4-FC ₆ H ₄	139 4-nC4H9C6H4	140 3,4-diClC ₆ H ₃	141 C ₆ H ₅	142 C ₆ H ₅	143 C ₆ H ₅	144 C ₆ H ₅	145 4-FC ₆ H4	146 4-CH30C6H4	147 C ₆ H ₅	148 4-FC ₆ H4	149 4-CH30C6H4	150 C ₆ H ₅	151 4-FC ₆ H4	152 4-CH ₃ 0C ₆ H ₄	153 C ₆ H ₅	154 3-F, 4-C1C6H3	155 4-CH ₃ 0C ₆ H ₄	156 4-FC ₆ H4
	_	_,																				

) di				oil(e)																
5		શ્ર	(CH ₂) ₆ CH ₃	(СН2) 6СН3	(CH ₂) ₅ CH ₃	(CH ₂) ₆ CH ₃	(СН2) 6СН3	(CH ₂) ₆ CH ₃	(СН2) 6СН3	CH2)6CH3	(CH ₂) ₆ CH ₃	(сн2) есн3	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	CH2)6CH3	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(сн2) 5сн3			
10		=1	2	80	6	5	2	8	2	2	8	8	2	8	8	8	2	2	8	2	~	6
15	Table 1 (continued)	R4	2,4-diFC ₆ H3	2,4-diCH30C6H5	C ₆ H ₅	2,4-diFC ₆ H ₃	2,4-diCH30C ₆ H3	2,4-diFC ₆ H ₃	n-C3H7	2,4-diFC ₆ H3	2,4-diFC6H3	C6H5	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	n-C3H7	2,4-diCH30C6H3	2,5-diClC ₆ H ₃	2,4-diFC ₆ H3	2,4-diFC ₆ H3	2,4-diCH30C6H3	n-C3H7	n-C3H7
20	1	23	=	=	×	=	×	=	×	×	· =	=	=	×	×	×	=	×	=	=	=	=
25	Tabl	R2	C ₆ H ₅	C ₆ H ₅	3,4-diCH3OC6H3	=	×	=	*	*	×	I	CH3	CH3	CH ₃	CH3	CH3	n-C4Hg	n-C4Hg	n-C4Hg	n-C4Hg	n-C8H17
30 35		R1	4-BrC6H4	158 4-CH ₃ 0C ₆ H ₄	159 3,4-diCH30C6H3	160 C ₆ H ₅	161 C ₆ H ₅	162 C ₆ H ₅	163 C ₆ H ₅	164 4-FC ₆ H4	165 4-CH30C6H4	166 C ₆ H ₅	167 C ₆ H ₅	168 C ₆ H ₅	169 C ₆ H ₅	170 C ₆ H ₅	4-FC6H4	172 C ₆ H ₅	173 C ₆ H ₅	174 C ₆ H ₅	175 C ₆ H ₅	176 C ₆ H ₅
	<u>ж</u>	9	157	158	159	160	161	162	163	164	165	166	167	168	169	170	17	172	173	174	175	176
40																						

5			J.dui										oil(f)		91-93	144-146	02-89	187-189	119-121	78-80	80-83 (HCl salt)	100-102	(b)
15			92l U	4 (CH ₂) ₇ CH ₃	8 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₈ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	8 (CH ₂) ₆ CH ₃	8 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	8 (СН2)6СН3	5 (CH ₂) ₆ CH ₃	2 (CH ₂) ₆ CH ₃	5 (CH ₂) ₂ CH ₃	2 н	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃
20	Table 1 (continued)		R4	2,4-diC1C ₆ H ₃	2,4-diFC ₆ H ₃	,4,5-triC1C ₆ H2	C ₆ H ₅	2,4-diFC ₆ H ₃	,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	n-C ₃ H ₇	2,4,6-triFC ₆ H2	',4-diFC _{6H3}	,4-diFC ₆ H ₃	,4-diFC ₆ H ₃	.,4-diFC ₆ H ₃	,4-diFC ₆ H ₃	',4-diFC ₆ H ₃	(C ₆ H ₄) (C ₆ H ₅)	,4-diFC ₆ H ₃	',4-diFC ₆ H ₃	,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃
25	Table 1		낊	н 2,	Н 2,	Н 2,	9° ±	=	=	=	±	H 2,	Н 2,	Ξ	н 2	н 2	H 2	±	=	Ξ	±	=	н 2,
30			묎	n-CgH17	C5H9	C5H9	C6H11	C6H11-CH2	C6H11-(CH2)2	CH3	CH3	n-C4Hg	-	=	(СН3)5СН	CeH5	C6H5	C6H5	CeHs	сн3сн2сн2	2-pyridinyl	3-CH30C6H4	2-CH30C6H4
35					Ü	Ü		Ü	J	Ü	Ö	_	_	_		_	J	J					•
40			R1		C6H5	C ₆ H ₅	4-CH30C6H4	181 C ₆ H ₅	182 C ₆ H ₅	CH3	CH ₃	185 n-C4Hg	186 н	±	188 (СН3)2СН	189 C ₆ H ₅	C ₆ H ₅	191 C ₆ H ₅	192 C ₆ H ₅	193 СН3СН2СН2	2-pyridi	195 3-СН30С6Н4	196 2-CH30C6H4
45		Ē.	No.	171	178	179	180	181	182	183	184	185	186	187 н	188	189	190	191	192	193	194	195	196

			-	Table 1 (continued)	ě	÷.	
Ë.							
No.	No. R.	R2	2	R4	⊏ I	Re	mp*C
197	197 4-(CH3)2NC6H4	4-(CH3)2NC6H4	Ŧ	2,4-diFC ₆ H ₃	2	5 (CH ₂) ₆ CH ₃	(h) 04-70
198	198 4-(CH ₃) ₂ NC ₆ H ₄	4-(CH3)2NC6H4	×	2,4-diFC6H3	2	5 (CH ₂) ₆ CH ₃	142-145 (HCl salt)
199	199 C ₆ H ₁₁	C6H11	=	2,4-diFC ₆ H ₃	2	(CH ₂) ₆ CH ₃	55-58(i)
200	200 C ₆ H ₅	4-(CH3)2NC6H4	=	2,4-diFC ₆ H ₃	2	(CH ₂) ₆ CH ₃	011(3)
201		2-furanyl	=	2,4-diFC ₆ H ₃	2	(CH ₂) ₆ CH ₃	liq(k)
202	202 4-CH306H4	4-CH30C6H4	=	CH ₂ (CH ₃) ₂	2	(CH2) 6CH3	(1)
203	203 4-(t-C4H9)C6H4 4-(t-C4H9)C6H4	4-(t-C4H9)C6H4	=	2,4-diFC ₆ H ₃	S	(CH ₂) ₆ CH ₃	78-80 (m)
204	204 4-CH30C ₆ H4	4-CH30C6H4	=	2,4-diFC ₆ H ₃	S	5 CH ₃	65-75(n)
202	205 4-(CH3)2NC6H4	4-(CH3)2NC6H4	=	СН(СН3)2	2	(CH ₂) ₆ CH ₃	70-72(0)
506	206 C ₆ H ₅	CeHS	=	(CH ₂) ₇ CH ₃	'n	2,4,6-triFC6H2	oil(p)
207	207 C ₆ H ₅	CeHs	=	(CH ₂) ₇ CH ₃	2	CeHs	74-76
208	208 C ₆ H ₅	CeHs	=	(CH ₂) ₇ CH ₃	S	2,4,6-triFC6H2	99-101
209	209 4-HOC ₆ H ₄	4-HOC6H4	=	£	2	5 (CH ₂) ₆ CH ₃	110-112
210	210 (СИ3)2СИ	(CH ₃) ₂ CH	=		2	(CH ₂) ₆ CH ₃	oil(q)
211	С644-2-0СН20-2'-С6Н4	.2C6H4	=	2,4-diFC ₆ H ₃	2	(CH ₂) ₆ CH ₃	65-70
212	C6H4OC6H4	. 4	=	2,4-diFC ₆ H ₃	2	(CH ₂) ₆ CH ₃	82-87
213	213 n-C ₃ H ₇	n-C3H7	=	n-C3H7	2	5 (CH ₂) ₆ CH ₃	
214	214 2-pyridinyl	2-pyridinyl	=	C6H11	2	5 (CH ₂) ₆ CH ₃	
215	215 3-pyridinyl	3-pyridinyl	=	2,4-diCH30C6H3 5 (CH2)6CH3	2	(CH ₂) ₆ CH ₃	
216	216 4-pyridinyl	4-pyridinyl	=	2,4,6-triFC6H2 5 (CH2)6CH3	S	(CH ₂) ₆ CH ₃	

		J. Om																				
5		R ₆	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	5 (CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH2)6CH3	(CH ₂) ₃ CH ₃	(CH ₂) ₈ CH ₃	CH3	5 C6H5	3-FC6H4	(CH ₂) ₃ CH ₃
10		-			٠.		٠,	٠,	٠.	٠,	۵,	٠,	""	٠٠,	w	w	u,	u,	4,	u,	u,	Ľ
15	Table 1 (continued)	₩ ₩	3-FC6H4	СН(СН3)2	C6H5	(CH ₂) ₇ CH ₃	2,6-diClC ₆ H ₃	CH3	(C6H4) (C6H5)	2,4-diFC ₆ H ₃	C6H11	C6H5	2,4-diFC ₆ H ₃	C6H11	2,4-diFC ₆ H3	C6H11	2,4-diFC ₆ H3	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC6H3	(СН2) 7СН3
20	able 1	<u>س</u>	Ŧ	Ŧ	=	±	±	Ŧ	±	(3	CH3	뜐	=	=	=	=	±	±	±	±	СН2СН3	C ₆ H ₅
25	I	~	2-CH30C ₆ H4	3-CH30C6H4	C6H11	220 C6H5 4-(CH3)2NC6H4 P	2-furanyl	1 4-(t-C4H9)C6H4	2-thienyl	4-H0-C ₆ H4	(сн3) 5сн	C6H5-CH2	:'-C6H4	,6H4	4-CH3C6H4	4-(CH3)2NC6H4	C6H11	(СН3) 5СН	C6H11	(СН3) 2СН	(СН3)5СН	4-CH30C6H4
35		R1	217 2-CH ₃ 0C ₆ H ₄	218 3-CH30C6H4	219 C6H11	C ₆ H ₅	2-furanyl	4-(t-C4H9)C6H4	2-thienyl	4-H0-C ₆ H4	225 (СН3)2СН	226 C ₆ H5-CH2	C6H4-2-0	C6H40C6H4	229 4-CH ₃ 0C ₆ H ₄	230 4-СН30С6Н4	231 4-CH ₃ 0C ₆ H ₄	232 4-CH ₃ 0C ₆ H ₄	233 4-(CH3)2NC6H4	234 4- (CH3) 2NC6H4	235 C6H11	236 C ₆ H ₅
40	2	No.	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236

	Table 1 (continued)	1 (cont	inued)		
겙	<u>M</u>	~ !	R4	ΕI	<u>8</u>
4-(CH3)2NC6H4		CH ₂ C ₆ H ₅	(CH ₂) ₇ CH ₃	2	C6H5
C6H11	Ŧ		n-C3H7	2	(CH ₂) ₆ CH ₃
(CH ₃) ₂ CH	=		C6H11	2	$(CH_2)_6CH_3$
1-CH3SC6H4	H4 H		2,4-diCH30C ₆ H3	S	(CH ₂) ₆ CH ₃
1-CH3SC6H4	H4 H		2,4,6-triFC ₆ H ₂	2	(CH ₂) ₆ CH ₃
1-CH3SO2C6H4	C6H4 H		3-FC ₆ H ₄	2	(CH ₂) ₆ CH ₃
4-CH3SC6H4	Н4 Н		СН(СН3)2	2	(CH ₂) ₆ CH ₃
-сн ₃ S0С ₆ H ₄	.6H4 H		C ₆ H ₅	ß	(CH ₂) ₆ CH ₃
4-СН3502С6Н4	C ₆ H ₄ H		(CH ₂) ₇ CH ₃	2	(CH ₂) ₆ CH ₃
CH ₃ 0С ₆ H ₄	Н4 Н		n-C3H7	ß	(CH ₂) ₆ CH ₃
4-сн30сен4	Η H		C6H11	2	(CH ₂) ₆ CH ₃
-сн30сен4	H Н		C ₆ H ₅	2	(CH ₂) ₆ CH ₃
4-сн30С6Н4	Н4 н		2,4-diFC ₆ H ₃	m	(CH ₂) ₆ CH ₃
-сн30сен4	Н4 Н		C6H11	æ	(CH ₂) ₆ CH ₃
1-CH30C6H4	H H		(CH ₂) ₇ CH ₃	2	C ₆ H ₅
4-(CH3)2NC6H4	NC6H4 H		n-C3H7	2	(CH ₂) ₆ CH ₃
4-(CH3)2NC6H4	NC ₆ H ₄ H		C6H11	2	(CH ₂) ₆ CH ₃
4-(CH3)2NC6H4	NC ₆ H ₄ H		C6H5	2	(CH ₂) ₆ CH ₃
4-(CH3)2NC6H4	NC6H4 H		2,4-diFC ₆ H ₃	m	(CH ₂) ₆ CH ₃
4-(CH3)2NC6H4	MC.U. U		C6H11	œ	(CH ₂) ₆ CH ₃
4-(CH3)2NC6H4	eud		(CH2)-(CH2)	ď	CAHR

Footnotes to Table 1

5

10

15

20

25

30

35

40

45

50

- (a) 1_H NMR (CDCl₃) δ 11.6(s,1H), 7.7-7.1(m,10H),
 4.4(t,1H,J=5Hz), 3.4(t,2H,J=6.7Hz), 3.2-2.9(m,5H),
 1.8-1.0(m,29H), 1.0-0.8(m,7H).
- (b) ¹H NMR (CDCl₃) δ 8.79-7.63(m,7H), 7.29-7.12(m,2H), 6.87-6.73(m,2H), 6.44(bs,1H), 3.34-3.08(m,6H), 1.83-1.18(m,16H), 0.86(t,3H).
- (C) 1H NMR (CDC1₃) δ 10.6-10.0(bs.1H), 7.80(m,1H),7.35-7.00(m,8H), 6.8-6.57(m,2H) 6.4(bs.1H), 3.89(t,2H), 3.25(t,2H), 3.00(t,2H) 2.33(s,3H), 2.32(s,3H), 1.79-1.29(m,16H), 0.88(t,3H).
- (d) 1H NMR (CDC1₃) δ 11.1-11.0(bs,1H), 7.64(m,1H), 7.5(d,2H), 7.27(m,6H), 6.75(m,1H), 6.53(m,1H), 6.33(bs,1H), 3.45(t,2H), 3.26(t,2H), 2.98(t,2H), 1.82-1.25(m,16H), 0.90(t,3H).
- (e) 1H NMR (CDC1₃) δ 10.8-10.7(m,1H), 8.0-7.2(m,7H), 6.9-6.6(m,2H), 6.0-5.9(m,1H), 3.4(t,2H,J=6.6H2), 3.3(t,2H,J=7.6H2), 3.0(t,2H,J=6.5H2), 1.9-1.2(m,18H), 0.9(t,3H,J=7.2Hz).
- (f) 1 H NMR (CDCl₃) δ 10.4-10.1(m,1H), 8.0-7.8(m,1H), 7.2-6.9(m,2H), 6.9-6.75(m,2H), 6.5-6.4(m,1H), 3.4-3.2(m,4H), 3.0(t,2H,J=7Hz), 1.9-1.1(m,19H), 0.9(t,3H,J=8Hz).
 - (g) 1 H NMR (DMSO-d₆) δ 12.17(bs,1H), 7.94(bs,1H), 7.43-6.77(m,11H), 3.57(s,3H), 3.24(m,4H), 3.19(s,3H), 3.07(t,2H), 1.76-1.18(m,16H), 0.85(t,3H).
 - (H) 1H NMR (CDCl₃) δ 10.03-9.55(bs,1H), 7.86(m,1H), 7.58-7.20(bm, 4H), 6.82-6.61(m,6H), 6.42(bs,1H), 3.30-3.21(m,2H), 2.94(bs,1H), 1.78-1.26(m,16H), 0.88(t,3H).
 - (1) ¹H NMR (CDC1₃) δ 9.50-9.18(bs,1H), 7.97(m,1H), 6.80(m,2H),6.41(bs,1H), 3.31(m,4H), 2.86(t,2H), 2.68-2.37(m,2H), 1.91-1.13(m,36H), 0.89(t,3H).
- (j) 1_H NMR (CDC1₃) δ 10.2-9.8(bs,1H), 7.85(m,1H), 7.70-7.16(m,7H), 6.75(m,1H), 6.89(d,3H), 6.39(bs,1H), 3.38(t,2H), 3.25(t,2H), 3.01(t,2H), 2.95(s,6H), 1.85-1.25(m,16H), 0.9(t,3H).

Footnotes to Table 1 (continued)

- (k) ¹H NMR (CDC1₃) δ 10.35-10.15(bs,1H), 7,95(m,1H), 7.50-7.36(m,2H), 6.98-6.69(m,4H), 6.49-6.38(m,3H), 3.35(t,2H), 3.25(t,2H), 3.05(t,2H), 1.79-1.27(m,16H), 0.90(t,3H).
 - (1) 1H NMR (CDC1₃) δ 7.47(d,4H), 6.84(d,4H), 4.12(d,1H), 3.84(m,1H), 3.80(s,6H), 3.33(t,2H), 3.07(t,2H), 2.96(t,2H), 1.8-1.24(m,16H), 1.08(d,6H), 0.90(t,3H).
 - (m) 1_H NMR (CDC1₃) δ 10.15-10.0(bs,1II), 7.82(m,1H), 7.53(m,2H), 7.31(m,6H), 6.73(m,1H), 6.61(m,1H), 3.4(t,2H), 3.26(t,2H), 3.00(t,2H), 1.82-1.49(m,12H), 1.33(bs,22H), 0.9(t,3H).
 - (n) 1H NMR (CDC1₃) δ 10.8-10.76(bs,1H), 7.70(m,1H), 7.15(m,2H), 7.31(m,2H), 6.82(m,4H), 6.73(m,1H), 6.58(m,1H), 6.40(bs,1H), 3.8(s,6H), 3.46(t,2H), 3.01(s,3H), 2.94(t,2H), 1.78-1.44(m,6H).
 - (o) 1_{H NNR} (CDC1₃) δ 7.56-7.33(bs,4H), 6.67(d,4H), 4.11(d,1H), 3.89(m,1H), 3.3(t,2H), 3.08(t,2H), 2.95(bs,14H), 1.84-1.25(m,16H), 1.1(d,6H), 0.9(t,3H).
- (p) 1H NMR (CDC1₃) δ 7.7-6.9(m,14H), 4.1(t,1H,J=5.4Hz), 3.8-3.65(m,2H), 3.1-2.9(m,4H), 1.9-1.0(m,18H), 0.85(t,3H,J=6.7Hz).
 - (q) 1H NMR (DMSO-d₆) δ 11.58(s,1H), 5.71(d,1H), 3.75(m,1H), 3.07(t,4H), 2.95-2.78(m,4H), 1.57-1.1(m,16H), 1.14(d,6H), 1.10(d,6H), 1.03(d,6H), 0.85(t,3H).

EXAMPLE 267

5

10

15

20

25

30

35

40

Preparation of N'-(2,4-difluorophenyl)-N-I5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylthiourea

Employing the method of Example 1, Part E, using 2,4-diffluorophenylisothiocyanate (0.14 g, 0.0008 mol), the title compound (0.19 g, 0.00031 mol) was obtained as a white solid, mp 116-118*. ¹H NMR (CDCl₂) 8 9.5-9.4(s,1H), 7.8-7.1(m,11H), 7.0-6.7(m,3H), 3.8(t,2H,J=7.6Hz), 3.6(t,2H,J=7.8Hz), 3.1-(t,2H,J=7Hz), 1.9-1.1(m,18H), 0.9(t,3H,J=4Hz).

50 EXAMPLE 269

Preparation of N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylsulfinyl)pentyl]-N-heptylurea

To a solution of N-(2,4-dfibucrophery)N-NE-(4,5-diphery)+IH-imidazol-2-ythio)penty[I-N-heptylurea (0.59 g, 0.001 mol) in methylene chloride (60 mL) cooled to '78' was added, dropwise, a solution of meta-chloroperbenzoic acid (0.286 g, 0.0017 mol) in methylene chloride (10 mL). The reaction mixture was stirred at -78' for 1 hour and then allowed to warm to ambient temperature. The reaction mixture was then cooled to 0' and then added, dropwise, was a solution of saturated sodium bisulifie. The layers were separated

and the organic layer was washed with saturated sodium bisulfile. The layers were separated and the sodium chloride solution, dried over magnesium sulfate, and concentrated under vacuum. The residue (0.76 g) was chromatographed with 1:1 hexame-ethyl acetate to give the title compound (0.43 g, 0.00071 mol) as a yellow solid, mp 77-79'. 'It MMR (CDCls) & 8.1-7.9(m,11H), 7.6-7.2 (m,10H), 6.9-6.7(m,2H), 6.4-5 (1,H,I), -3.3.Hz), 3.4-3. (Inchl), 2.0.1-1.(Inslh), 0.9(3.Hz), 12-6.4Hz).

EXAMPLE 272

10

25

30

35

an

45

50

55

Preparation of N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurea

To a solution of N-(2-4-difluoropheny)-N-(5-4,5-dipheny)-H-Himidazoi-2-ythiolpheny)-N-hepplyurea (0.11 g, 0.00019 mo) in methanol (5 ml.) was added, portionwise as a solid, Oxone* (0.234 g, 0.0038 mol) and the reaction mixture was stirred at ambient temperature for 7 hours. The solids were filtered and washed with methanol. The filtrate was concentrated under vacuum and the residue was chromatographed with 64 hexane-ethyl acetate to give the title compound (0.06 g, 0.000096 mol) as a glassy, colorless solid, mp 66-68*. 'H NMR (CDCI) § 7.68-7.76(m.1H), 7.67-1(m.1H), 6.8-6.6(m.2H), 6.4(s.1H), 3.4(t.4H.J = 10Hz), 3.25(t.2H.J = 7Hz), 1.9-1.75(m.2H), 1.75-1.4(m.6H), 1.4-1.1(m.8H), 0.9(3.4H.J = 9Hz).

EXAMPLE 329

Preparation of N'-(2,4-diffuorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)phenyl]-N-heptylurea

Part A. A solution of 2-bromo-4,5-diphenyl-1H-imidazole (3,5 g, 0.0117 mol) in 1,5-diaminopentane (20 mL) was heated to reflux for 48 hours. The reaction mixture was concentrated in vacuo to give a viscous oil which was taken up in methylene chloride (80 mL) and washed with 10% aqueous NaHcO₃, water (2 x 50 mL), brine, dried over magnesium sulfate and concentrated in vacuo to give 5-(4,5-diphenyl-1H-imidazol-2-ylamino)aminopentane as a viscous oil (3,5 g, 0.0109 mol). "IH NMR (CDCl₃) 8 7,55-7.09-(m,10H), 47-93-79(bs,3H), 3.14(£2H), 2.59(£2H), 1.79-1.22(m,6H).

Part B. To a solution of 5-(4,5-diphenyl-1H-imidazol-2-ylamino)aminopentane (1.7 g. 0.00531 mol) and triethylamine (0.58 g. 0.0058 mol) in methylamine cooled to 0° under a nitrogen atmosphere, heptanoyl chloride (0.788 g. 0.00531 mol) was added slowly. The reaction mixture was stirred for 1 hour at 0°, poured into water and extracted with methylene chloride (2 x 50 mL). The combined organic extract was washed with water, brine, dried over magnesium sulfate and concentrated to give N-15-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl/peptanamide as a viscous oil. The product was purified by flash chromatography on sities gel (250 mL) oluting methylene chloridemethanol (955 xy), to give an amber foam (1.3 g. 0.003 mol). 'H NMR (CDCl_b) δ 7.43-7.15(m,10H), 6.3(m,1H), 3.24-3.1(m,4H), 2.09-(1.2H), 1.8-1.16(m,14H), 0.48(1.3H).

Part C. Employing the method of Example 118, Part B, but using N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]heptaamide, N-[5-(4,5-diphenyl-1H-imidazol-2-ylamino)pentyl]hN-heptylamine was obtained as an amber oil (1.00 g, 0.00238 mol). ¹H NMR (CDCl₅) \$7.56-6.85(m,10H), 3.23(m,2H), 2.49-(m,4H), 1.69-0.90(m,16H), 0.88(i,3H).

Part D. Employing the method of Example 118, Part C, but using N-[5-(4,5-diphenyl-1H-imidazol-2-ylaminoipentyl]-N-heptylamine, the title compound was obtained as a yellow foam (0.395 g, 0.000688 mol). 'H NMR (CDCl₃) δ 8.37-7.1(m,11H), 6.9-6.67(m,2H), 6.44(d,1H),4.53(bs,1H), 3.27(m,6H), 1.74-1.23-(m,16H), 0.99t(.3H).

EXAMPLE 330

Preparation of N'-(2,4-difluorophenyl)-N-[6-(4,5-diphenyl-1H-imidazol-2-yl)hexyl]-N-heptylurea

Part A. To a solution of 4,5-diphenyh1-I{dtimethylsilyhethoxymethyl}:H-Imidazole (2.5 g, 0.00734 mo) (B. Lipshutz, B. Huff, W. Hazen, Tetrahedron Letters, 29, 3411-14, 1988), in dry tetrahydrofuran (50 mL) cooled to -78* under a nitrogen atmosphere, n-butyl lithium in hexane (2.5 M, 0.00734 mol) was added slowly. The reaction mixture was stirred for 1 hour and 1,6-dibromohexane (2.68 g, 0.0011 mol) was added rapidly, stirred for 12 hour and was allowed to warm to ambient temperature and stirred for 2 additional hours. The reaction mixture was poured into water and extracted with ethyl acetate (2 x 50 mL). The combined organic layer was washed with water, brine, dried over magnesium suitate and concentrated to give a viscous oil. The product was purified by flash chromatography on sliica gel (250

mL) eluting with hexane:ethyl acetate (70:30 v:v) to give 6-bromo-1-(4,5-diphenyl-1-[(trimethylsily)-ethoxymethyl]piindsod-2-yl)hexane as an oil (2.18 g, 0.00424 mol). ¹H NMR (CDCl₃) a 7.53-7.16(m,10H), 5.10s.2H), 3.48(l.2H), 3.34(l.2H), 2.90(l.2H), 1.99-1.5(m,8H), 0.875(l.2H), 0.008(s.9H).

Part B. A solution of 6-bromon-1-4,5-diphenyl-1-f(trimethylsily)/ethoxymethyl-1-H-inidazol-2-y)/hexane (1.0 g., 0.00195 mol) and n-heptylamine (0.45 g., 0.00389 mol) in acclontific (25 mL) was heated to 60 for 8 hours. The reaction mixture was poured into 10% aqueous sodium bicarbonate and extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with water, brine, dried over magnesium sulfate and concentrated to give N-[6-4(4-5-diphenyl-1-f(timethylsily)/ethoxymethyl-1-H-inidazol-2-y)/hexyl-1-N-eptylamine as colorless viscous oil (1.04 g. 0.00189 mol). H MMR (CDCl₃) 8 7.52-7.2(m.10H), 5-1(1.62H), 4.7-4.2(bs.1H), 3.3(1.2H), 2.98-2.7(m.6H), 1.95-1.34(m.18H), 0.33(3H), 0.98-

7.2(m,10H), 5.11(s,2H), 4.7-4.2(bs,1H), 3.3(t,2H), 2.93-2.70(m,6H), 1.95-1.34(m,18H), 0.93(t,3H), 0.86-(t,2H), 0.005(s,9H).
Part C. Employing the method of Example 118, Part C, but using N-[6-(4,5-diphenyl-1-[(trimethylsityl)-ethoxymethyl-imida.zole-2-v)hexyl-N-heptylamine.
N*2.4-difluorophenyl-N-16-(4,5-diphenyl-1-1-

(trimethylsily)jethoxymethylj-imidazole-2-yl)hexyl}-N-heptylurea was isolated as a viscous oil (1.40 g. 0.00199 mol). ¹H NMR (CDCl₃) & 8.12(m,1H), 7.53-7.16(m,10H), 6.88(m,2H), 6.48(d,1H), 5.1(s,2H), 3.33-(m,6H), 2.90(,2H), 2.0-1.34(m,18H), 0.88(,3H), 0.79(,2H), 0.055(s,9H).

Parl D. To a solution of N-(2,4-diffluorophenyl)-N-[6-(4,5-diphenyl-1-[(trimethylsily)]ethoxymethyl]-1Himidazol-2-y)[hexyl]-N-heptylurea (0.60 g. 0.000583 mol) in dry tetrahydrofuran (10 mL) under a nitrogen
atmosphere, tetrabutylammonium fluoride (1 Min I tetrahydrofuran, 3.41 mL), was added and the reaction
mixture was heated to reflux 7 hours. The reaction mixture was cooled, poured into water (50 mL) and
extracted with ethyl acetate (2x50 mL). The combined organic layer was washed with water, brine, dried
over magnesium sulfate and concentrated in vacuo. The product was purified by flash chromatography
on silica gel (75 mL) eluting hexane:ethyl acetate (60:40 v:v) to give the title compound as a colorless
glass (0.26 g. 0.000454 mol). ¹H MIMI (CDCh) s 8.5-9.0(bs.1H), 7.87(m,1H), 7.5-7.2(m,10H), 6.83-6.7(m.2H), 6.4(1.H), 3.28(m,4H), 2.67(2.H), 1.75-1.26(m,18H), 0.88(3.H).

		O di										116-118	
		હ્યુ	(CH ₂) ₆ CH ₃	(CH2) 6CH3	(CH2) 6CH3	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH2) ₆ CH3	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃	(CH ₂) ₆ CH ₃ 116-118	(CH ₂) ₆ CH ₃
		= 1	S	2	8	œ	2	æ	œ	2	2	2	8
-R ⁶ NHR ⁴		>-I	0	0	0	0	S	0	0	0	0	S	S
 		×I	0	0	0	0	0	0	0	0	0	s	S
N		R4	2,4-diFC ₆ H ₃	2,4-diCH30C ₆ H3	2,4-diFC6H3	n-C3H7	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4,6-triFC ₆ H ₂	2,4,6-triFC ₆ H ₂	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		ଅ	<b>=</b>	<b>=</b>	<b>±</b>	<b>±</b>	=	CH3	C6H5	=	<b>=</b>	=	=
		묎	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	4-FC ₆ H4	3-pyridinyl	C ₆ H ₅	4-FC6H4
		RJ	258 C ₆ H ₅	259 C ₆ H ₅	C ₆ H ₅	261 C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	264 C ₆ H ₅	265 4-FC ₆ H4	266 C ₆ H ₅	267 C ₆ H ₅	268 4-FC ₆ H ₄
	<u>а</u>	Š	228	259	560	261	262	263	264	265	266	267	268

6			O. CIM	97-77			89-99															
10			₩ ₆	(CH ₂ ) ₆ CH ₃	(CH ₂ )8CH ₃	(CH ₂ ) ₅ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH2) ACH2	(CH2) 6CH2	(CH ₂ ) ₆ CH ₃	(CH2) 5CH3										
15			E	'n	89	2	2	80	œ	'n	2	2	2	80	4	7	2	80	9	2	æ	4
			<b>&gt;-</b> I	0	0	0	0	0	0	S	0	0	0	0	0	0	0	0	0	0	0	0
20	(par		×I	S0	80	S0	202	202	202	202	. Z ₀ S	¥	¥	¥	₹	¥	NCH ₃	NCH ₃	NCH ₂ C ₆ H ₅	NCH ₂ C ₆ H ₅	NC3H7	NC3H7
25	able 2 (continued)			6H3	6H3		6H3	6H3				iFC ₆ H ₂	30C ₆ H ₃	6H3			6H3	6H3		iFC ₆ H ₂	C6H3	,4,5-triCH30C ₆ H ₂
30	Table		₽.J	2,4-diFC ₆ H3	2,4-diFC	n-C3H7	2,4-diFC	2,4-diFC	n-C3H7	n-C3H7	n-C3H7	2,4,6-triFC ₆ H ₂	2,4-diCH	2,4-diFC	n-C5H11	CeH5	2,4-diFC	2,4-diFC	n-C3H7	2,4,6-triFC ₆ H ₂	2,4-diClC ₆ H ₃	3,4,5-tr
35			ଅ	=	=	=	=	=	=	Ŧ	뜐	=	=	=	Ŧ	£	Ŧ	Ŧ	Ŧ	=	Ŧ	Ŧ
40			ZJ	C ₆ H ₅	C6H5	C6H5	C6H5	C ₆ H ₅	C ₆ H ₅	C6H5	C ₆ H ₅	C6H5	C ₆ H ₅	C ₆ H ₅	4-FC6H4	C ₆ H ₅	C ₆ H ₅	C6H5	C ₆ H ₅	C ₆ H ₅	C6H5	C ₆ H ₅
45			딥	C6H5	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C6H5	C ₆ H ₅	C6H5	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅					C ₆ H ₅			C ₆ H ₅	C ₆ H ₅
50		Ä	No.	569	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287

45	40	35	25 30	20	,,,	15	10	5
*			<u> Table 2</u> (continued)	inued)				
No. R ¹	R ²	₈ 3	R4	×I	≻∣	<b>C</b> I	બ્રી	) Om
		<b>±</b>	CH ₃	NC ₆ H ₁₃	0	2	(CH ₂ ) ₆ CH ₃	
		=	2,4,6-triFC ₆ H ₂	S	S	2	(CH ₂ ) ₆ CH ₃	124-126
		=	(CH ₂ ) ₂ CH ₃	S	S	2	(CH ₂ ) ₆ CH ₃	89-91
		<b>±</b>	3-FC6H4	S	S	2	(CH ₂ ) ₆ CH ₃	161-163
		=	C6H11	풒	0	2	(CH ₂ ) ₆ CH ₃	
293 (СН3)2СН		=	2,4-diCH30C6H3	CH ₂	0	2	(CH ₂ ) ₆ CH ₃	
294 4-CH ₃ 0C ₆ H ₄		=	2,4,6-triFC ₆ H ₂	S	0	2	(CH ₂ ) ₆ CH ₃	
295 4-СН30С6Н4		=	3-FC ₆ H4	202	0	2	(CH ₂ ) ₆ CH ₃	
296 4-CH ₃ 0C ₆ H ₄		=	СН(СН3)2	0	S	2	(CH ₂ ) ₆ CH ₃	
297 4-СН3ОС6Н4		<b>=</b>	C ₆ H ₅	풀	S	2	(CH ₂ ) ₆ CH ₃	
298 4-CH ₃ 0C ₆ H ₄		×	(CH ₂ ) ₇ CH ₃	CH2	S	2	(CH ₂ ) ₆ CH ₃	
299 4-СН ₃ ОС ₆ Н4		Ŧ	2,6-diClC ₆ H ₃	0	0	2	(CH ₂ ) ₆ CH ₃	
300 4-CH ₃ 0C ₆ H ₄	4	=	GH3	¥	0	2	(CH ₂ ) ₆ CH ₃	
301 4-CH ₃ 0C ₆ H ₄		=	$(C_6H_4)(C_6H_5)$	CH2	0	2	(CH ₂ ) ₆ CH ₃	
302 4-CH ₃ 0C ₆ H ₄		€	2,4-diFC ₆ H ₃	S	0	2	(CH ₂ ) ₆ CH ₃	
303 (СН3)2СН	(сн3)5сн	€	C6H11	202	0	2	(CH ₂ ) ₆ CH ₃	
304 (СН3)2СН	(СН3)5СН	€	C6H5	0	¥	2	(CH ₂ ) ₆ CH ₃	
305 C ₆ H ₅	C ₆ H ₅	Ŧ	2,4-diFC ₆ H ₃	¥	£	3	(CH ₂ ) ₆ CH ₃	
306 4-CH ₃ 0C ₆ H ₄	4	=	C6H11	CH2	£	3	(CH ₂ ) ₆ CH ₃	
307 C ₆ H ₅	C ₆ H ₅	×	n-C3H7	0	S	2	(CH ₂ ) ₆ CH ₃	

			O C																			
10			શ્વ	(CH ₂ ) ₆ CH ₃	(CH2)6CH3	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	C6H5	(CH2)6CH3	(CH ₂ ) ₆ CH ₃	(CH2)6CH3	(CH ₂ ) ₆ CH ₃	(CH2)6CH3	(CH ₂ ) ₆ CH ₃	C6H5	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	$(CH_2)_6CH_3$	(CH ₂ ) ₃ CH ₃	(CH ₂ )8CH ₃
			<b>=</b> !	2	2	2	ო	8	5	2	2	2	2	٣	æ	2	2	2	æ	80	2	2
15			×	S E	CH ₂ S	0 H ₂	NH H ₂	CH ₂ H ₂	0 0 0 0	202 0	o ₩	CH ₂ 0	CH ₂ S	s F2	s F2	s F2	S H ₂	S H ₂	_	0 H ₂	CH ₂ S	O H
20	Table 2 (continued)		R4	C6H11	сн(сн3)2	C ₆ H ₅	,4-diFC ₆ H ₃	6H11	CH2) 7CH3	n-C3H7	6H11	н(сн ₃ )2	6H5	.4-diFC6H3	6H11	CH2) 7CH3	.4-diFC6H3	.4-diFC6H3	,4-diFC6H3	C6H11	.4-diFC6H3	2,4-diFC ₆ H ₃
25 30	Table 2		찗		·	ت ±	H 2	ت =	<u> </u>	=	ن ±	ن ±	ت ±	н 2	ت ±			CH ₂ C ₆ H ₅ 2		ت ±	н 2	H 2
35			R ²	(сн3) 5сн	C6H5	4-CH30C6H4	(сн3) 2сн	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-CH30C6H4	C6H5	C ₆ H ₅	(CH ₃ ) ₂ CH	4-CH ₃ SC ₆ H ₄	4-CH3SOC6H4	4-CH3SO2C6H4	C6H5
40			$\mathbb{R}^1$	.сн₃)₂сн	(сн3)2сн	C6H5	(сн3)2сн	1-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	1-(CH3)2NC6H4	4-(CH3)2NC6H4	1-(CH3)2NC6H4	4-(CH3)2NC6H4	4-CH30C6H4	:6H5	.6H5	(CH ₃ ) ₂ CH	323 4-CH ₃ SC ₆ H ₄	124 4-CH3SOC6H4	325 4-CH ₃ S0 ₂ C ₆ H ₄	326 4-CH ₃ SC ₆ H ₄
50		Ex.	₩.	308		310 0		312 4	313 4	314 4	315 4	316 4	317 4	318 4	319 4	320 C ₆ H ₅	321 C ₆ H ₅	322 (	323 4	324 4	325 4	326 4

5			J. du			foam	qlass
10			잃	CH3	C ₆ H ₅	(CH ₂ ) ₆ CH ₃	(CH2) 6CH3
			<b>c</b> l	S	S	2	'n
15			≻I	¥	S	0	0
			×I	S	S	¥	ક
20	<u>lable 2</u> (continued)		R4	2,4-diFC ₆ H3	2,4-diFC ₆ H ₃	2,4-diFC ₆ H3	2,4-diFC ₆ H3
30	<u>Table</u>		ଅ	I	=	Ŧ	x
35			묎	CeH5	C ₆ H ₅	C ₆ H ₅	CAHS
40				C6H4	2C6H4		
45			립	7 4-CH ₃ SO	328 4-CH3SO2C6H4	9 C ₆ H ₅	O C ₆ H ₅
50		Ĕ.	Š.	32	32	32	33

EXAMPLE 331

## ${\color{red}^{55}} \quad \underline{\text{Preparation of 2,4-difluoro-N-[(5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl)]-N-heptylbenzeneacetamide}$

To a solution of N-[5-(4,5-diphenyl-1H-imidazol-2-yithio)pentyl]-1-heptanamine (2.2 g, 0.005 mol), 1-hydroxybenzotriazole hydrate (0.81 g, 0.006 mol), and 2.4-diffuorophenylacetic acid (1.12 g, 0.0065 mol) in

N.N-dimethylformamide (50 mL) at 0 * was added, portionwise as a solid, dicyclohexylcarbodimide (1.24 g. 0.006 md). The reaction mixture was sitred at 0 * for 2.5 hours, then at ambient temperature for 72 hours. The solids were filtered and washed with chloroform. The filtrate was concentrated under vacuum and the residue (5.2 g) was chromatographed with 7.3 hexane-ethyl acetate. The resulting solid was triturated with hexane to give the title compound (2.59 g. 0.0044 mol) as a yellow oil, *H MMR (CDCla) 5.76-70(m;11H) 6.8-6.5(m,2H), 3.7(d,2H,J=13.7Hz), 3.5(t,2H,J=6.4Hz), 3.4-3.0(m,3H), 2.9(t,2H,J=6.1Hz), 1.8-1.1(m,17H), 0.9(t,2H,J=6.8Hz), **The control of the control of t

#### EXAMPLE 344

10

30

40

45

50

55

Preparation of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneethan-eamine

To a solution of lithium aluminium hydride (1 N in tetrahydrofuran, 2 mt) in dry tetrahydrofuran (30 mt), a solution of N-5f-14.5-bisf- mtetroxypheny)-1 H-imidizac)-2-yhiloplenyti)-2-drifluoro-N-heptylbon-zeneacetamide (0.70 g., 0.00107 mol) in dry tetrahydrofuran (15 mt), was added slowly. The reaction mixture was poured into a mixture of 10% aqueous sodium sulfate (150 mt), and ice (150 mt). The resultant emulsion was filtered through Ceite® and the filtrate was extracted with ethyl acetate (3 x 100 mt). The organic layer was washed with water, brine, dried over magnesium sulfate and concentrated in vacuo to give a crude oil. The product was purified by flash chromatography on silica gel (100 mt) eliuting metanol: methylene chloride (6.59 k·v) to give the title compound as a viscous coolorless oil (0.46 g., 0.000723 mol). 'H NMF (CDCis) § 8.2-9.15(bs.1H), 7.56-7.25(m.4H), 7.11(m.1H), 0.914-8.70(m.6H), 3.81(m.6H), 3.07(t.2H), 2.74-2.58(m.4H), 2.41(m.4H), 2.41(m.4H), 2.41(m.4H), 2.41(m.4H), 3.01(m.6H), 3.07(t.2H),

#### EXAMPLE 346

1.73-0.81(m.30H).

Preparation of N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-yithio]pentyl]-N-heptylcyclohexaneacetamide

Part A. Employing the method of Example 118. Part C. but using 2-cyclohexane acetyl chloride. N-

- heptyl-N-(5-hydroxypentyl)cyclohexaneacetamide was obtained as an oif (1.5 g., 0.0046 mol). ¹H NMR (CDC) à 8.70-3.81(m,2H), 3.37-3.18(m,4H), 2.03(d,2H), 1.97-1.08(m,28H), 1.02-0.88(m,4H). Part B. Employing the method of Example 118, Part D, but using N-heptyl-N-(5-hydroxypentyl)-cyclohexaneacetamide, N-(5-bromopentyl)-N-heptylcyclohexaneacetamide was isolated as an oil (1.3 g. 0.00334 mol). ¹H NMR (DCD) à 3.47-3.39(m,2H), 3.38-3.18(m,4H), 2.17(d,2H), 1.96-0.88(m,30H). Part C. Employing the method of Example 118, Part E, but using N-(5-bromopentyl)-N-heptylcyclohexaneacetamide, the title compound was isolated as an oil (0.47 g. 0.00376 mol), ¹H NMR (DMSO-d), ² 8 12.34(s,1H), 7.29(d,2H), 0.89(d,2H), 3.71(s,3H), 3.73(s,3H), 3.78(m,4H), 3.78(m,2H), 2.09(d,2H), 3.76(m,2H), 3.76(m,2H), 2.09(d,2H), 3.76(m,2H), 2.09(d,2H), 3.76(m,2H), 3.76(m,2H), 2.09(d,2H), 3.76(m,
  - Additional amides, which are listed in Table 3, were prepared or could be prepared analogously according to the procedures of Examples 331, 344 and 346.

5					D. C	ان	oi 1 (a)	91 (b)	57-58	oi1(c)	oi1(d)	oil(e)	oi1(f)	oi1(g)	oi1(h)	011(1)
10					읾	(сн2)есн3	(CH ₂ ) ₆ CH ₃ oil ^(a)	(СН ₂ )6СН3 оі1 ^(b)	(CH ₂ ) ₆ CH ₃ 57-58	(CH ₂ )6CH ₃ oil ^(c)	(CH ₂ )6CH ₃ oil ^(d)	(CN ₂ )6CH ₃ oil ^(e)			(CH ₂ )6CH ₃ oil ^(h)	(CH2)6CH3 oil(i)
10		å	*		디	S	5	2	2	2	5	5	2	5	5	2
		1	,		×	0	0	0	0	0	0	0	0	0	0	0
15		—(CH ₃ ), N—B ⁶			×	S	S	S	S	S	S	S	S	S	S	S
20	Table 3	)=    -  -	: `z-% =(		R4	CH2-2,4-diFC ₆ H3	СИ2СИ2СИ3	CH2 (CH2) 2CH3	CH2 (C6H4) (C6H5)	CH2C6H11	2,4-diFC ₆ H ₃	C ₆ H ₅	CH2-C6H11	(СН2)2СН3	CH2-3,4-diClC ₆ H ₃	CH2-C6F5
25		~	` <u>`</u>		മ	=	=	=	=	=	=	=	=	=	=	=
30		<b>L</b>			₈ 2	C6H ₅	CeH5	C6H5	C6H5	C6H5	C6H5	C ₆ H ₅	(сн3) 5сн	4-CH30C ₆ H4	4-CH30C6H4	4-сн30с6н4
35					립	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	C ₆ H ₅	335 C ₆ H ₅	336 C ₆ H ₅	C ₆ H ₅	338 (СН ₃ ) ₂ СН	339 4-CH ₃ 0C ₆ H ₄	340 4-CH ₃ 0C ₆ H ₄	341 4-CH30C6H4
				Ë.	<u>%</u>	331	332 (	333	334	335	336	337	338	339	340	341
45																

# Table 3 (continued

Ex.	~	~	4	,	:		4	;
No.	묇	2	اء	×ı	<b>-</b> -I	<b>⊏</b> I	잁	) dii
342 4-CH30C ₆ H4	4-CH30C6H4	=	CH2-2,4-diFC6H3	S	0	2	0 5 (CH ₂ ) ₆ CH ₃	oil(j)
343 C ₆ H ₅	C ₆ H ₅	=	(CH ₂ ) ₂ CH ₃	S	£	2	H ₂ 5 (CH ₂ )6CH ₃	oil(k)
344 4-CH ₃ OC ₆ H ₄	4-CH30C6H4	=	CH2-2,4-diFC6H3	S	£	2	(CH ₂ ) ₆ CH ₃	Oil
345 4-(CH3)2NC6H4	4-(CH3)2NC6H4	=	CH ₂ C ₆ H ₁₁	S	0	2	(CH ₂ ) ₆ CH ₃	(1)(1)
346 4-CH ₃ 0C ₆ H ₄	4-CH30C6H4	=	CH2C6H11	S	0	2	(CH ₂ ) ₆ CH	oil
347 n-C ₃ H ₇	n-C3H7	=	n-C3H7	S	0	2	0 5 (CH ₂ ) ₆ CH ₃	
348 3-pyridinyl	3-pyridinyl	=	CH2-2,4-diCH30C6H3 CH2	€	0	2	0 5 (CH ₂ ) ₆ CH ₃	
349 4-pyridinyl	4-pyridinyl	=	CH2-2,4,6-triFC ₆ H2 NH	풒	0	2	0 5 (CH ₂ ) ₆ CH ₃	
350 2-СН ₃ 0С ₆ Н4	2-CH30C6H4	=	CH2-3-FC6H4	S	¥	2	(CH ₂ ) ₆ CH ₃	
351 3-CH ₃ 0C ₆ H ₄	3-CH ₃ 0C ₆ H ₄	=	Сн(СН3)2	0	0	2	(CH ₂ ) ₆ CH ₃	
352 C ₆ H ₁₁	C6H11	=	C ₆ H ₅	CH2	0	S	0 5 (СН ₂ ) ₆ СН ₃	
353 C ₆ H ₅	4-(CH3)2NC6H4	=	(CH ₂ ) ₇ CH ₃	₹	0	2	(СН2) 6СН3	
354 2-furanyl	2-furanyl	=	2,6-diClC ₆ H ₃	S	0	2	(СН2) 6СН3	
355 4-(t-C4Hg)C6H4 4-(t-C4Hg)C6H4	4-(t-C4H9)C6H4	=	CH ₃	0	H2	2	0 H ₂ 5 (CH ₂ ) ₆ CH ₃	
_	2-thienyl	=	CH2(C6H4)(C6H5)	꿆	0	2	(CH ₂ ) ₆ CH ₃	
	4-HOC ₆ H4	₤	CH ₃ 2,4-diFC ₆ H ₃	垩	0	2	(CH ₂ ) ₆ CH ₃	
358 (СН3)2СН	(СН3)2СН	€	CH3 C6H11	S	0	2	(CH ₂ ) ₆ CH ₃	
359 С ₆ Н5СН2	C6H5CH2	€	CH ₃ C ₆ H ₅	0	0	2	(CH ₂ ) ₆ CH ₃	
360 C6H4-2-0CH20-2'-C6H4	-C6H4	×	H 2,4-diFC ₆ H ₃	$_{\rm H}$	£	~	CH2 H2 3 (CH2) 6CH3	

Ĕ.									
<u>8</u>	R1	²	R3	R4	×	×	=	βę	Je dw
361	361 4-CH ₃ C ₆ H ₄	4-CH3C6H4	<b>=</b>	2,4-diFC ₆ H ₃	S	0	8	(CH2) ACH3	
362	362 4-CH30C6H4	4-(CH3)2NC6H4	<b>±</b>	C6#11	0	0	8	0 8 (CH2) 6CH3	
363	363 4-CH ₃ 0C ₆ H ₄	C6H11	<b>=</b>	CH2-2,4-diFC6H3	£	0	2	(CH2) 3CH3	
364	364 4-CH30C6H4	(CH3)2CH	<b>=</b>	CH2-2,4-diFC6H3	, ≆	£	'n	H2 5 (CH) ACH2	
365	365 4-(CH3)2NC6H4	C6H11	=	2,4-diFC ₆ H ₃	S	۰ ،	2		
366	366 4-(CH3)2NC6H4 (CH3)2CH	(СН3)2СН	=	CH2-2,4-diFC6H3	0	0	5	CAH.	
367	C6H40C6H4	6H4	=	C6H11	丢	0	٣	(CH2) ACH2	
368	368 C ₆ H ₅	4-CH30C6H4	CH ₂ C ₆ H ₅		垩	0	2	0 5 (CH2)3CH3	
369	369 C ₆ H ₅	4-(CH3)2NC6H4	CeHs		S	£	2	CAR	
370	370 (СН3)СН	(СН3)2СН	=	2,4-diFC6H3	S	٠,	2	(CH2) ACH2	
371	371 4-CH3SC6H4	4-CH3SC6H4	=	CH2-2,4-diFC6H3	v	0	2	0 5 (CH2) 6CH3	
372	372 4-CH3SOC6H4	4-CH3SOC6H4	<b>=</b>	CH2-2,4-diFC6H3	₹	0	2	(CH2) ACH3	
373	373 4-СН3502С6Н4	4-CH3SO2C6H4	<b>=</b>	CH2-2,4-diFC6H3	ક	0	2	(CH2) 6CH3	
374	374 C6H5	4-CH3SC6H4	=	CH2-2,4-diFC6H3	S	0	2	(CH ₂ ) ₆ CH ₃	
375	375 C ₆ H ₅	4-CH3SOC6H4	=	CH2-2,4-diFC6H3	ŧ	0	2	(CH2) ACH3	
376	376 C ₆ H ₅	4-CH3S02C6H4	<b>±</b>	CH2-2,4-diFC6H3	CH ₂ 0	0	2	5 (CH ₂ ) ₆ CH ₃	
377	377 4-СН30С6Н4	4-CH30C6H4	CH ₃	n-C3H7	S	0	2	5 (CH ₂ ) ₆ CH ₃	
378	378 4-СН30С6Н4	4-CH30C ₆ H4	=	CH2C6H11	S	0	2	0 5 (CH ₂ )6CH ₃	
379	379 4-сн30с6н4	4-CH30C6H4	_	CH(CH ₃ ),	S	0	ĸ	(CH) A CH2	

	J. di											
	⁸ 9	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	C6H5	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	SO ₂ 0 5 C ₆ H ₅
	<b>=</b> 1	2	m	œ	2	2	2	2	2	~	8	5
	≻I	0	S	0	0	0	0	Ŧ	0	0	0	0
	×I	S	S	s	S	<b>S0</b> 2	S	S	s	S	S	202
	R4	CH ₂ C ₆ H ₅	CH2-2,4-diFC ₆ H3	CH ₂ C ₆ H ₁₁	(CH ₂ ) ₇ CH ₃	n-C3H7	C6H11	сн(сн3)2	C ₆ H ₅	2,4-diFC ₆ H ₃	C6H11	(CH ₂ ) 7CH ₃
	జ్ఞ	=	Ŧ	Ŧ	=	=	Ŧ	=	Ŧ	=	=	Ŧ
	<u>R</u> 2	4-CH ₃ OC ₆ H ₄	4-CH ₃ 0C ₆ H ₄	4-CH ₃ 0C ₆ H ₄	4-CH30C6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4
	R1	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2C6H4	390 4-(CH ₃ ) ₂ NC ₆ H ₄
Ĕ.	Š.	380	381	382	383	384	382	386	387	388	389	390
	Ēr.	R ² R ³ R ⁴ X Y n R ⁶	$rac{R_1}{4}$ $rac{R^2}{4}$ $rac{R^3}{2}$ $rac{R^4}{4}$ $rac{K}{2}$ $rac{K}{2}$ $rac{R^6}{4}$ 14-CH3OC6H4 H CH2C6H5 S O 5 (CH2)6CH3	$\frac{R^1}{4}$ $\frac{R^2}{4}$ $\frac{R^3}{4}$ $\frac{R^4}{1}$ $\frac{K}{1}$ $\frac{R^6}{1}$ $\frac{R^6}{4}$ $\frac{1}{4}$ $\frac{1}{4}$ $\frac{R^6}{4}$ $\frac{1}{4}$ $\frac{1}{4}$ $\frac{R^6}{4}$ $\frac{1}{4}$	R ² R ³ R ⁴ X Y n R ⁶ 4-CH30CeH4 H CH2CeH5 S 0 5 (CH2)6CH3 4-CH30CeH4 H CH2-2.4-diFCeH3 S 3 (CH2)6CH3 4-CH30CeH4 H CH2CeH11 S 0 8 (CH2)6CH3	R2         R3         R4         X         Y         R6         1           4-CH30C6H4         H         CH2C6H5         S         0         5 (CH2)6CH3           4-CH30C6H4         H         CH2-Z-4-diFC6H3         S         3 (CH2)6CH3           4-CH30C6H4         H         CH2C6H1         S         0         8 (CH2)6CH3           4-CH30C6H4         H         (CH2)7CH3         S         0         5 C6H5	R2 R3 R4 X X X R R6 R4-CH30C6H4 H CH2C6H5 S O 5 (CH2)6CH3 4-CH30C6H4 H CH2-C2,4-d1FCGH3 S S 3 (CH2)6CH3 4-CH30C6H4 H CH20-C5H1 S O 5 GH2)6CH3 4-CH30CGH4 H CH20-CH3 S O 5 GH5 GH3 6H4 4-(CH3)2MCGH4 H n-C3H7 SO ₂ O 5 (CH2)6CH3	R2         R3         R4         K         X         X         R6         R5           4-CH30C6H4         H         CH2C6H5         S         G         G         CH2)C6H3           4-CH30C6H4         H         CH2-C3-4-d1FC6H3         S         S         G         CH2)GH3           4-CH30C6H4         H         CH2)CH3         S         G         C6H5           6H4         4-CH30ZH4         H         CH3)ZHG4         H         CH3)ZHG4           6H4         4-CH3)2MC6H4         H         C6H1         S         G         CGH5	R2         R3         R4         K         X         X         R6         R5           4-CH30C6H4         H         CH2C6H5         S         0         S         CH2)C6H3           4-CH30C6H4         H         CH2-Z4-GH7C6H3         S         S         3         CH2)CH3           4-CH30C6H4         H         CH2)CH3         S         S         CH2)CH3           4-CH3)2MC6H4         H         CH11         S         S         CH2)CH3           4-(CH3)2MC6H4         H         CH(CH3)2         S         S         CH2)CH3	R2         R3         R4         X         X         R         R6         R5           4-CH30C6H4         H         CH2C6H5         S         0         5         (CH2)GCH3           4-CH30C6H4         H         CH2-C4-d1FGCH3         S         S         3         (CH2)GCH3           4-CH30C6H4         H         CH2-D7CH3         S         S         G         GCH2)GCH3           4-CH30Z6H4         H         CH2)TCH3         S         S         G         GCH2)GCH3           4-CH312MCGH4         H         CH11         S         S         G         GCH2)GCH3           4-(CH3)2MCGH4         H         CH(H3)2         S         G         GCH2)GCH3	R2         R3         R4         X         X         R         R6         R5           4-CH3OC6H4         H         CH2C6H5         S         0         5         (CH2)6CH3           4-CH3OC6H4         H         CH2-2,4-difC6H3         S         3         3         (CH2)6CH3           4-CH3OC6H4         H         CH2)7CH3         S         S         6         CH2)6CH3           4-CH3)2MC6H4         H         CGH11         S         S         CGH2)6CH3           4-CH3)2MC6H4         H         CGH3         S         S         CGH2)6CH3	R2         R3         R4         X         Y         R6         R5           4-CH3OC644         H         CH2C6H5         S         0         5 (CH2)6CH3         4-CH3OC6H4         H         CH2-2,4-diFC6H3         S         3 (CH2)6CH3         4-CH3)6CH3         S         S         3 (CH2)6CH3         S         S         3 (CH2)6CH3         S         CH2)6CH3         4-CH3)2CH4         H         CH2)7CH3         S         D         S         CH2         CH3         CH2)6CH3         A-CH3)2CH4         H         CH2)4T         S         D         S         CH2)6CH3         A-CH3)2CH4         H         CGH1         S         D         S         CGH2)6CH3         A-CH3)2CH4         H         CGH3         CGH2)6CH3         A-CH3)2CH4         H         CGH3         S         D         S         CGH2)6CH3         A-CH3)2CH4         CGH3         CGH2)6CH3         A-CH3)2CH4         CGH3         CGH3<

#### Footnotes To Table 3

5

10

15

20

25

30

35

40

45

50

- (a) ¹H NMR (CDCl₃) 5 11.7-11.6(bs,1H), 7.7-7.1(m,10H), 3.4(t,2H,J=7Hz), 3.3-3.2(m,2H), 2.9(t,2H,J=7Hz), 2.35-2,25(m,2H), 1.8-1.1(m,18H), 1.0-0.8(m,6H).
- (b) ¹H NMR (CDCl₃) 5 11.8-11.7(bs,1H), 7.7-7.1(m,10H), 3.4(t,2H,J=6.6Hz), 3.2(t,2H,J=8.7), 2.9(t,2H,J=6.5Hz), 2.4-2.2(m,2H), 1.8-1.1(m,20H), 0.85(sextet, 6H,J=4.1Hz).
- (c) ¹H NMR (CDCl₃) δ 7.6-7.1(m,11H), 3.4-2.9(m,6H), 2.2-2.1(m.2H), 1.8-1.0(m,27H), 0.9-0.8(m,3H).
- (d) ¹H NMR (CDCl₃) δ 7.6-7.2(m,11H), 6.9-6.8(m,2H), 3.7-3.4(m,2H), 3.2-3.0(m,4H), 1.9-1.0(m,17H).
- (e) ¹H NMR (CDCl₃) & 7.6-7.1(m,16H), 3.6-3.4(m,2H), 3.3-2.9(m,4H), 1.9-1.0(m,16H), 0.9-0.8(m,3H).
- (f)  1 H NMR (DMSO-d₆)  $\delta$  11.64(bs,1H), 3.18(m,4H), 2.98-2.74(m,4H), 2.08(d,2H), 1.77-0.81(m,42H).
- (g) ¹H NMR (OMSO-d₆) δ 12.36(s,1H), 7.39(d,2H), 7.31(d,2H), 6.95(d,2H), 6.85(d,2H), 3.76(s,3H), 3.74(s,3H), 3.28-3.03(m,6H), 2.22(t,2H), 1.75-1.11(m,18H), 0.83(m,6H).
- (h) ¹H NMR (DMSO-d₆) δ 12.35(bs,1H), 7.62-7.17(m,7H), 6.95(d,2H), 6.85(d,2H), 3.8-3.66(m,8H), 3.35-3.02(m,6H), 1.78-1.14(m,16H), 0.85(m,3H).
- (1) ¹H NMR (DMSO-d₆) δ 12.33(bs,1H), 7.37(d,2H), 7.31(d,2H), 6.94(d,2H), 6.83(d,2H), 3.82(d,2H), 3.77(s,3H), 3.73(s,3H), 3.42-3.01(m,6H), 1.81-1.16(m,16H), 0.85(m,3H).
- 1H NMR (DMSO-d₆) δ 12.32(bs,1H), 7.43-6.8(m,11H), 3.78(s,3H), 3.73(s,3H), 3.65(s,2H), 3.35-3.01(m,6H), 1.77-1.16(m,16H), 0.87(m,3H).
- (k) ¹H NMR (CDCl₃) δ 7.6-7.2(m,10H), 2.1(t,2H,J=7.4Hz), 2.5-2.3(m,7H), 1.8-1.6(m,2H), 1.5-1.2(m,18H), 0.9(quintet, 6H.J=5.1Hz).
- (1) ¹H NMR (DMSO-d₆) & 12.12(s,1H), 7.31(d,2H), 7.20(d,2H), 6.70(d,2H), 6.63(d,2H), 3.18(m,4H), 3.03(m,2H), 2.91(s,6H), 2.87(s,6H), 2.08(d,2H), 1.64-0.82(m,30H).

#### **EXAMPLE 391**

#### Preparation of cyclohexyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate

To a solution of N-15-(4,5-diphenyl-IH-Imidazol-2-ythio)pentyl-I-heptanamine (0.87 q. 0.002 mol) and sodium bicarbonate (5% f. ml.) in toluene (10 ml.) at 0' was added, dropwise, a solution of cyclohexylch-loroformate (0.32 g. 0.002 mol) in toluene (5 ml.). The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The solvent was removed under vacuum. The residue (1.0 g) was chromatographed with 7.3 hexane-ethyl acetate to give the title compound (0.61 g. 0.0011 mol) as a yellow oi. IH NMR (CDCb) 8 11.1(bs,1H), 7.7-2(m.10H), 4.6(bs,1H), 3.3(t,2H,J=5.1Hz), 3.2(t,2H,J=7.5Hz), 3.0 (1.2H,J=5.2Hz), 19.12(m.2Bh), 0.90.8(m.3H).

#### EXAMPLE 401

(m,2H), 0.86(m,3H).

20

30

35

40

45

50

55

#### Preparation of phenyl N-[5-(4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcarbamate

Part A. Employing the method of Example 118, Part B, but using phenyl chloroformate and triethylamine, phenyl, N-heptyl-N-(5-hydroxypentyl)carbamate was obtained as an oil (3.18 g, 0.00989 mol). ¹H NMR (CDCl₃) § 7.40-7.06(m,5H), 3.68-3.63(m,2H), 3.42-3.27(m,4H), 2.08-1.95(bs.1H), 1.75-1.26(m,16H), 0.90-(1.3H).

Part B. Employing the method of Example 118, Part C, but using phenyl N-heptyl-N-(5-hydroxypentyl)-carbamate, phenyl N-5-bromopentyl)-N-heptylcarbamate was isolated as an oil (3.8 g. 0.0099 mol). 'H NMR (CDCIs) 7-39-707(m,5H), 347-3 26(m,6H), 1.97-1.8(m,2H), 1.75-1.2(6(m,14H), 0.87(3.5H).

Part C. Employing the method of Example 118, Part D, but using phenyl N-(5-bromopentyl-N-heptylcarbamate, the title compound was isolated as an oil (0.3 g. 0.000615 mol). 'H NMR (DNISO-d₃) 8 11.07(s.1H). 7.58(m,2H). 3.7(m,2H). 3.20(m,2H). 2.9(m,3H). 2.8(m,1H). 1.87-1.06

Additional carbamates, which are listed in Table 4, were prepared or could be prepared analogously according to the procedures of Examples 391 and 401.

				O du	oi]	oil(a)	(b) ا زو	oi1(c)	oi1(d)	oil(e)	oi1(f)	(g) (io	(i) (ji)	oi1(i)	oi.]
5				શ્રી	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(сн2) есн3	(сн2)есн3	(сн2) есн3	(CH ₂ ) ₆ CH ₃	(сн2) есн3	(сн2)есн3	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃
10				디	S	'n	S	S	2	S	S	'n	ß	ß	2
		- F.		<b>&gt;</b> -I	0	0	0	0	0	0	0	0	0	0	0
15		-(CH ₂ ) _n N—R ⁶		×I	S	S	S	S	S	S	S	S	S	S	S
20	Table 4	2 × × × × × × × × × × × × × × × × × × ×		R ₄	C6H11	C6H5	СН2СН(СН3)2	СН2СН3	(CH ₂ ) ₇ CH ₃	4-FC6H4	(СН2)2СН3	CH ₂ C ₆ H ₅	C ₆ H ₅	C6H5	C ₆ H ₅
25				2	±	×	=	=	±	=	×	×	=	±	±
30				x. <u>lo. R¹ R² R³ R⁴</u>	C6H5	CeHs	CeHs	C6H5	C ₆ H ₅	C6H5	C6H5	C ₆ H ₅	4-(CH3)2NC6H4	4-CH30C6H4	(сн3) 2Сн
35				긺	ł.	<del>1</del> 2	ŧ.	<del>1</del> 5	ł,	ţ.	Ť.	ţ.	(CH3)2NC6H4	400 4-CH30C6H4	401 (СН3)2СН
40					9	30	30	30	30	39	3	3	4	4	9
			i	₹	391	392	393	394	395	396	397	338	336	400	401

			Table	Table 4 (continued)					
Ex.									
Ş.	R1	R ²	<u>س</u>	R4	×I	<b>≻</b> I	=	શ્વ	O du
402	402 n-C3H7	n-C ₃ H ₇	Ŧ	n-C3H7	s	0	2	$(CH_2)_6CH_3$	
403	403 2-pyridinyl	2-pyridinyl	=	C6H11	0	0	2	(CH ₂ ) ₆ CH ₃	
404	404 3-pyridinyl	3-pyridinyl	=	2,4-diCH30C ₆ H3	댽	0	2	(CH ₂ ) ₆ CH ₃	
405	405 4-pyridinyl	4-pyridinyl	Ŧ	CH2-2,4,6-triFC ₆ H2	¥	0	2	(сн2) есн3	
406	406 2-CH30C ₆ H4	2-CH30C6H4	Ŧ	3-F-C6H4	S	¥	2	(CH ₂ ) ₆ CH ₃	
407	407 3-CH ₃ 0C ₆ H ₄	3-CH30C6H4	±	сн(сн3)2	0	0	2	(CH ₂ ) ₆ CH ₃	
408	408 C ₆ H ₁₁	C6H11	=	C ₆ H ₅	CH2	0	2	(CH ₂ ) ₆ CH ₃	
409	409 C ₆ H ₅	4-(CH3)2NC6H4	=	(CH ₂ ) ₇ CH ₃	¥	0	2	(CH ₂ ) ₆ CH ₃	
410	410 2-furanyl	2-furanyl	=	2,6-diCl-C ₆ H ₃	S	0	2	(CH ₂ ) ₆ CH ₃	
411	411 4-(t-C4H9)C6H4 4-(t-C4H9)C6H4	4-(t-C4H9)C6H4	=	<del>З</del>	0 H ₂	£	2	(CH ₂ ) ₆ CH ₃	
412	412 2-thienyl	2-thienyl	=	(C6H4) (C6H5)	CH2	0	2	(СН2) 6СН3	
413	413 4-НО-С6Н4	4-HO-C6H4	£	2,4-diFC ₆ H ₃	¥	0	2	(СН2) 6СН3	
414	414 (CH ₃ ) ₂ CH	(сн3)5сн	품	C6H11	S	0	2	(СН2) 6СН3	
415	415 C ₆ H ₅ CH ₂	C ₆ H ₅ CH ₂	€	C ₆ H ₅	0	0	2	(сн2) есн3	
416	-19	-C6H4	=	2,4-diFC ₆ H ₃	CH2	£	ო	(CH ₂ ) ₆ CH ₃	
417	С6440С644		=	C6H11	o ₹	0	٣	(CH ₂ ) ₆ CH ₃	
418	418 4-CH ₃ 0C ₆ H ₄	4-(CH3)2NC6H4	Ŧ	C6H11	0	0	æ	(CH ₂ ) ₆ CH ₃	
419	419 4-CH ₃ 0C ₆ H ₄	C6H11	=	CH2-2,4-diFC6H3	CH2 0	0	2	(CH ₂ ) ₃ CH ₃	
450	420 4-CH30C6H4	(сн3)5сн	=	CH2-2,4-diFC ₆ H3	¥	¥ ¥2	2	(СН2)8СН3	

		) di																			
		إي9	CH3	CeHs	3-FC ₆ H4	(CH ₂ ) ₃ CH ₃	C ₆ H ₅	(CH ₂ ) ₆ CH ₃	(CH2)6CH3	(CH ₂ ) ₆ CH ₃	(CH2)6CH3	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₆ CH ₃	(сн2) есн3	(CH2)6CH3	(CH2)6CH3	(CH ₂ ) ₆ CH ₃	C ₆ H ₅			
		디	2	2	2	2	S	2	2	2	2	2	2	2	2	2	2	2	က	8	2
		≻∣	0	0	0	0		0		0	CH ₂ 0	0	0	0	0	¥	0	0	0	0	0
		×I	S	0	CH ₂	풎	S	s	S	풎	욼	S	풒	CF2	S	S	S	S	S	S	202
Table 4 (continued)		₩ ₩	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	CH2-2,4-diFC6H3	(CH ₂ ) ₇ CH ₃	(CH ₂ ) ₇ CH ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	2,4-diFC ₆ H ₃	CH2C6H5 2,4-diFC6H3	n-C3H7	C6H11	СН(СН3)2	C ₆ H ₅	2,4-diFC ₆ H ₃	C6H11	(CH ₂ ) ₇ CH ₃
Table 4		띪	=	I	Ŧ	I	<b>±</b>	<b>=</b>	=	Ŧ	<b>=</b>	C ₆ H ₅	CH ₂ CH ₃	CH ₂ C ₆ H ₅	3	=	=	<b>=</b>	<b>±</b>	=	<b>=</b>
		R2	C6H11	(CH ₃ ) ₂ CH	(сн3)5сн	4-CH30C6H4	4-(CH3)2NC6H4	(сн3)5сн	4-CH3SC6H4	4-CH3SOC6H4	4-CH3SO2C6H4	4-CH3SC6H4	4-CH3SOC6H4	4-CH3SO2C6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4
		. R1	421 4-(CH3)NC6H4	422 4-(CH3)NC6H4	423 C6H11	424 C ₆ H ₅	425 C ₆ H ₅	426 (СН3)2СН	427 4-CH3SC6H4	428 4-CH3SOC6H4	429 4-CH3SO2C6H4	130 C ₆ H ₅	131 C ₆ H ₅	432 C ₆ H ₅	133 4-(CH3)2NC6H4	434 4-(CH3)2NC6H4	435 4-(CH3)2NC6H4	436 4-(CH3)2NC6H4	137 4-(CH3)2NC6H4	438 4-(CH3)2NC6H4	439 4-(CH3)2NC6H4
	Ë.	No.	42	42	42	42	42	42	42	42	45	43	43	43	43	43	43	43	43	43	4.

		J. dui							
		읾	(CH ₂ ) ₆ CH ₃	S H ₂ 5 (CH ₂ )6CH ₃	(CH ₂ ) ₆ CH ₃	CAHE			
		<b>=</b> I	2	2	2	2	ო	80	S
		<b>&gt;</b> -I	0	¥	0	0	0	0	S
		×I	S	S	S	S	S	202	S
Table 4 (continued		R4	n-C ₃ H ₇	C6H11	СН(СН3)2	C ₆ H ₅	2,4-diFC ₆ H ₃	C6H11	(CH2),7CH2
Table		교	=	±	뜐	· =	I	=	æ
		교	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH ₂ OC ₆ H ₄
		밂	4-CH30C6H4	441 4-CH ₃ 0C ₆ H ₄	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	446 4-CH20CAHA
	Ÿ	<b>.</b>	440 4	441	442	443	444	445	446

#### Footnotes To Table 4

5

10

15

20

25

30

35

40

45

50

55

- (a) ¹H NMR (CDCl₃) 5 10.6(s,1H), 7.7-7.0(m,15H), 3.4(q,4H,J=4.7Hz),2.9(t,2H,J=5.8Hz), 1.8-1.2(m,16H), 0.95-0.75(m,3H).
- (b) ¹H NMR (CDCl₃) δ 10.9(s,1H), 7.75-7.1(m,10H), 3.75(d,2H,J=6.3Hz), 3.3(t,2H,J=6.0Hz), 3.15(t,2H,J=7.5Hz), 3.0(t,2H,J=6.2Hz), 2.0-1.2(m,17H), 0.9(t,9H,J=3.2Hz).
- (c) ¹H NMR (CDCl₃) δ 10.9(s,1H), 7.75-7.1(m,10H), 4.0(d,2H,J-6.8Hz), 3.4-2.95(m,6H), 1.9-1.1(m,19H), 1.0-0.8(m,3H).
- (d)  1 H NMR (CDC1₃)  $\delta$  10.7(s,1H), 7.7-7.2(m,10H), 4.1 to 3.9(m,2H), 3.4-2.9(m,6H), 1.8-1.2(m,28H), 0.9-0.8(m,6H).
- (e) ¹H NMR (CDCl₃) 5 10.4(s,1H), 7.7-6.8(m,14H), 3.5-2.9(m,6H), 1.9-1.1(m,16H), 1.0-0.8(m,3H).
- (f) ¹H NMR (CDC1₃) δ 10.9(s,1H), 7.75-7.1(m,10H), 4.0(q,2H,J=6.9Hz), 3.3(t,2H,J=9.5Hz), 3.2(t,2H,J=7.5Hz), 3.0(t,2H,J=7.8Hz), 1.8-1.1(m,18H), 0.9(t,3H,J=7.2Hz).
- (g) ¹H NMR (CDC1₃) δ 10.5(s,1H), 7.7-7.2(m,15H), 5.05(s,2H), 3.3(q,2H,J=5.7Hz), 3.2(t,2H,J=7.4Hz), 3.0(q,2H,J=5.4Hz), 1.8-1.1(m,16H), 0.9(t,3H,J=6.4Hz).
- (h) ¹H NMR (CDC1₃) δ 10.0-9.8(bs,1H), 7.57-7.03(m,9H), 6.63(m,4H), 3.43-3.26(m,4H), 3.09-2.86(bs,14H), 1.81-1.25(m,16H), 0.89(t,3H).
- (i) ¹H NMR (DMSO-d₆) δ 12.34(s,1H), 7.39-7.22(m,6H), 7.19(t,1H), 7.06(d,2H), 6.94(d,2H), 6.84(d,2H), 3.77(s,3H), 3.72(s,3H), 3.40-3.20(m,4H), 3.09(m,2H), 1.75-1.17(m,16H), 0.84(m,3H).

			잂	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₃ CH ₃	(CH ₂ ) ₈ CH ₃	CeHs	2,4-diFC ₆ H ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₃ CH ₃	유3	CeHs	(CH ₂ ) ₆ CH ₃	(CH ₂ ) _{3.7H₃}
			7	NH-2,4-diFC ₆ H ₃ (CH ₂ ) ₆ CH ₃	NH-2,4-diFC6H3 (CH2)3CH3	NH-2,4-diFC6H3 (CH2)8CH3	CH ₂ CH(CH ₃ ) ₂	CH ₂ CH(CH ₃ ) ₂	<b>Н2 СН2СН(СН3)</b> 2	0(CH ₂ ) ₇ CH ₃	0(CH ₂ ) ₇ CH ₃	H2 0(CH2)7CH3	NHCH(CH ₃ ) ₂	<b>М</b> НСН(СН3)2
			H	0	S	H2	0	S	H2	0	S	¥	0	S
Table 5	X-A-N-R ⁶		<b>V</b> i	сн ₂ сн(сн ₃ ) (сн ₂ ) ₃	(СН2)3СН(СН3)СН2	(CH2)3C(CH3)2CH2	(CH2)CH(C5H11)(CH2)2 0 CH2CH(CH3)2	СН(СН3) (СН2)4	сн2сн=сн(сн2)2	(CH2)3CH=CH(CH2)2	CH ₂ C≡C(CH ₂ ) ₂	(CH ₂ )3C≡C(CH ₂ ) ₂	СН2СН(СН3) (СН2)3	(сн2)3сн(сн3)сн2
	ν/ Σ Ζ-α		×I	S	당	¥	_	S	CH ₂	ŧ		S	6	至
	£ &		ଥ	<b>=</b>	_	_	<b>.</b>	£			CH ₂ C ₆ H ₅ (	CeHs	_	=
			²	C ₆ H ₅	C ₆ H ₅	C6H5	C6H5	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4
			R ₁	447 C ₆ H ₅	448 C ₆ H ₅	449 C ₆ H ₅	450 C ₆ H ₅	451 4-(CH3)2NC6H4 4-(CH3)2NC6H4 CH3	452 4-(CH3)2NC6H4 4-(CH3)2NC6H4 H	453 4-(CH3)2NC6H4 4-(CH3)2NC6H4 CH2CH3	454 4-(CH3)2NC6H4 4-(CH3)2NC6H4 CH2C6H5 0	455 4-CH ₃ 0C ₆ H ₄	456 4-CH ₃ 0C ₆ H ₄	457 4-CH ₃ 0C ₆ H ₄
		Ä.	è	447	448	449	420	421	452	453	454	455	456	457

5		શ્વ	(CH ₂ ) ₈ CH ₃	C6H5	2,4-diFC ₆ H ₃	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₃ CH ₃	G <del>1</del> 3	C ₆ H ₅	(CH ₂ ) ₆ CH ₃	(CH2)3CH3	(CH ₂ )8CH ₃	C6H5	2,4-diFC6H3	(CH ₂ ) 6CH ₃	(CH ₂ ) ₃ CH ₃	CH ₃	C6H5	(CH ₂ ) ₃ CH ₃	(CH ₂ ) ₆ CH ₃	(CH2)6CH3
10		7	NHCH(CH3)2	(CH ₂ ) ₇ CH ₃	(CH ₂ ) ₇ CH ₃	(CH ₂ ) ₇ CH ₃	0C ₆ H ₅	OC6H5	OC ₆ H ₅	NH (CH ₂ ) 7CH ₃	NH(CH2)7CH3	NH(CH ₂ )7CH ₃	CH ₂ C ₆ H ₅	C ₆ H ₅	CH2C6H5	0СН(СН3)2	ОСН(СН3)2	0СН(СН3)2	CH2CH(CH3)2	0(CH ₂ ) ₇ CH ₃	NH-2,4-diFC6H3 (CH2)6CH3
		<b>≻</b> I	£	0	s	¥	0	s	£	0	S	£	0	S	£	0	S	£	0	0	0
20	Table 5 (continued	Ą	(CH2)3CH(CH3)2CH2	(CH2)2CH(C5H11)(CH2)2	CH(CH ₃ ) (CH ₂ ) 4	СН2СН=СН(СН2)2	(CH ₂ ) ₃ CH=CH(CH ₂ ) ₂	CH ₂ C≡C(CH ₂ ) ₂	(CH ₂ )3C≡C(CH ₂ )2	СН2СН(СН3) (СН2)3	(CH ₂ ) ₃ CH(CH ₃ )CH ₂	(CH ₂ ) ₃ C(CH ₃ ) ₂ CH ₂	(CH2)2CH(C5H11) (CH2)2	СН(СН3) (СН2) 4	CH ₂ CH=CH(CH ₂ ) ₂	(CH2)3CH=CH(CH2)2	сн₂с≡с(сн₂)₂	(CH2)3C≡C(CH2)2	СН2СН(СН3) (СН2)3	(сн2) зсн(сн3) сн2	(CH ₂ ) ₃ C(CH ₃ ) ₂ CH ₂
30		×I	۰	S	CF2	풎	0	s	똜	₹	0	S	움	₹	0	S	CH2	≢	s	S	S
		<u>س</u> ا	=	<b>=</b>	CH3	=	=	Ŧ	C6H5	=	±	<b>=</b>	=	€	<b>=</b>	=	=		=	_	<b>=</b>
35		R2	4-CH30C6H4	(сн3)5сн	(сн3)5сн	(сн3) 2сн	(сн3) 2сн	C6H11	C6H11	C6H11	C6H11	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-CH30C6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4	4-(CH3)2NC6H4 C6H5	474 4-(CH3)2NC6H4 4-(CH3)2NC6H4	475 4-(CH3)2NC6H4 4-(CH3)2NC6H4	476 4-(CH3)2NC6H4 4-(CH3)2NC6H4 H
40																			6H4	₽49	6H4
45		립	458 4-CH30C6H4	459 (СН3)2СН	460 (СН3)2СН	461 (СН3)2СН	462 (СН3)2СН	463 C ₆ H ₁₁	464 C ₆ H ₁₁	465 C6H11	466 C ₆ H ₁₁	467 C ₆ H ₅	468 C ₆ H ₅	469 C ₆ H ₅	470 C ₆ H ₅	471 C6H5	472 C6H5	473 C6H5	4 4-(CH3)2NC	75 4-(CH3)2NC	'6 4-(CH3)2NC
	ž	<u>§</u>	45	45	46	46	46	46	46	46	46	46	46	46	4	47	47	47	47	47	4
50																					

m m m m m

5			ଥ	(CH ₂ ) _{8CH₃}	(CH ₂ ) ₆ CH ₃	(CH ₂ ) ₃ CH ₃	(CH ₂ ) ₃ CH ₃	(CH ₂ ) ₆ CH ₃	(СН2) 6СН3
10			7	4-diFC ₆ H ₃	2)2CH3	0 CH2-2,4-diFC6H3	0 0-2,4-diFC6H3	0 CH2-CH(CH3)2	
15			≻∣	2 0 NH-2,	0 NH(CH ₂ ) ₂ CH ₃	0 CH2-2	0 0-2,4	0 CH2-CI	0 сн2сн3
20	Table 5 (continued			(CH2)2CH(C5H11)(CH2)2 0 NH-2,4-diFC6H3	12)4	3H2)2	CH(CH ₂ ) ₂	2)2	(CH ₂ ) ₂
25	Table 5		¥		SO ₂ CH(CH ₃ )(CH ₂ ) ₄	CH2CH=CH(CH2)2	(CH ₂ ) ₃ CH=CH(CH ₂ ) ₂	CH ₂ C≡C(CH ₂ ) ₂	(CH ₂ )3C≡C(CH ₂ ) ₂
30			الع الع	S	202	s	S	s	S
			മി	Ŧ	Ŧ	Ξ.	Ŧ	Ŧ	=
35			R2	477 4-(CH3)2NC6H4 4-(CH3)2NC6H4	478 4-(CH3)2NC6H4 4-(CH3)2NC6H4	4-CH30C6H4C6H4 1	4-CH30C6H4	4-СН30С6Н4	4-сн30С6Н4
40			R1	1-(CH3)2NC6H4	1-(CH3)2NC6H4	479 4-CH ₃ OC ₆ H ₄	480 4-CH ₃ 0C ₆ H ₄	481 4-CH ₃ 0C ₆ H ₄	482 4-СН ₃ ОС ₆ Н4
		<u>۲</u>	į	477 4	478 4	479 4	480 4	481 4	482 4
50		_		-	•	-	•	-	-

Utility

The compounds of the present invention are inhibitors of the enzyme acyl-CoA: cholesterol acyltransferase and are thus effective in inhibiting esterification and transport of cholesterol across the intestinal wall.

#### A. Asssay of the Inhibition of Acyl-CoA: Cholesterol Acyltransferase (ACAT) in Hepatic Microsomes

The ability of the compounds to inhibit ACAT, the enzyme responsible for the intracellular synthesis of cholestery leaters, was tested as follows. Male Sprague Dawley rats weighing 150-300, were fed rate shows a dibitium. The animals were fasted for twenty-four hours prior to being sacrificed by decapitation. The livers were perfused in situ with 50 ml of cold 0.25 M sucrose, excised, and homogenized in three volumes of 0.1 M phosphate Duffer, pH 7.4, that contained 0.5 mM EDTA (othylenediaminetetracetic acid), 1.0 mM glutathione, 0.25 M sucrose and 20 mM leupeptin. Microsomes were obtained by differential centrifugation; the superneatent from an initial spir at 15,000 x g for 15 minutes was centrifugad at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centrifugated at 105,000 x g for 15 minutes was centreal to 105,000 x g for 15 minutes was centreal to 105,000 x g for 15 minutes was centreal to 105,000 x g for 15 minutes was centreal to 105,000 x g for 15 minutes was centreal to 105,000 x g for 15 minutes was centreal ton 105,000 x g for 15 minutes was centreal to 105,000 x g for 15 m

The control assay in a final volume of 200 μl consisted of 200 μg of microsomal protein, 75 μm ¹⁴ Coleoyi-CoA (10,000 dpm/mmol) in 0.1 M phosphate, pH 7-A, that contained 1 mM glutathione. Compounds were added in 5-10 μl of DMSO (dimethyl sulfoxide) and additional controls were run with DMSO only. All reaction by the addition of loely-CoA, were preincubated for 15 min. at 37 °C prior to the initiation of the reaction by the addition of loely-CoA. The assay was terminated after 10 min by the addition of 500 μl of hexane: isopropanol (3:2, v/v). 20,000 dpm of 3+t-cholesteryl oleate and 10 μg of unlabeled cholesteryl oleate and oleic acid were added as an internal standard and carriers, respectively. After allowing 10 min. for lipid extraction, the samples were centrifuged at 1,000 x g for 10 min. to separate the solvent layers. 200 at 1 of the top (hexane) layer containing the neutral lipids was spotted onto a Baker S1250-Pa slica gel TLC plate and the piate developed using a hexaner: delthyl ether: acetic acid (170:30:1 v/v/v) mobile phase. The lipids were visualized by their interaction with iodine vapor and the cholesteryl ester spot was scraped into a scrillation vall and counted. The specific activity of ACAT in the control incubation averaged (16.5) the data are expressed as the concentration at which ACAT activity is hinbited by 50% (16.5).

#### B. Assay of the Inhibition of Cholesterol Esterification in Mammalian Cells

The esterification of cholesterol was determined in the murine macrophage-like cell line J774.A1. Cells 30 were seeded in 35 mm wells at a density of 300,000 cells per well in 2 mls of Dulbecco's Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were incubated at 37 °C in an atmosphere of 5% CO2 and 93% humidity. After 24 hours the media was changed to 0.68 mls 10% FBS-DMEM containing 34 µg of acetylated human low density lipoprotein (ac-LDL) to increase the intracellular concentration of cholesterol and promote esterification. At 41 hours, various inhibitors were added to the 35 cells in DMSO (10 μl/ml maximum). At 43 hours, the cells were pulsed with 0.1 mM 14 C-oleic acid (10,000 dpm/nmol) complexed with BSA (bovine serum albumin) to follow cholesterol ester formation. The experiment was terminated at 45 hours by washing the monolayers 3 times with 3 ml of Tris-buffered saline at 4 °C. The lipids were extracted by incubating the monolayers with 1.5 ml of hexane: isopropanol (3:2, v/v) for 30 min. under gentle agitation. During this period, 10,000 dpm 3H-cholesteryl linoleate and 10 µg of 40 cholesteryl oleate were added as an internal standard and carrier respectively. The organic solvent was removed and the cells were washed with an additional 1.0 ml of hexane: isopropanol which was combined with the original extract. The cells were allowed to dry overnight, digested with 1.5 ml of 0.2 N sodium hydroxide for 1 hour and an aliquot of the solubilized protein used for protein determination using the Lowry method. The organic extract was taken to dryness, the residue resuspended in 100 µl of chloroform and the 45 lipids separated on silica gel impregnated glass fiber plates using a hexane: diethylether: acetic acid (170:30:1, v/v/v) solvent system. Individual lipids were visualized with iodine and the cholesteryl ester spot cut out and transferred to scintillation vials to determine the amount of radioactivity. The conversion of oleic acid to cholesteryl ester in control averaged 0.54 mmol/hour/mg protein and was increased upon the addition of ac-LDL to about 10.69 ± 0.69 mmol/hour/mg protein. The inhibition of esterification by the 50 compounds is shown in Table 7; the data are expressed as the concentration at which ACAT activity is inhibited by 50% (IC50). It should be noted that many of the intermediates had inhibitory activity in the in vitro ACAT assay and in the macrophage assay. For example, N-[5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]-1-heptanaminehydrochloride had IC50's of 100 nM and 6 µm in the in vitro ACAT and macrophage assay, respectively.

#### C. Assay of Antihypercholesterolemic Activity in Cholesterol-fed Hamsters

Inhibition of ACAT activity in the gut reduces the absorption of cholesterol in cholesterol-fed animals. Hamsters weighing approximately 100 g, were maintained on a diet supplemented with 0.8% cholesterol. The treatment group received 1-100 mg/kg/day, p.o., of the test compound dissolved in 500 µl of com oil for a period of two weeks. The control group were pair-fed to the treatment group and were dosed with 500 µl of the com oil vehicle. At sacrifice, the hamsters were anesthetized with CO₂ and exsanguinated via cardiac puncture. Total serum cholesterol was determined on a Du Pont aca® IV. The data were expressed in terms of mg cholesterol per 100 ml of serum (mg %). The antihypercholesterolemic activity of the roompound of Example 1 is shown in Table 8.

<u>Table 6</u>

Inhibition of <u>In Yitro</u> Hepatic ACAT Activity
by Various Compounds

10	Compound of Example	In Vitro ACAT IC ₅₀ (nM)
	1	13
	2	23
15	3	8
	4	60
	5	12
	6	3,600
20	7	41
	8	10
	9	930
25	53	17
	64	30
	71	16
	85	60
30	94	10
	97	25
	105	20
35	107	1,000
	110	60
	114	40
	118	170
40	122	80
	160	490
	186	2,850
45	188	20
	189	70
	190	30
	191	400
50	192	70

Table 6 (continued)

5	Compound of Example	In Vitro ACAT IC ₅₀ (nM)
10	193	60
	195	40
	. 196	300
	197	119
15	198	40
	199	20
	200	710
20	201	200
20	204	500
	206	40
	207	9
25	208	20
	209	1,400
	212	60
30	267	58
30	269	8
	272	16
	289	30
35	290	140
	291	130
	329	3,500
	330	280
40	331	25
	332	3
	333	30
45	334	160
	335	30
	338	30
	339	700
50	340	200

<u>Table 6</u> (continued)

Compound of Example	<u>In Vitro</u> ACAT IC ₅₀ (nM)
341	605
342	250
343	300
344	240
392	20
393	35
394	33
395	500
396	10
397	40
398	9
399	120

Table 7

# Inhibition of Cholesterol Esterification in Macrophage by Various Compounds

Compound of Example	Cholesterol Esterification IC ₅₀ (µM)
1	1.0
2	0.8
3	17.5
4	4.6
5	2.5
6	3.8
7	7.5
8	0.5

<u>Table 7</u> (continued)

# Inhibition of Cholesterol Esterification in Macrophage by Various Compounds

10	Compound of Example	Cholesterol Esterification IC ₅₀ (μM)
	9	11.2
15	53	0.4
	64	0.6
	71	1.9
20	85	3.1
	94	0.1
	97	0.7
25	105	0.3
20	107	2.3
	110	0.9
	114	3.5
30	118	0.1
	122	0.3
	160	1.6
35	186	6.2
	188	0.9
	189	2.2
	191	2.4
40	192	2.0
	193	2.7
	195	0.4
45	196	1.4
	197	0.1
	199	0.6
	206	0.4
50	207	0.6

5

Iable 7 (continued)

## Inhibition of Cholesterol Esterification

in Macrophage by Various Compounds

Compound of Example	Cholesterol Esterification IC ₅₀ (µM)
209	4.8
212	1.7
267	6.1
269	1.2
272	3.5
289	2.5
290	1.2
291	0.9
329	3.4
330	4.4
331	0.2
332	0.1
333	1.6
334	1.1
338	0.3
339	0.2
392	0.4
393	0.5
394	0.5
395	3.9
396	0.6
397	0.8
398	1.3

Table 8

Dose Response	Evaluation of Example	1 in Hypercholesterole	mic Hamsters						
Dose (mg/kg/day)	Dose (mg/kg/day) Serum Cholesterol (mg %) ^a								
	Control	Treated							
1	400 ± 25	295 ± 12	26						
3	381 ± 17	279 ± 16	27						
10	371 ± 7	201 ± 12	46						
30	368 ± 15	197 ± 11	46						
100	400 ± 17	162 ± 8	60						

a) Values are the mean ± SEM, n = 9-10 per group

#### Dosage Forms:

5

10

15

The compounds of the present invention can be administered orally using any pharmaceutically a acceptable dosage form known in the art for such administration. The active ingredient can be supplied in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treaties with respect to pharmaceutical dosage forms is Reminioton's Pharmaceutical Sciences, 16th Edition, 1980.

In the therapeutic use of intestinal ACAT inhibitors, the compounds utilized are administered to the patient at dosage levels of 1 to 28 g per day. For a normal male adult human of approximately 70 kg of body weight, this translates into a dosage of 14 to 400 mg per kilogram body weight per day. The dosage administered will, of course, vary depending upon known factors such as the age, health, and weight of the recipient, nature and extent of symptoms, kind of concurrent treatment, frequency of treatment, and see feet desired. Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows:

#### Tablets

Tablets are prepared by conventional procedures so that the dosage unit is 500 milligrams of active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose and 10 milligrams of magnesium stearate.

#### Capsules

40 Capsules are prepared by conventional procedures so that the dosage unit is 500 milligrams of active ingredient, 100 milligrams of cellulose and 10 milligrams of magnesium stearate.

#### Syrup

45

50

55

Active Ingredient 10
Liquid Sugar 50
Sorbitol 20
Glycerine 5
Flavor, Colorant and Preservative as required as required

The final volume is brought up to 100% by the addition of distilled water.

#### Aqueous Suspension

5

10

20

25

35

an

50

55

	Wt. %
Active Ingredient	10
Sodium Saccharin	0.01
Keltrol® (Food Grade Xanthan Gum)	0.2
Liquid Sugar	5
Flavor, Colorant and Preservative	as required
Water	as required

Xanthan gum is slowly added into distilled water before adding the active ingredient and the rest of the formulation ingredients. The final suspension is passed through a homogenizer to assure the elegance of the final products.

#### Resuspendible Powder

 Wt. %

 Active Ingredient
 50.0

 Lactose
 35.0

 Sugar
 10.0

 Acacia
 4.7

 Sodium Carboxylmethylcellulose
 0.3

Each ingredient is finely pulverized and then uniformly mixed together. Alternatively, the powder can be prepared as a suspension and then spray dried.

#### Semi-Solid Gel

Active Ingredient 10 0.02 Ociatin Saccharin 0.02 2 Colorant, Flavor and Preservative as required as required as required

Gelatin is prepared in hot water. The finely pulverized active ingredient is suspended in the gelatin solution and then the rest of the ingredients are mixed in. The suspension is filled into a suitable packaging container and cooled down to form the gel.

#### Semi-Solid Paste

Gelcarin® is dissolved in hot water (around 80°C) and then the fine-powder active ingredient is suspended in this solution. Sodium saccharin and the rest of the formulation ingredients are added to the suspension while it is still warm. The suspension is homocenized and then filled into suitable containers.

#### 5 Emulsifiable Paste

10

15

30

35

40

45

50

55

	Wt. %
Active Ingredient	30
Tween® 80 and Span® 80	6
Keltrol®	0.5
Mineral Oil	63.5

All the ingredients are carefully mixed together to make a homogenous paste.

The term "consisting essentially of" in the present disclosure is intended to have its customary meaning; namely, that all specified materials and conditions are very important in practicing the invention but that unspecified materials and conditions are not excluded so long as they do not prevent the benefits of the invention from being realized.

The foregoing disclosure includes all the information deemed essential to enable those of skill in the art to practice the claimed invention. The cited publications and applications may provide further useful information.

#### Claims

Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE

## 1. A compound of the formula

R 1 N X -A -N -R 6

wherein

R1 and R2

are selected independently from H, C₇-C₈ alkyl, provided that when R¹ is H, then R² cannot be H and when R¹ is C₁-C₈ alkyl, then R² cannot be C₁-C₈ alkyl, C₁-C₉ cycloalkyl, C₂-C₇ cycloalkyl, C₃-C₉ cycloalkylalkyl, C₇-C₁ a aralkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C₁-C₄ alkyl, C₃-C₆ branched alkyl, CH₃S(O), NO₂, CF₅ or NR/R² cr

R1 and R2 can also be taken together as



where L is O, O(CH2)m+1O, or (CH2)m where m is 0-4; 15

> $R^3$ is H, C1-C6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH3, CH3O,

or CFa;

R4

5

10

20

25

30

45

50

55

is straight chain C1-C8 alkyl optionally substituted with F; C3-C8 branched alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy, F. Br. Cl. NH2. OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; C3-C6 alkenyl or alkynyl, C1-C3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C1-C4 alkvI.C1-C4 alkoxy, F. Br. Cl. NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8 or NCOR7; pentafluorophenyl, benzyl optionally substituted with

1 to 3 groups selected from C1-C4 alkyl or alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

R⁵ is H, C1-C6 alkyl, or benzyl; R6 is H, C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C3-C8 alkenyl or alkynyl,

phenyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy. F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF2, NO2, C1-C4 carboalkoxy,

NR7R8, or NCOR7;

R7 and R8 are selected independently from H or C1-C4 alkyl; 35

> Х is S(O),, O, NR5, CH2;

Α is C2-C10 alkyl, C3-C10 branched alkyl, C3-C10 alkenyl, or C3-C10 alkynyl;

Υ is O, S, H2;

z is NHR4, OR4, or R4;

is 0-2 40

or a pharmaceutically acceptable salt thereof.

#### 2. A compound of Claim 1 wherein

R1 and R2 are selected independently from C₁-C₈ alkyl, provided that when R¹ is C₁-C₈ alkyl,

> then R2 cannot be C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl, 2-, 3-, or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 2 groups selected from F, Cl, Br, OH, C1-C4 alkoxy,

C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃S(O)_r, NO₂, CF₃, or NR⁷R⁸; or

R1 and R2 can also be taken together as



- 15 where L is O, O(CH₂)_{m+1}O, or (CH₂)_m where m is 0-4.
  - 3. A compound of Claim 2 wherein

R³ is H, CH₃, phenyl;

5

10

20

30

35

40

45

50

55


R⁵ is H, C₁-C_a alkyl, C₃-C_b branched alkyl, C₃-C₇ cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Br, Cl, NH₅, OH, CN, CO₂H, CF₃, or di(C₁-C₄)-alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, or di(C₁-C₄)alkylamino;

br, Cl, Nn₂, On, CN, CO₂n, Cr₃, or αl(C₁-C₄)alkylamino; X is S(O)r, CH₂:

A is C2-C10 alkyl, C4-C9 branched alkyl.

A compound of Claim 3, wherein R¹ and R² are selected independently from C₁-C₂ alkyl, C₂-C₂ branched alkyl, C₂-C₂ cycloalkyl, C₂-C₁₀ cycloalkylalkyl, C₂-C₁₄ araalkyl, 2₂, 3₃, or 4-pyridinyl, 2² thienyl, or phenyl optionally substituted with 1 to 2 groups selected from F, Br, Cl, C₁-C₄ alkyl, C₃-C₃ branched alkyl, Ch₃-Q, Ch₃-QO₂, NO₂, CF₃, or di(C₁-C₄ )alkylamino; or

R1 and R2 can also be taken together as



where L is O or OCH₂O;

R³ is H;

R⁵ is C₁-C₆ alkyl, C₂-C₆ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₆ araalkyl, phenyl substituted with 1 to 3 groups selected from CH₃, F, Cl, CH₃O, CN; or benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Cl, or benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Cl, or benzyl optionally substituted.

CN; R⁶ is C₁-C₈ alkyl or phenyl optional

R⁶ is C₁-C₈ alkyl or phenyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F, Cl. or CN;

is C₄-C₉ alkyl;

X is S(O)_r;

Y is O, H₂.

- Compounds of claims 1 to 4, selected from N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2vlthio)pentyl-N-heptylurea:
  - N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea;
  - N-butyl-N'-(2,4-dlfluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]urea;
  - N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;
    - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylurea;
    - N-[5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyl]-N-heptyl-N'-propylurea;
    - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea;
      - N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl])pentyl]-N-heptylurea;
- 10 N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)urea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluoro-N-heptylbenzeneacetamide;
    - N'-cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;
    - N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurea;
    - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide;
- 15 N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea;
  - N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide;
  - N-[5-[4,5-bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea; phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate;
  - N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-
  - heptylurea;

5

20

25

30


35

40

45

50

- N-[5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea;
- N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide; phenyl [5-[4,5-bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl[heptylcarbamate;
- and N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.
- A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1 to 5 and a pharmaceutically acceptable carrier.
- 7. A process for preparing a compound of Formula (I):



wherein

R² and R² are selected independently from H, C, -C_a alkyl, provided that when R¹ is H, then R² cannot be H and when R¹ is C, -C_a alkyl, then R² cannot be C, -C_a alkyl, C, -C_a colladily, C, -C_a -C_a colladily, C, -C_a -C_a colladily, C, -C_a -C_a colladily, C, -C_a -C_a arailyl, 2-, 3 or 4 pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, G, -C_a alkowy, C, -C_a alkyl, C₃ -C_b branched alkyl, CH₃S(D), NO₂,

CF₃, or NR⁷R⁸; or

R1 and R2 can also be taken together as

55

where L is O. O(CH2)m+1O, or (CH2)m where m is 0-4; 15

> $\mathbb{R}^3$ is H, C1-C6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH3, CH3O, or CFa;

is straight chain C1-C8 alkyl optionally substituted with F; C3-C8 branched alkyl, C3-C7 R⁴ cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; C3-C6 alkenyl or alkynyl, C1-C3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl,C₁-C₄ alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR7R8 or NCOR7; pentafluorophenyl, benzyl optionally substituted with

1 to 3 groups selected from C1-C4 alkyl or alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF2, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; 2-, 3- or 4-pyridinyl, pyrimidinyl, or biphenyl;

R5 is H, C1-C6 alkyl, or benzyl;

R⁶ is H, C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C3-C8 alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy. F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C1-

C4 alkyl or alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7;

R7 and R8 are selected independently from H or C1-C4 alkyl; 35

Х is S(O), O, NR5, CH2:

Α is C2-C10 alkyl, C3-C10 branched alkyl, C3-C10 alkenyl, or C3-C10 alkynyl; Υ

is O, S, H2; z is NHR4, OR4, or R4;

is 0-2

5

10

20

25

30

40

45

50

55

or a pharmaceutically acceptable salt thereof, comprising the steps of: reacting a compound of the formula



where R1, R2, X, A, and R6, are as defined above, and R3 is as defined above, or a suitable protecting group, such as a silvl or a trityl group. with:

i) an isocyanate of the formula, R4-N=C=O, where R4 is as defined above, to yield a compound of Formula (I) above, where Y is O, and Z is NHR4; or

ii) an isothiocvanate of the formula, R4-N=C=S, where R4 is as defined above, to yield a compound of Formula (I) above, where Y is S, and Z is NHR4; or

iii) a chloroformate of the formula,

5

10

15

20

an

45

50

55

where  $R^4$  is as defined above, to yield a compound of Formula (I) above where Y is O and Z is  $OR^4$ ; or

iv) an acid chloride of the formula,



or other activated carboxylic acid, where R⁴ is as defined above, to yield a compound of Formula (I) above where Y is O and Z is R⁴.

- A process of Claim 7, further comprising removing any protecting group on R³, to yield a compound of Formula (I), where R³ is H.
- A process of Claim 7, further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.
- 10. A process of Claim 7, further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H₂.
- 11. A process of Claim 7, further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO₂, where r is 2.
- 12. A process of Claim 7, further comprising reacting a compound of Formula (I) where R³ is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where R³ is C₁-C₅ alkyl. alkyl. or benzyl.
- 13. A process comprising the steps of alkylating a compound of the formula,

### wherein B¹ and B²

are selected independently from H, C;-C₈ alkyl, provided that when R¹ is H, then R² cannot be H and when R¹ is C;-C₈ alkyl, then R² cannot be C;-C₈ alkyl, C₉-C₉ branched alkyl, C;-C₁-C₉ cycloalkyl, C;-C₁-C₉ cycloalkylakyl, C;-C₁-C₁ araalkyl, 2·, 3· or 4-pytidinyl, 2·-thienyl, 2·-turanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C;-C₉ aranched alkyl, C;-C₉ branched alkyl, C

CF3, or NR7R8; or

can also be taken together as R1 and R2

where L is O, O(CH2)m+1O, or (CH2)m where m is 0-4;

**R**3 is H, C1-C6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH3, CH3O, CF3, or an appropriate protecting group, such as a silvl or trityl group, and

х is O or S, with a compound of the formula,

where 30

5

10

15

20

25

35

40

45

50

55

М is halide or tosylate,

Α is C2-C10 alkyl, C3-C10 branched alkyl, C3-C10 alkenyl, or C3-C10 alkynyl;

is H. C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₃-C₈ alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy, F, Br, Cl, NH2, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂,

OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7;

is O, S, or H2, and

z is NHR4, OR4, or R4,

to yield a compound of Formula (I):

wherein

R1 and R2

are selected independently from H, C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C1-C4 alkoxy, C1-C4 alkyl, C3-C8 branched alkyl, CH3S(O), NO2, CF3, or NR7R8; or

R1 and R2 can also be taken together as

10 15

where L is O, O(CH2)m+1O, or (CH2)m where m is 0-4;

 $R^3$ is H, C1-C6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH3, CH3O,

R⁴

5

20

25

30

is straight chain C₁-C₈ alkyl optionally substituted with F; C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; C3-C6 alkenyl or alkynyl, C1-C3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl, C1-C4 alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8 or NCOR7; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; 2-, 3- or 4-pyridinyl,

pyrimidinyl, or biphenyl;

R5 is H, C1-C6 alkyl, or benzyl: R6

is H, C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C3-C8 alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy, F. Br. Cl. NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy; F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy,

35 NR7R8, or NCOR7:

> R7 and R8 are selected independently from H or C1-C4 alkyl;

х is S(O), O, NR5, CH2;

A is C2-C10 alkyl, C3-C10 branched alkyl, C3-C10 alkenyl, or C3-C10 alkynyl;

Υ is O. S. Ho: 40

> z is NHR4, OR4, or R4;

is 0-2.

and, optionally forming a pharmaceutically acceptable salt thereof.

- 45 14. A process of Claim 13 further comprising removing any protecting group on R3.
  - 15. A process of Claim 13 further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.
- 16. A process of Claim 13 further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H2.
- 17. A process of Claim 13, further comprising reacting a compound of Formula (I) where X is S with a suitable exidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO, where r is 2.
- 18. A process of Claim 13 further comprising reacting a compound of Formula (I) where R3 is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where R3 is C1-C6

alkyl, allyl, or benzyl.

### Claims for the following Contracting State: ES

### 1. A process for preparing a compound of Formula (I):

wherein

10

15

20

25


30

35

R1 and R2

are selected independently from H, C1-C8 alkyl, provided that when R1 is H, then R2 cannot be H and when R1 is C1-C2 alkvl, then R2 cannot be C1-C2 alkvl, C3-C3 branched alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl, 2-, 3- or 4pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F. Cl. Br. OH. C1-C4 alkoxy, C1-C4 alkyl, C2-C8 branched alkyl, CH2S(O), NO2. CF3, or NR7 R8; or

R1 and R2 can also be taken together as



40

45

50

55

R4

 $R^6$ 

where L is O, O(CH2)m+1O, or (CH2)m where m is 0-4;

is H, C1-C6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH3, CH3O,  $R^3$ or CF3:

is straight chain C₁-C₈ alkyl optionally substituted with F; C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; C3-C6 alkenyl or alkynyl, C1-C3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl,C1-C4 alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8 or NCOR7; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF2, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; 2-, 3- or 4-pyridinyl, pyrimidinyl, or

biphenyl:  $R^5$ is H, C₁-C₆ alkyl, or benzyl;

is H, C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C3-C8 alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C1-C4 alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C1 $C_4$  alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NB⁷R⁸, or NCOR⁷:

R7 and R8 are selected independently from H or C1-C4 alkyl;

X is S(O)₆, O, NR⁵, CH₂;

A is C₂-C₁₀ alkyl, C₃-C₁₀ branched alkyl, C₃-C₁₀ alkenyl, or C₃-C₁₀ alkynyl;

Y is O, S, H₂; Z is NHR⁴, OR⁴, or R⁴;

r is 0-2.

or a pharmaceutically acceptable salt thereof, comprising the steps of:

reacting a compound of the formula

$$\begin{array}{c|c} R^1 & & \\ & & \\ R^2 & & \\ & & \\ R^3 & & 6 \end{array}$$

where R1, R2, X, A, and R6, are as defined above, and R3 is as defined above, or a suitable protecting group, such as a silvi or a tritvi group.

with:

5

10

15

20

25

30

35

an

45

50

55

- i) an isocyanate of the formula, R⁴-N=C=O, where R⁴ is as defined above, to yield a compound of Formula (I) above, where Y is O, and Z is NHR⁴; or
- ii) an isothiocyanate of the formula, R*-N=C=S, where R* is as defined above, to yield a compound
  of Formula (I) above, where Y is S, and Z is NHR*; or
   iii) a chlordormate of the formula.

where R⁴ is as defined above, to yield a compound of Formula (I) above where Y is O and Z is OR⁴; or

iv) an acid chloride of the formula,

or other activated carboxylic acid, where R⁴ is as defined above, to yield a compound of Formula (I) above where Y is O and Z is R⁴.

2. A process of Claim 1 wherein

R1 and R2

R1 and R2 can also be taken together as



where L is O, O(CH₂)_{m+1}O, or (CH₂)_m where m is 0-4.

3. A process of Claim 2 wherein

5

10

20

30


35

40

45

50

- R3 is H, CH3, phenyl;
- R⁶ is H, C₁-C₂ alkyl, C₃-C₂ branched alkyl, C₃-C₇ cycloalkyl, phenyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, Fi, Br, Cl, NH₂, OH, CN, CO-H, CF₃, or di(C₁-C₃)-alkylamino; or benzyl optionally substituted with 1 to 3 groups selected from CH₃, CH₃O, F.
- Br, Cl, NH₂, OH, CN, CO₂H, CF₃, or di(C₁-C₄)alkylamino; X is S(O)r, CH₂:
- A is C2-C10 alkyl, C4-C9 branched alkyl.
- 4. A process of Claim 3, wherein R¹ and R² are selected independently from C₁-C₂ alkyl, C₂-C₂ branched alkyl, C₂-C₂ cycloalkyl, C₂-C₁ cycloalkyl, C₂-C₁, a rasalkyl, 2₂, 3₂, or 4-pyridinyl, 2-thienyl, or phenyl optionally substituted with 1 to 2 groups selected from F, Br, Cl, C₁-C₂ alkyl, C₂-C₂ branched alkyl, C₁-C₁-Cl, Slow, Cf₂, or di(C₁-C₂) alkyl, mino; or
  - R1 and R2 can also be taken together as



where L is O or OCH₂O;

R³ is H

F^k is C₁-C₆ alkyl, C₃-C₆ branched alkyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, C₇-C₁₄ arallyl, phenyl substituted with 1 to 3 groups selected from CH₃, F, Cl, CH₃O, CN; or benzyl coloinally substituted with 1 to 3 groups selected from CH₃ CH₃O, F, Cl, or benzyl coloinally substituted with 1 to 3 groups selected from CH₃ CH₃O, F, Cl, or benzyl coloinally substituted with 1 to 3 groups selected from CH₃ CH₃O, F, Cl, or benzyl coloinally substituted with 1 to 3 groups selected from CH₃ CH₃O, F, Cl, or benzyl colored from CH₃O, CH₃O

cn;

 $\mbox{R}^6$  is  $C_1\text{-}C_8$  alkyl or phenyl optionally substituted with 1 to 3 groups selected from  $\mbox{CH}_3,$   $\mbox{CH}_3O,$  F, Cl, or CN;

is C₄-C₉ alkyl;

55 X is S(O)_r;

Y is O, H₂,

- 5. A process of claims 1 to 4, wherein the compounds prepared are selected from N'-(2,4-difluorophenyl)-N-f5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyll-N-heptylurea:
  - N'-(2,4-difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylurea;
  - N-butyl-N'-(2,4 difluorophenyl)-N-[8-(4,5-diphenyl-1H-imidazo]-2-ylthio)octyl]urea;
  - N'-(2,4-dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea;
    - N-[5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyll-N-heptyll-N'-methylurea:
    - N-[5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurea:
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophenyl)-N-heptylurea;
    - N'-(2,4-difluorophenyl)-N-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfonyl])pentyl]-N-heptylurea;
- 10 N-[5-(4.5-diphenyl-1H-imidazol-2-vlthio)pentyl]-N-heptyl-N'-(1-methylethyl)urea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluoro-N-heptylbenzeneacetamide;
    - N'-cyclohexyl-N-f5-(4.5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea:
    - N'-(2.4-diffuorophenyl)-N-I5-I(4.5-diphenyl-1H-imidazol-2-yl)sulfinyl)pentyl]-N-heptylurea;
  - N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide;
- 15 N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea; N-[5-[4,5-bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacetamide;
  - N-[5-[4,5-bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea;
  - phenyl [5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]heptylcarbamate;
  - N-[5-[4,5-bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophenyl)-N-
- 20 heptylurea: N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylurea;
  - N-[5-[4,5-bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-heptylbenzeneacetamide;
  - phenyl [5-[4,5-bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptyl]carbamate:
  - and N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophenyl)-N-heptylurea.
  - 6. A process of Claim 1, further comprising removing any protecting group on R3, to yield a compound of Formula (I), where R3 is H.
- 7. A process of Claim 1, further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S. 30
  - 8. A process of Claim 1, further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H2.
  - 9. A process of Claim 1 , further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO2, where r is 2.
- 10. A process of Claim 1, further comprising reacting a compound of Formula (I) where R3 is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where R3 is C1-C6 an alkyl, allyl, or benzyl.
  - 11. A process comprising the steps of alkylating a compound of the formula.

#### 55 wherein

5

35

45

50

R1 and R2 are selected independently from H, C1-C8 alkyl, provided that when R1 is H, then R2 cannot be H and when R1 is C1-C8 alkyl, then R2 cannot be C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl, 2-, 3- or 4-

### EP 0 372 445 B1

pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C₁-C₄ alkoxy, C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃S(O)_r, NO₂, CF₃, or NR⁷R⁸; or

R1 and R2 can also be taken together as

where L is O. O(CH2)m+1O, or (CH2)m where m is 0-4:

R³ is H, C1-C6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH3, CH3O. CF3, or an appropriate protecting group, such as a silyl or trityl group, and

with a compound of the formula,

is O or S.

where

5

10

15

20

25

30

35

40

45

50

55

М is halide or tosvlate.

Α is C2-C10 alkyl, C3-C10 branched alkyl, C3-C10 alkenyl, or C3-C10 alkynyl;

is H, C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C3-C8 alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂. OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂,

OH, CN, CO2H, CF3, NO2, C1-C4 carboalkoxy, NR7R8, or NCOR7; Υ

is O, S, or H2, and

Z is NHR4, OR4, or R4,

to yield a compound of Formula (I):

wherein

R1 and R2 are selected independently from H, C1-C8 alkyl, C3-C8 branched alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkylalkyl, C7-C14 araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C₁-C₄ alkoxy, C₁-C₄ alkyl, C₃-C₈ branched alkyl, CH₃S(O)₇, NO₂, CF₃, or NR⁷R⁸; or

R1 and R2 can also be taken together as

where L is O, O(CH2)m+1O, or (CH2)m where m is 0-4;

R3 is H, C1-C6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH3, CH3O,

or CF₃;

R⁴

5

10

15

20

25

30

35

40

45

50

55

is straight chain G.-Ca alkyl optionally substituted with F. Gg-C_b branched alkyl, Gg-C_c cycloalkyl, C-Ch₀ cycloalkyl, CF-Ch₁ arealkyl where the anyl group is optionally substituted with 1 to 3 groups selected from Gg-C_b alkyl or alkoxy, F. Br, Cl, NH₅, OH, CN, COg-H, CF₅, NO₅, Cr-C_c carboalkoxy, NR PR or NCORP'; Cg-C_c alkenyl or alkynyl, Cg-C_g perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from G-C_c alkyl,Gg-C_c alkoxy, F. Br, Cl, NH₅, OH, CN, COg-H, CF₅, NO₅, Gr-C_c carboalkoxy, NR'PR or NCORP pentalfurophenyl, benzyl optionally substituted with 1 to 3 groups selected from G-C₆ alkyl or alkoxy, F. Br, Cl, NH₅, OH, CN, COg-H, CF, NO₅, Gg-C_c carboalkoxy, NR'PR or NCORPS'; 2-3 or d-pyridinyl, penylmidinyl, or

biphenyl; R⁵ is H, C₁-C₆ alkyl, or benzyl;

R⁶ is H, C₁-C₈ alkyl, C₃-C₈ branched alkyl, C₃-C₇ cycloalkyl, C₃-C₈ alkenyl or alkynyl,

phenyl optionally substituted with 1 to 3 groups selected from C₁-C₄ alkyl or alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NP²R³, or NCOR²; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C₁-C₄

C4 alkyl or alkoxy; F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄ carboalkoxy, NR⁷R⁸, or NCOR⁷;

R⁷ and R⁸ are selected independently from H or C₁-C₄ alkyl;

X is S(O),, O, NR⁵, CH₂;

A is C₂-C₁₀ alkyl, C₃-C₁₀ branched alkyl, C₃-C₁₀ alkenyl, or C₃-C₁₀ alkynyl;

Y is O. S. H₂:

Z is NHR⁴, OR⁴, or R⁴;

r is 0-2,

- and, optionally forming a pharmaceutically acceptable salt thereof.
- 12. A process of Claim 11 further comprising removing any protecting group on R3.
- 13. A process of Claim 11 further comprising reacting a compound of Formula (I) where Y is O with Lawesson's reagent or diphosphorous pentasulfide to yield a compound of Formula (I) where Y is S.
- 14. A process of Claim 11 further comprising reacting a compound of Formula (I) where Y is O with a reducing agent such as lithium aluminum hydride or sodium borohydride, to yield a compound of Formula (I) where Y is H₂.
- 15. A process of Claim 11 further comprising reacting a compound of Formula (I) where X is S with a suitable oxidizing agent to yield either the sulfoxide, SO, where r is 1, or the sulfone, SO₂, where r is 2.

- 16. A process of Claim 11 further comprising reacting a compound of Formula (I) where R3 is H with a suitable alkylating agent such as an alkyl halide, to yield a compound of Formula (I) where R3 is C1-C6 alkyl alkyl, or benzyl.
- 5 17. A process for preparing a pharmaceutical composition comprising mixing a therapeutically effective amount of a compound prepared according to any one of claims 1 to 16 and a pharmaceutically acceptable carrier.

### Patentansprüche

15

20

25

30

35

40

45

# 10 Patentansprüche für folgende Vertragsstaaten : AT. BE. CH. DE. FR. GB. GR. IT. LI. LU. NL. SE

### 1. Verbindung der Formel

R 2 N X -A -N -R (

# Formel (I)

zusammengenommen auch

### in welcher R1 und R2

unabhängig ausgewählt sind aus H, C₁-C₂-Alkyl, vorausgesetzt, daß wenn R¹ H ist, R² nicht H sein kann und wenn R¹ - C₁-C₂-Alkyl ist, R² nicht C₁-C₂-Alkyl sein kann, verzweigtern C₂-C₂-Alkyl, C₂-C₇-Cycloalkyl, C₂-C₁-Cycloalkyl, C₇-C²-Cy-Alkyl, Z, C₇-Cycloalkyl, C₇-C²-Cycloalkyl, C₇-C²-Cycloalkyl, C₇-C₇-Cycloalkyl, C₇-C₇-Cycloalkyl, C₇-C₇-Cycloalkyl, C₇-C₇-Cycloalkyl, C₇-Cycloalkyl, C₇-Cycloalkyl,

R1 und R2

R4

50

55

sein können, worin L O, O(CH2)m+1O oder (CH2)m ist, worin m 0-4 ist,

R³ H, C₁-C₆-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH₃, CH₃O oder CF₃ substituiertes Phenyl ist.

geraldettiges C₁-C₈-Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes C₉-Alkyl, C₉-C₇-Cycloalkyl, C₄-C₁₉-Cycloalkylalkyl, C₇-C₁₋-Aralkyl, worin die Aryl-gruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C₁-C₆-Alkyl oder Alkoxy, F. Br, Cl, NH₉, OH, CN, CO₉H, CF₉, NO₉, C₁-C₆-Carbalkoxy, NIF²R³ oder NOCDF ausgewählt sind, C₇-C₈-Alkenyl oder -Alkinyl, C₁-C₉-Perfluoralkyl, Phenyl, das

### EP 0 372 445 B1

gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus Cı-Cı-Alkyl, Cı-CıAlkoxy, F. Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, Cı-Cı-Carbalkoxy, NRYR^a oder
NCOR^a ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3
Gruppen substituiert ist, die aus Cı-Cı-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN,
CO₂H, CF₃, NO₂, Cı-Cı-Carbalkoxy, NRYR^a oder NCOR^a ausgewählt sind, 2-, 3- oder
4-Pvridinvl, Vermidninvl oder Bibnehvl ist.

R⁵ H, C₁-C₆-Alkyl oder Benzyl ist.

H. C.-Ca-Alkyl, verzweigtes Ca-Ca-Alkyl, Ca-Ca-Cycloalkyl, Ca-Ca-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C₁-Ca-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-Ca-Carbalkoxy, NR'R[®] oder NCOR' ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenen-ralk mit 1 bis 3 Gruppen substituiert ist, die aus C₁-Ca-Alky oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-Ca-Carbalkoxy, NR'R[®] oder NCOR' ausgewählt.

unabhängig aus H oder C₁-C₄-Alkyl ausgewählt sind,

R⁷ und R⁸

R6

5

10

15

20

25

30

35

40

45

50

55

X S(O)_r, O, NR⁵, CH₂ ist,

A C₂-C₁₀-Alkyl, verzweigtes C₃-C₁₀-Alkyl, C₃-C₁₀-Alkenyl oder C₃-C₁₀-Alkinyl ist,

Y O, S, H₂ ist,

Z NHR⁴, OR⁴ oder R⁴ ist, r 0-2 ist.

oder ein pharmazeutisch annehmbares Salz derselben.

2. Verbindung des Anspruchs 1, in welcher

R¹ und R² unabhāngig ausgewählt sind aus C₁-C₂-Alkyl, vorausgesetzt, daß wenn R¹ C₁-C₂-Alkyl ist, R² nicht C₁-C₂-Alkyl sein kann, verzweigtem C₃-C₂-Alkyl, C₂-C₂-C₂-Colelkyl, C₂-C₁-Cycloalkylalkyl, C₂-C₃-C₂-Aralkyl, 2₂-3 oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phe-

nyl, das gegebenentalls mit 1 bis 2 Gruppen substituiert ist, die aus F, Cl, Br, OH, Cı-Cı-Alkoyy, Cı-Cı-Alkyl, verzweigtem C₃-C₂-Alkyl, CH₃S(O), NO₂, CF₃ oder NR? Räussewählt sind, oder

ausgewanit sind, oder

R1 und R2 auch als



zusammengenommen werden können, worin L O,  $O(CH_2)_{m+1}O$  oder  $(CH_2)_m$  ist, worin m 0-4 ist.

- 3. Verbindung des Anspruchs 2, in welcher
  - R³ H, CH₃, Phenyl ist,
    - R^E H, C; -Ca-Alkyl, verzweigles C₂-Ca-Alkyl, Ca-C₂-Cycloalkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH₂, CH₃O, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃ oder Di(C; -Ca-)alkylamino ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH₃, CH₃O, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃ oder Di(C; -Ca-lalkylamino ausgewählt sind.
    - X S(O), CH2 ist,
    - A C₂-C₁₀-Alkyl, verzweigtes C₄-C₉-Alkyl ist.

### 4. Verbindung des Anspruchs 3, in welcher

R¹ und R² unabhängig ausgewählt sind aus C₁-C₂-Alkyl, verzweigtem C₃-C₃-Cklyl, C₂-C₂-Cycloalkyl, C₄-C₁-Cycloalkylalkyl, Cȝ-C₁-A-ralkyl, 2₋, T₃-oder 4-Pyridinly, 2-Thienyl, das gegebenerfalls mit 1 bis 2 Gruppen substituiert ist, die aus F. Br.

C₁-C₄-Alkyl, verzweigtem C₃-C₈-Alkyl, CH₃O, CH₃S(O)_r, NO₂, CF₃ oder Di(C₁-C₄)-

alkylamino ausgewählt sind, oder

R1 und R2 auch als

5

10

15

20

25

35

40

50

55

zusammengenommen werden können, worin L O oder OCH2O ist,

- R³ Hist
- R⁴ C₁-C₂-Alkyl, verzweigtes C₂-C₃-Alkyl, C₃-C₇-Cycloalkyl, C₄-C₁₉-Cycloalkylalkyl, C₇-C₁₁-Aralkyl, Phenyl, das mit 1 bis 3 Gruppen substitutert ist, die aus CH₃, F, Cl, CH₃O, CN ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substitutert ist, die aus CH₃, CH₃O, F, Cl oder CN ausgewählt sind.
- 30 R⁶ C₁-C₈-Alkyl oder Phenyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH₃, CH₃O, F, Cl oder CN ausgewählt sind,
  - A C4-C9-Alkyl ist.
  - X S(O), ist.
  - Y O, H₂ ist.

5. Verbindungen der Ansprüche 1 bis 4, die aus

N'-(2,4-Difluorphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylharnstoff,

N'-(2,4-Difluorphenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptylharnstoff,

N-Butyl-N'-(2,4-difluorphenyl)-N-[8-(4,5-diphenyl-1H-imidazol-2-ylthio)octyl]harnstoff,

N'-(2.4-Dimethoxyphenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-yl-thio)pentyl]-N-heptylhamstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylharnstoff,

N-[5-(4.5-Diphenyl-1H-imidazol-2-vlthio)pentyl]-N-heptyl-N'-propylharnstoff.

N-[5-(4.5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorphenyl)-N-heptylharnstoff,

N'-(2,4-Diffuorphenyl)-N-[5-[(4,5-Diphenyl-1H-imidazol-2-yl)sulfonyl])pentyl]-N-heptylhamstoff,

45 N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-methylethyl)harnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluor-N-heptylbenzolacetamid,

N'-Cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl)-N-heptylharnstoff,

N'-(2,4-Diffuorphenyl)-N-[5-[(4,5-Diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylharnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamid,

N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff,

N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexanacetamid,

N-[5-[4,5-Bis(2-methoxyphenyl)-1H-imidazol-2-ylthio] pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff, and the sum of the property of the pr

[5-(4.5-Diphenyl-1H-imidazol-2-vlthio)pentyl]heptylcarbaminsäure-phenylester.

N-[5-[4,5-Bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-

hepty/harnstoff,

N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylharnstoff,

N-[5-[4,5-Bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluor-N-heptylbenzolacetamid,

[5-[4,5-Bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]heptylcarbaminsäure-phenylester und

N-[5-(4,5-Dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-diffuorphenyl)-N-heptylharnstoff ausgewählt sind.

- Pharmazeutische Zusammensetzung umfassend eine therapeutisch wirksame Menge einer Verbindung der Ansprüche 1 bis 5 und einen pharmazeutisch annehmbaren Träger.
  - 7. Verfahren zum Herstellen einer Verbindung der Formel (I)

in welcher

10

15

20

25

30

35

40

45

50

55

R4

R¹ und R² unabhängig ausgewählt sind aus H, C₁-C₀-Alkyl, vorausgesetzt, daß wenn R¹ H ist, R² nicht H sein kann und wenn R¹ C₁-C₀-Alkyl ist, R² nicht C₁-C₀-Alkyl sein kann.

verzweigtem C₂-C₂-Alkyl, C₃-C₇-Cycloalkyl, C₄-C₁₀-Cycloalkylalkyl, C₇-C₁₋-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH, C₁-C₄-Alkoxy, C₁-C₄-Alkyl, verzweigtem C₃-C₄-Alkyl, CH₃S(O), NO₂, CF₃ oder NR⁷R³ ausgewählt sind, oder

R1 und R2 zusammengenommen auch

sein können, worin L O, O(CH2)m+1O oder (CH2)m ist, worin m 0-4 ist,

R³ H, C₁-C₅-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH₃, CH₃O oder CF₃ substituiertes Phenyl ist.

R⁵ H, C₁-C₆-Alkyl oder Benzyl ist,

F^E H. C. -Ce-Alkyl, verzweigtes Ca-Ca-Alkyl, Ca-Cr-Cycloalkyl, Ca-Ca-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C; -Ca-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C; -Ca-Carbalkoxy, NR²/R³ oder NCOR² ausgewählt sind, Pentalluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C; -Ca-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C; -Ca-Carbalkoxy, NR²/R³ oder NCOR² ausgewählt sind.

R7 und R8 unabhängig aus H oder C1-C4-Alkyl ausgewählt sind,

X S(O)_r, O, NR⁵, CH₂ ist,

A C₂-C₁₀-Alkyl, verzweigtes C₃-C₁₀-Alkyl, C₃-C₁₀-Alkenyl oder C₃-C₁₀-Alkinyl ist,

Y O, S, H₂ ist,

5

10

15

20

25

30

35

40

45

50

Z NHR⁴, OR⁴ oder R⁴ ist,

oder eines pharmazeutisch annehmbaren Salzes derselben, umfas send die Schritte des Umsetzens einer Verbindung der Formel

$$\begin{array}{c|c} R^2 & N \\ & N \\ & R^2 \end{array}$$

worin R¹, R², X, A und R⁶ wie vorstehend definiert sind, und R³ wie vorstehend definiert oder eine geeignete Schutzgruppe ist, wie etwa eine Silyl- oder Tritylgruppe, mit

- i) einem Isocyanat der Formel R⁴-N=C=O, worin R⁴ wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z NHR⁴ ist, oder
- ii) einem Isothiocyanat der Formel R⁴-N=C=S, worin R⁴ wie vorstehend definiert ist, unter Liefem einer Verbindung der vorstehenden Formei (I), worin Y S ist und Z NHR⁴ ist, oder iii) einem Chlorameisens≅üreester der Formel

worin R⁴ wie vorstehend definiert ist, unter Ergeben einer Verbindung der vorstehenden Formel (I), worin Y O ist und z OR⁴ ist, oder iv) einem Säurechlorid der Formel



oder einer anderen aktivierten Carbonsäure, worin  $R^4$  wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z  $R^4$  ist.

- Verfahren des Anspruchs 7, das weiter das Entfernen einer etwaigen Schutzgruppe an R³ unter Liefern einer Verbindung der Formel (I), worin R³ H ist, umfaßt.
  - Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit Lawessons Reagenz oder Diphosphorpentasulfid unter Liefern einer Verbindung der Formel (I),

worin Y S ist, umfaßt.

- Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y ½, ist, umfaßt.
- Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist, mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfons SO₂, wobei r 2 ist, umfaßt.
- 12. Verfahren des Anspruchs 7, das weiter das Umsetzen einer Verbindung der Formel (I), worin R³ H ist, mit einem geeigneten Alkylibengsmittel wie etwe einem Alkylhatogenid unter Liefern einer Verbindung der Formel (I), worin R³ C₁-C₂-Alkyl, Allyl der Benzyl ist, umfaßt.
- 15 13. Verfahren, umfassend die Schritte des Alkylierens einer Verbindung der Formel

$$\mathbb{R}^1 \longrightarrow \mathbb{N}$$

$$\mathbb{R}^2 \longrightarrow \mathbb{N}$$

$$\mathbb{R}^3$$

in welcher

10

20

25

30

35

40

45

R1 und R2

unabhängig ausgewählt sind aus H. C.-Cq-Alkyl, vorausgesetzt, daß wenn Ri' H ist, Richt H sein kann und wenn Ri' Cq-Cq-Alkyl ist, R² nicht Cq-Cq-Alkyl sein kann, verzweigtem Cq-Cq-Alkyl, Cq-Cq-Cycloalkyl, Cq-Cq-Cq-Cycloalkyl, Cq-Cq-Arkyl, Cq-Cq-Arkyl, 2- oder 4-Pyridinyl, 2-Tnienyl, 2-Furanyl, Phenyl, das gegebenerfalls mit 1 bis 3 Gruppen substitutert ist, die aus F, Cl, Br, OH, Cq-Cq-Alkyl, Cq-Cq-Alkyl, verzweigtem Cq-Cq-Alkyl, Cths Si(O), NOq, CFq oder NRTR ausgewählt sind, oder

B1 und B2

zusammengenommen auch



50 Sein B³ H. C

sein können, worin L O,  $O(CH_2)_{m+1}O$  oder  $(CH_2)_m$  ist, worin m 0.4 ist, H,  $G_1-G_2$ -Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl,  $CH_3$ ,  $CH_3O$  oder  $CF_3$  substituiertes Phenyl, oder eine geeignete Schutzgruppe ist, wie etwa eine Silyl-oder Tritylgruppe, und

X O oder S ist,

55 mit einer Verbindung der Formel

worin

5

10

15

20

25

30

35

40

45

50

55

М ein Halogenid oder Tosylat ist,

Α C2-C10-Alkyl, verzweigtes C3-C10-Alkyl, C3-C10-Alkenyl oder C3-C10-Alkinyl ist,

H, C1-C8-Alkyl, verzweigtes C3-C8-Alkyl, C3-C7-Cycloalkyl, C3-C8-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy. F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind,

Υ O. S oder H2 ist und

Z NHR⁴, OR⁴ oder R⁴ ist,

unter Liefern einer Verbindung der Formel (I)

in welcher

R1 und R2 unabhängig ausgewählt sind aus H. C1-C8-Alkvl, verzweigtem C3-C8-Alkvl, C3-C7-Cycloalkyl, C4-C10-Cycloalkylalkyl, C7-C14-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl. Br. OH, C1-C4-Alkoxy, C1-C4-Alkyl, verzweiatem C3-C8-Alkyl, CH3S(O), NO2, CF3 oder NR7R8 ausgewählt sind, oder

R1 und R2 zusammengenommen auch

sein können, worin L O, O(CH2)m+1O oder (CH2)m ist, worin m 0-4 ist, **R**3 H, C1-C6-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH3, CH3O oder CF3 substituiertes Phenyl ist, R4

geradkettiges C1-C8-Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes C3-

C₂-Alkyl, C₃-C₇-Cycloalkyl, C₃-C₁-Cycloalkylalkyl, C₇-C₁-Aralkyl, worin die Aryl-gruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C₁-C₄-Alkyl oder Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄-Carbailkoxy, NR² R³ oder NCOR² ausgewähnt sind, C₃-C₈-Alkenyl oder -Alkinyl, C₁-C₃-Perfluoralkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substitutiert ist, die aus C₁-C₄-Alkyl, C₁-C₄-Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄-Carbailkoxy, NR² R³ oder NCOR² ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C₁-C₄-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C-C₄-Carbailkoxy, NR² R³ oder NCOR² ausgewählt sind, 2-, 3- oder 4-Pyrdight, Pyrmidighty oder Biphenyl ist.

R⁵ H, C₁-C₆-Alkyl oder Benzyl ist,

R⁵ H, C₁-C₆-Alkyl, verzweigtes C₂-C₆-Alkyl, C₃-C₇-Cycloalkyl, C₃-C₆-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C; C₄-Alkyl oder -Alkoy, F, Br, Cl, NH₂, OH, Ch, CQ+I, CF₃, NQ₂, C; C₄-Carbalkoxy, NR⁷R⁸ oder NCOR⁷ ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenen

falls mit 1 bis 3 Gruppen substituiert ist, die aus C;-Ca-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-Ca-Carbalkoxy, NR⁷ R⁸ oder NCOR⁷ ausgewählt sind,

R7 und R8 unabhängig aus H oder C1-C4-Alkyl ausgewählt sind,

X S(O)_r, O, NR⁵, CH₂ ist,

A C₂-C₁₀-Alkyl, verzweigtes C₃-C₁₀-Alkyl, C₃-C₁₀-Alkenyl oder C₃-C₁₀-Alkinyl ist,

Y 0, S, H₂ ist,

Z NHR⁴, OR⁴ oder R⁴ ist,

r 0-2 ist,

5

10

15

20

30

35

an

50

55

- 25 und gegebenenfalls das Bilden eines pharmazeutisch annehmbaren Salzes derselben.
  - 14. Verfahren des Anspruchs 13, das weiter das Entfernen einer etwaigen Schutzgruppe an R3 umfaßt.
  - Verfahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y D ist, mit Lawessons Reagenz oder Diphosphorpentasulfid unter Liefern einer Verbindung der Formel (I), worin Y S ist, umfaßt.
  - 16. Verlahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y H₂ ist, umfaßt.
  - Verlahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist, mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfoxs SO₂, wobei r 2 ist, umfaßt.
  - 18. Verfahren des Anspruchs 13, das weiter das Umsetzen einer Verbindung der Formel (I), worin R3 H ist, mit einem geeigneten Alkylierungsmittel wie etwa einem Alkylhalogenid unter Liefern einer Verbindung der Formel (I), worin R3 Cr-Cs-Alkyl. Allyl oder Benzyl ist, umfaßt.
- 45 Patentansprüche für den Vertragsstaat : ES
  - 1. Verfahren zur Herstellung einer Verbindung der Formel (I)

in welcher

R1 und R2

unabhängig ausgewählt sind aus H, C1-C8-Alkyl, vorausgesetzt, daß wenn R1 H ist, R2 nicht H sein kann und wenn R1 C1-C2-AlkvI ist, R2 nicht C1-C2-AlkvI sein kann. verzweigtem C₃-C₈-Alkyl, C₃-C₇-Cycloalkyl, C₄-C₁₀-Cycloalkylalkyl, C₇-C₁₄-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl, Br, OH, C1-C4-Alkoxy, C1-C4-Alkyl, verzweigtem C₃-C₈-Alkyl, CH₃S(O), NO₂, CF₃ oder NR⁷R⁸ ausgewählt sind, oder

R1 und R2 zusammengenommen auch

10

5

15

20

**P**3 25

30

35

40

**P**5 R6

R4

45

R7 und R8 х

Α

Υ O. S. Ho ist.

Z NHR⁴, OR⁴ oder R⁴ ist.

0-2 ist,

sein können, worin L O, O(CH2)m+1O oder (CH2)m ist, worin m 0-4 ist,

H, C1-C6-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH3, CH3O oder CF3 substituiertes Phenyl ist.

geradkettiges C1-C8-Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes C3-C8-Alkyl, C3-C7-Cycloalkyl, C4-C10-Cycloalkylalkyl, C7-C14-Aralkyl, worin die Arylgruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind, C3-C6-Alkenyl oder -Alkinyl, C1-C3-Perfluoralkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl, C1-C4-Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄-Carbalkoxy, NR⁷R⁸ oder NCOR7 ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH2, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄-Carbalkoxy, NR⁷R⁸ oder NCOR⁷ ausgewählt sind, 2-, 3- oder

4-Pyridinyl, Pyrimidinyl oder Biphenyl ist, H, C1-C6-Alkyl oder Benzyl ist,

H, C1-C8-Alkyl, verzweigtes C3-C8-Alkyl, C3-C7-Cycloalkyl, C3-C8-Alkenyl oder -Alkinvl. Phenvl. das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F. Br. Cl. NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind.

unabhängig aus H oder C1-C4-Alkvl ausgewählt sind.

S(O), O, NR5, CH2 ist,

C2-C10-Alkyl, verzweigtes C3-C10-Alkyl, C3-C10-Alkenyl oder C3-C10-Alkinyl ist,

oder eines pharmazeutisch annehmbaren Salzes derselben, umfassend die Schritte des Umsetzens einer Verbindung der Formel

55

50

$$\begin{array}{c|c} R^2 & N \\ & N \\ & R^3 & 6 \end{array}$$

worin R¹, R², X, A und R⁵ wie vorstehend definiert sind, und R³ wie vorstehend definiert oder eine geeignete Schutzgruppe ist, wie etwa eine SilvI- oder Tritylgruppe, mit

- einem Isocyanat der Formel R⁴-N=C=O, worin R⁴ wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (D. worin Y O ist und Z NHR⁴ ist, oder
- ii) einem Isothiocyanat der Formel R¹-N=C=S, worin R¹ wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y S ist und Z NHR⁴ ist, oder
- iii) einem Chlorameisensäureester der Formel

5

10

15

20

25

30

an

45

50

55

worin  $R^4$  wie vorstehend definiert ist, unter Ergeben einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z  $OR^4$  ist, oder

iv) einem Säurechlorid der Formel



35 oder einer anderen aktivierten Carbonsäure, worin R⁴ wie vorstehend definiert ist, unter Liefern einer Verbindung der vorstehenden Formel (I), worin Y O ist und Z R⁴ ist.

2. Verfahren des Anspruchs 1, bei welchem

R1 und R2 auch als

zusammengenommen werden können, worin L O, O(CH₂)_{m+1}O oder (CH₂)_m ist, worin m 0-4 ist.

- 3. Verfahren des Anspruchs 2, bei welchem
- R³ H, CH₃, Phenyl ist,
  - R⁶ H. C.-C₃-Alkyl, verzweigles C₇-C₃-Alkyl, C₇-C₇-Cycloalkyl, Phenyl, das gepsbenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH₃, CH₂O, F. Br, Cl, NH₂, OH, CN, CO₂H, CF₃ oder Di(C₁-C₂)alkylamino ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH₃, CH₃O, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃ oder Di(C₁-C₂)alkylamino ausgewählt sind.
- 25 X S(O)_r, CH₂ ist,

5

10

15

20

30

35

40

45

55

- A C₂-C₁₀-Alkyl, verzweigtes C₄-C₂-Alkyl ist.
- 4. Verfahren des Anspruchs 3, bei welchem
  - R¹ und R² unabhängig ausgewählt sind aus C₁-C₂-Alkyl, verzweigtem C₂-C₂-Alkyl, C₂-C₂-Cycloalkyl, C₄-C₁-Cycloalkylalkyl, C₂-C₁-Aralkyl, 2₂-3₂- oder 4-Pyridinyl, 2-Thienyl oder Phenyl, das gegebenentalls mit 1 bis 2 Gruppen substituiert ist, die aus F, Br, Cl, C₁-C₄-Alkyl, verzweigtem C₂-C₂-Alkyl, Ch₃-O, Ch₃-S(O), NO₂, CF₂- oder Di(C₁-C₄)-alkylamino ausgewählt sind, oder
  - B1 und B2 auch als



- zusammengenommen werden k\u00f6nnen, worin L O oder OCH2O ist,
  - R3 Hist,
  - R⁴ C₁-C₈-Alkyl, verzweigtes C₃-C₈-Alkyl, C₃-C₇-Cycloalkyl, C₄-C₁₉-Cycloalkylalkyl, C₇-C₁₅-Aralkyl, Phenyl, das mit 1 bis 3 Gruppen substituiert ist, die aus CH₃, F, Cl, CH₃O, CN ausgewählt sind, oder Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH₃, CH₃O, F, Cl oder CN ausgewählt sind,
  - R⁶ C₁-C₈-Alkyl oder Phenyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus CH₃, CH₃O, F, Cl oder CN ausgewählt sind,
  - A C₄-C₉-Alkyl ist,

### EP 0 372 445 B1

- X S(O), ist,
  - O. H₂ ist.
- Verfahren der Ansprüche 1 bis 4, wobei die hergestellten Verbindungen aus
   N°.24.-Diffluorphenly)-N-15-(4.5-diphonyl-1H-imidazol-2-ylthio)pentyl-N-heptytharnstoff,
   N°.42.4-Diffluorphenyl-N-18-(4.5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptytharnstoff,
   N-Butyl-N°.42.-diffluorphenyl-N-18-(4.5-diphenyl-1H-imidazol-2-ylthio)octyl]-N-heptytharnstoff,
   N°.24.-Diffluorphenyl-N-18-(4.5-diphenyl-1H-imidazol-2-yl-thio)octyl]-N-heptytharnstoff,
- N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-methylharnstoff, N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylharnstoff,
  - o N-j3-(4,5-Dipheny)+ IH-Imidazo2-zymno;pernyj-N-repryk-N-popynamson; N-j5-(4,5-Dipheny)+ Ihridazo2-zymno;pernyj-N-repryk-N-popynamson; N-(2,4-Difluorpheny)-N-j5-(4,5-Dipheny)+ IH-Imidazo2-zyhjaufonyi);pernyj-N-reprykhamstoff, N-j5-(4,5-Dipheny)+ Ihridazo2-zyhiopernyi-N-ri-nerhyt-N-ri-nerhyt-thylhamstoff.
- N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-2,4-difluor-N-heptylbenzolacetamid,
  N-Cyclohexyl-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylharnstoff,
  N'(2,4-Difluoryhenyl-N-[5-(4,5-Diphenyl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylharnstoff,
  N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamid,
  - N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff, N-[5-[4,5-Bis(1-methylethyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexanacetamid,
- 20 N-[5-[4,5-Bis(2-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff, [5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentylheptylcarbarninsäure-phenylester, N-[5-[4,5-Bis[4-(dimethylamino)phenyl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorphenyl)-N-heptylharnstoff.
  - N-[5-(4,5-Diphenyl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phenylharnstoff,
- 25 N-[5-[4,5-Bis(4-methoxyphenyl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluor-N-heptylbenzolacetamid, [5-[4,5-Bis(4-(dimethylamino)phenyl)-1H-imidazol-2-ylthio]pentyl]hoptylcarbaminsäure-phenylester und N-[5-(4,5-Dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N-(2,4-difluorphenyl)-N-heptylhamstoff ausgewählt sind.
- Verfahren des Anspruchs 1, das weiter das Entfernen einer etwaigen Schutzgruppe an R³ unter Liefern einer Verbindung der Formel (I), worin R³ H ist, umfaßt.
- Verfahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit Lawessons Reagenz oder Diphosphorpentasultid unter Liefern einer Verbindung der Formel (I), worin Y S ist umfahr.
  - Verlahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y H₂ ist, umfaßt.
  - Verfahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfons SO, wobei r 2 ist, umfaßt.
- 46 10. Verfahren des Anspruchs 1, das weiter das Umsetzen einer Verbindung der Formel (I), worin R³ H ist, mit einem geeigneten Alkylierungsmittel wie etwa einem Alkylhalogenid unter Liefern einer Verbindung der Formel (I), worin R³ C₁-C₂-Alkyl, Allyl oder Benzyl ist, umfaßt.

an

### 11. Verfahren, umfassend die Schritte des Alkylierens einer Verbindung der Formel

H₂ N X

in welcher

5

10

15

20

25

30

R' und R²
unabhängig ausgewählt sind aus H, C₁-C₈-Alkyl, vorausgesetzt, daß wenn R¹ H ist, R²
nicht H sein kan und wenn R¹ C₁-C₈-Alkyl ist, R² nicht C₁-C₈-Alkyl sein kann,
verzweigtem C₉-C₈-Alkyl, C₉-Cy-Cycloalkyl, C₁-C₁-C₁-Cycloalkyl, C₂-C₁-C₁-Alkyl, 23- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3
Gruppen substituiert ist, die aus F, C₁, Br, OH, C₁-C₄-Alkoyl, C₁-C₄-Alkyl, verzweigtem C₂-C₈-Alkyl, CH₈S(D), NC₉, CF₉ oder NR²R ausgewählt sind, oder

R1 und R2 zusammengenommen auch

35

40

45

55

R3

sein können, worin L O, O(CH2)m+1O oder (CH2)m ist, worin m 0-4 ist,

H, C₁-C₆-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH₃, CH₃O oder CF₃ substituiertes Phenyl, oder eine geeignete Schutzgruppe ist, wie etwa eine Silyl- oder Tritivloruppe, und

X O oder S ist, mit einer Verbindung der Formel

50 worin

R6

M ein Halogenid oder Tosylat ist,

A C2-C10-Alkyl, verzweigtes C2-C10-Alkyl, C2-C10-Alkenyl oder C2-C10-Alkinyl ist.

H, C. -C₈-Alkyl, verzweigtes C₃-C₂-Alkyl, C₃-C₇-Cycloalkyl, C₃-C₆-Alkenyl oder -Alkinyl, Phenyl, das gegebenentalls mit 1 bis 3 Gruppen substitueri tst, die aus C₁-C.-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄-Carbalkoxy, NH² Pl³ oder NCOPl² ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C₁-C₄-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂-H, CF₃, NO₂, C₁-C₄-Carbalkoxy, NH² Pl³ oder NCOPl² ausgewählt sind,

O, S oder H2 ist und

z NHR⁴, OR⁴ oder R⁴ ist.

unter Liefern einer Verbindung der Formel (I)

in welcher

5

10

15

20

25

30

R1 und R2

unabhängig ausgewählt sind aus H, C₁-C₈-Alkyl, verzweigtem C₃-C₈-Alkyl, C₃-C₇-Cycloalkyl, C4-C10-Cycloalkylalkyl, C7-C14-Aralkyl, 2-, 3- oder 4-Pyridinyl, 2-Thienyl, 2-Furanyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus F, Cl. Br. OH. C1-C4-Alkoxy, C1-C4-Alkyl, verzweigtem C3-C8-Alkyl, CH3S(O), NO2, CF3 oder NR7R8 ausgewählt sind, oder

R1 und R2 zusammengenommen auch

35

40

45

50

sein können, worin L O, O(CH2)m+1O oder (CH2)m ist, worin m 0-4 ist,

 $R^3$ R⁴ H, C₁-C₆-Alkyl, Allyl, Benzyl oder gegebenenfalls mit F, Cl, CH₃, CH₂O oder CF₃ substituiertes Phenyl ist.

geradkettiges C1-C8-Alkyl, das gegebenenfalls mit F substituiert ist, verzweigtes C3-C8-Alkyl, C3-C7-Cycloalkyl, C4-C10-Cycloalkylalkyl, C7-C14-Aralkyl, worin die Arylgruppe gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH₂, OH, CN, CO₂H, CF₃, NO₂, C₁-C₄-Carbalkoxy, NR⁷R⁸ oder NCOR7 ausgewählt sind, C3-C6-Alkenyl oder -Alkinyl, C1-C3-Perfluoralkyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl, C1-C4-Alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind, Pentafluorphenyl, Benzyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind, 2-, 3- oder 4-Pyridinyl, Pyrimidinyl oder Biphenyl ist,

R⁵

H. C1-C6-Alkyl oder Benzyl ist. R6

55

H, C1-C8-Alkyl, verzweigtes C3-C8-Alkyl, C3-C7-Cycloalkyl, C3-C8-Alkenyl oder -Alkinyl, Phenyl, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind, Pentafluorphenyl, Benzyl ist, das gegebenenfalls mit 1 bis 3 Gruppen substituiert ist, die aus C1-C4-Alkyl oder -Alkoxy, F, Br, Cl, NH2, OH, CN, CO2H, CF3, NO2, C1-C4-Carbalkoxy, NR7R8 oder NCOR7 ausgewählt sind.

B⁷ und B⁸ unabhängig aus H oder C₁-C₄-Alkyl ausgewählt sind.

X S(O), O, NR⁵, CH₂ ist.

A C₂-C₁₀-Alkyl, verzweigtes C₃-C₁₀-Alkyl, C₃-C₁₀-Alkenyl oder C₃-C₁₀-Alkinyl ist,

Y O, S, H₂ ist,

Z NHR⁴, OR⁴ oder R⁴ ist.

r 0-2 ist

5

15

30

40

45

50

55

und gegebenenfalls das Bilden eines pharmazeutisch annehmbaren Salzes derselben.

- 10. 12. Verfahren des Anspruchs 11, das weiter das Entfernen einer etwaigen Schutzgruppe an R3 umfaßt.
  - Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit Lawessons Reagenz oder Diphosphorpentasulfid unter Liefern einer Verbindung der Formel (I), worin Y S ist, umfalt.
  - Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin Y O ist, mit einem Reduktionsmittel, wie etwa Lithiumaluminiumhydrid oder Natriumborhydrid, unter Liefern einer Verbindung der Formel (I), worin Y H₂ ist, umfaßt.
- 15. Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin X S ist, mit einem geeigneten Oxidationsmittel unter Liefern entweder des Sulfoxids SO, wobei r 1 ist, oder des Sulfons SO₂, wobei r 2 ist, umfaßt.
  - 16. Verfahren des Anspruchs 11, das weiter das Umsetzen einer Verbindung der Formel (I), worin R³ H ist, if til einem geigneten Alkylerungsmittel wie erbar einem Alkylhalogenid unter Liefern einer Verbindung der Formel (I), worin R³ C₁-C₄-Alkyl, Allyl oder Benzyl ist, umfaßt.
    - 17. Verfahren zum Herstellen einer pharmazeutischen Zusammensetzung umfassend das Mischen einer therapeutisch wirksamen Menge einer gemäß einem der Ansprüche 1 bis 16 hergestellten Verbindung und eines pharmazeutisch annehmbaren Trägers.

### Revendications

Revendications pour les Etats contractants sulvants : AT, BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE

Un composé de formule:

Formule (I)

dans laquelle:

R1 et R2

sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_6$ , à condition que lorsque  $R^1$  est un atome d'hydrogène, alors  $R^2$  ne peut être un atome d'hydrogène et que lorsque  $R^1$  est un radical alkyle en  $C_1$  à  $C_6$ , alors  $R^2$  ne peut pas être un radical alkyle en  $C_1$  à  $C_6$ , un radical alkyle en  $C_2$  à  $C_6$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkyle en  $C_7$  à  $C_7$  cycloalkyle en  $C_7$  cycloalkyle en

ment substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en C₁ à C₄, alkyle en C₁ à C₄, alkyle ramifié en C₃ à C₅, CH₅X(O₅, NO₇, CF₅ ou NP7Ps': ou NP7Ps' co

R1 et R2 peuvent former ensemble un groupe:

dans lequel:

5

10

15

20

25

30

35

40

45

50

R⁴

R6

L est O, O(CH₂)_{m+1}O, ou (CH₂)_m, m étant un nombre de 0 à 4; B³ est un atome d'hydropène, un radical alkyle en C₁ à C₅.

est un atome d'hydrogène, un radical alkyle en C₁ à C₅, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH₃, CH₃O ou

CF₃:

est un radical alkyle linéaire en C₁ à C₆ éventuellement substitué par un atome de fluor; un radical alkyle ramifié en C₂ à C₁₀, cycloalkyle en C₂ à C₇, cycloalkyle en C₂ à C₁₀, cycloalkyle en C₂ à C₂, cycloalkyle en C₂ à C₃, perfluoroalkyle en C₁ à C₄, plas diveryle en C₂ à C₅, perfluoroalkyle en C₁ à C₄, plas diveryle en C₂ à C₅, perfluoroalkyle en C₁ à C₄, plas diverse de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₃, NO₂, les radicaux carboalcoxy en C₁ à C₄, NR² R⁶ ou NCOR²; les radicaux pertadicaux pertadicaux pertadicaux pertadicaux carboalcoxy en C₁ à C₄, les altometer de l'unit come de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₃, NO₂, carboalcoxy en C₁ à C₄, NR² R⁶ ou NCOR²; les radicaux ax de cypridicityle, cypridicityle ou bliphényle;

R⁵ est un atome d'hydrogène ou un radical alkyle en C₁ à C₅ ou benzyle;

est un atome d'hydrogène, un radical alikyle en C, à Ca, alkyle ramifié en C3 à Ca, cycloalkyle en C3 à C5, alkynyle ou alkéfnyle en C3 à C5, phényle éventuellement substituté par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C, à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO3H, CF3, NO3, carboal-coxy en C1 à C4, NR' R° ou NCOR'; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en C7 à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO2H, CF3, NO3, carboalcoxy en C3 à C4, NR' R° ou NCOR';

R⁷ et R⁸ sont choisis, indépendamment l'un de l'autre, parmi l'atome d'hydrogène ou les radicaux alkyles en C₁ à C₄;

X est S(O)_r, O, NR⁵, CH₂; A est un radical alkyle en

est un radical alkyle en C₂ à C₁₀, alkyle ramifié en C₃ à C₁₀, alkényle en C₃ à C₁₀, ou alkynyle en C₃ à C₁₀;

Y est O, S ou H₂;

Z est NHR⁴, OR⁴ ou R⁴; r est un nombre de 0 à 2,

55 ou un sel pharmaceutiquement acceptable en dérivant.

2. Un composé selon la revendication 1, dans lequel:

R¹ et R2 sont choisis, indépendamment l'un de l'autre, parmi les radicaux alkyles en C₁ à C₃, à

condition que lorsque R¹ est un radical allyle en  $C_1$  à  $C_6$ , R² en puisse pas être un radical alkyle en  $C_1$  à  $C_6$ , un radical alkyle ramifié en  $C_3$  à  $C_6$ , cycloalkyle en  $C_6$  à  $C_{11}$ ,  $C_6$  and  $C_7$  à  $C_{11}$ ,  $C_7$  and  $C_8$  a

R1 et R2 peuvent former ensemble un groupe:

5

10

15

20

25

30

35

40

45

50

55


dans lequel:

est O, O(CH₂)_{m+1}O, ou (CH₂)_m, m étant un nombre de 0 à 4.

3. Un composé selon la revendication 2, dans leguel:

R³ est un atome d'hydrogène, un groupe CH₃, ou un groupe phényle; R⁶ est un atome d'hydrogène, un radical alkyle en C₁ à C₂, alk

- est un atome d'hydrogène, un radical alkyle en C, à C_a, alkyle ramifié en C, à C_a, cycloalkyle en C_a à C₇, phényle éventuellement substitué par 1 à 3 groupes choisis parmi CH₃, CH₅O, F, Br, CI, NH₂, OH, CN, CO₂H, CF₃ ou dialkyl-(C) à C₃-amino; ou benzyle éventuellement substitué par 1 à 3 groupes choisis parmi CH₃, CH₃O, F, Br, CI, NH₂, OH, CN, CO₂H, CF₃ ou dialkyl-(C) à C₃-amino;
- X est S(O), CH₂:
- A est un radical alkyle en C2-C10, ou alkyle ramifié en C4- C9.
- Un composé selon la revendication 3, dans lequel:
  - R¹ et R² sont choists, indépendamment l'un de l'autre, parmi les radicaux alkyle en C₁ à C₂, alkyle ramifié en C₃ à C₃, cycloalkyle en C₂ à C₃, cycloalkylalkyle en C₂ à C₁, aralkyle en C₂ à C₁, z², 3 ou 4-pyridinyle, 2-thiényle ou phényle éventuellement substitué par 1 ou 2 groupes choisis parmi F, Br, Cl, alkyle en C₁ à C₄, alkyle ramifié en C₂ à C₃, CH₃Q, CH₃S(Q), NQ₂, CF₃ qu'diakly-H(c₁ à C₂)-hamipo; ou
  - R1 et R2 peuvent former ensemble un groupe:



dans lequel:

### EP 0 372 445 B1

est 0 ou OCH2O;

 $R^3$ est un atome d'hydrogène:

R⁴ est un radical alkyle en C1 à C8, alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7, cycloalkylalkyle en C4 à C10, aralkyle en C7 à C14, phényle substitué par 1 à 3 groupes choisis parmi CH3, F, Cl, CH3O, CN, ou benzyle éventuellement substitué par

1 à 3 groupes choisis parmi CH3, CH3O, F, CI ou CN; R6 est un radical alkyle en C1 à C8 ou phényle éventuellement substitué par 1 à 3 groupes choisis parmi CH3, CH3O, F, CI ou CN;

Α est un radical alkyle en C₄ à C₉;

х est S(O),:

5

10

15

25

30

35

45

50

55

Υ est O, H2.

- 5. Composé selon les revendications 1 à 4, choisi parmi ceux appartenant à la liste comprenant:
  - N'-(2,4-difluorophényl)-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;
  - N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]-N-heptylurée;
  - N-butyl-N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]urée;
  - N'-(2.4-diméthoxyphényl)-N-[5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;
  - N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-méthylurée;
- N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurée; 20 N-[5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophényl)-N-heptylurée:
  - N'-(2,4-difluorophényl)-N-[5-[(4,5-diphényl-1H-imidazol-2-yl)sulfonyl]pentyl]-N-heptylurée;

  - N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-méthyléthyl)urée;
  - N-I5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-2.4-difluoro-N-heptylbenzèneacétamide;
  - N'-cyclohexyl-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée;
  - N'-(2,4-difluorophényl)-N-[5-([4,5-diphényl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurée;
  - N-[5-(4.5-diphényl-1H-imidazol-2-vlthio)pentyl]-N-heptylbutanamide:
  - N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-vlthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée; N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacétamide;
  - N-[5-[4,5-bis(2-méthoxyphényl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;
  - Phényl-[5-(4.5-diphényl-1H-imidazol-2-vlthio)pentyl heptylcarbamate:
    - N-[5-[4,5-bis[4-(diméthylamino)phényl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-Nheptylurée:
    - N-[5-(4.5-diphényl-1H-imidazol-2-vlthio)pentyl]-N'-octyl-N-phénylurée;
    - N-[5-[4,5-bis(4-méthoxyphényl)-1H-imidazol-2-ylthio]pentyl]-2,4-difluoro-N-
  - heptylbenzèneacétamide:
    - Phényl-[5-[(4.5-bis-(4-diméthylamino)phényl)-1H-imidazol-2-vlthio]pentyl]-heptylcarbamate: et
    - N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophényl)-N-heptylurée.
- 6. Une composition pharmaceutique comprenant une quantité efficace du point de vue thérapeutique d'un composé selon une des revendications 1 à 5 ainsi qu'un support pharmaceutiquement acceptable. an
  - Un procédé de préparation d'un composé de formule (I):

dans laquelle:

R1 et R2 sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en C1 à C8, à condition que lorsque R1 est un atome

### EP 0 372 445 B1

d'hydrogène, alors  $\mathbb{R}^2$  ne pout être un atome d'hydrogène et que lorsque  $\mathbb{R}^1$  est un radical alkyle en  $\mathbb{C}_1$  à  $\mathbb{C}_4$  alors  $\mathbb{R}^2$  ne pout pas être un radical alkyle en  $\mathbb{C}_1$  à  $\mathbb{C}_4$  nu radical alkyle en  $\mathbb{C}_3$  à  $\mathbb{C}_6$ , cycloalkyle en  $\mathbb{C}_4$  à  $\mathbb{C}_{10}$ , aralkyle en  $\mathbb{C}_7$  à  $\mathbb{C}_{11}$ ,  $\mathbb{Z}^2$ .  $\mathbb{C}_{10}$  ou 4-pyridinyle,  $\mathbb{Z}^2$ -turanyle, phényle éventuellement substitué par  $\mathbb{I}_4$  à  $\mathbb{C}_{10}$  groupes sélectionnés parmi: atomes de fluor, chiore, brome, un groupe OH, un radical alcoxy en  $\mathbb{C}_1$  à  $\mathbb{C}_4$ , alkyle en  $\mathbb{C}_1$  à  $\mathbb{C}_4$ , alkyle ramifié en  $\mathbb{C}_2$  à  $\mathbb{C}_8$ ,  $\mathbb{C}_1$ +Si $\mathbb{C}_1$ 0, $\mathbb{N}_2$ 0, $\mathbb{C}_7$ 5 ou  $\mathbb{N}_7$ 7 $\mathbb{R}^2$ 5 ou

R1 et R2 peuvent former ensemble un groupe:

5

10

15

20

30

35

40

45

55

R⁴

R5

R

dans lequel:

25 L est O, O(CH₂)_{m+1}O, ou (CH₂)_m, m étant un nombre de 0 à 4;

R³ est un atome d'hydrogène, un radical alkyle en C₁ à C₅, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH₃, CH₃O ou CE₂.

est un radical alkyle inifiaire en  $C_1$  à  $C_6$  éventuellement substitué par un atome de fluor; un radical alkyle ramifié en  $C_3$  à  $C_6$ , cycloalkyle en  $C_3$  à  $C_7$ , cycloalkyle (en  $C_7$ ) à  $C_{14}$ , dans lequel le radical aryle est éventuellement substitué par un à trois groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_1$ , les atomes de fluor, brome, chlore, les groupes NH $_2$ , OH,  $C_1$ ,  $C_2$ ,  $C_1$ ,  $C_2$ ,  $C_1$ ,  $C_2$ ,  $C_1$ ,  $C_2$ ,  $C_2$ ,  $C_3$ ,  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_3$ ,  $C_3$ ,  $C_4$ ,  $C_3$ ,  $C_4$ ,  $C_4$ ,  $C_5$ 

est un atome d'hydrogène ou un radical alkyle en C₁ à C₆ ou benzyle;

est un atome d'hydrogène, un radical alkyle en C₁ à C₈, alkyle ramifié en C₃ à C₈, cycloalkyle en C₃ à C, alkynyle ou alkényle en C₃ à C₈, phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C; à C, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₃, NO₂, carboalcoxy en C; à C₄, NR^{*}R ou NCOR*; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en C; à C₄, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₃, NO₂.

50 carboalcoxy en C₁ à C₄, NR⁷R⁸ ou NCOR⁷;

 $R^7$  et  $R^8$   $\,$  sont choisis, indépendamment l'un de l'autre, parmi l'atome d'hydrogène ou les radicaux alkyles en  $C_1$  à  $C_4$  ;

X est S(O)_n, O, NR⁵, CH₂;
 A est un radical alkyle en C₂ à C₁₀, alkyle ramifié en C₃ à C₁₀, alkényle en C₃ à C₁₀, ou

alkynyle en  $C_3$  à  $C_{10}$ ; Y est O, S ou  $H_2$ ;

Z est NHR⁴, OR⁴ ou R⁴; r est un nombre de 0 à 2. ou un sel pharmaceutiquement acceptable en dérivant; comprenant les étapes de:

réaction d'un composé de formule:

dans laquelle:

R1, R2, X, A et R6 sont tels que définis ci-dessus; et

R³ est également tel que défini ci-dessus, ou est un groupe protecteur convenable tel qu'un groupe silyle ou trilyle,

avec:

5

10

15

20

25

30

35

an

45

50

i) un isocyanate de formule:

dans laquelle R⁴ est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est NHR⁴; ou ii) un isothicovante de formule:

dans laquelle R⁴ est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y est S et Z est NHR⁴; ou

iii) un chloroformiate de formule:

$$R^{4}$$
-O-C  $C_{C1}$ 

dans laquelle R⁴ est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est OR⁴; ou

iv) un chlorure d'acide de formule:



ou un autre acide carboxylique activé, dans laquelle R* est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est R*.

- Un procédé selon la revendication 7, comprenant en outre l'élimination de tout groupe protecteur sur R³ pour conduire à un composé de formule (I) dans laquelle R³ est H.
- Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un réactif de Lawesson ou un pentasulfure diphosphoreux, pour conduire à un composé de formule (I) dans laquelle Y est S.

- 10. Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un agent réducteur tel que l'hydrure d'aluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y est H₂.
- 11. Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans laquelle X est S, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans lequel r est égal à 1, soit la sulfone SO2, dans lequel r est égal à 2.
- 12. Un procédé selon la revendication 7, comprenant en outre la réaction d'un composé de formule (I) dans 10 laquelle R3 est un atome d'hydrogène, avec un agent d'alkylation convenable tel qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R3 est un radical alkyle en C₁ à C₆, allyle ou benzyle.
  - 13. Un procédé comprenant les étapes d'alkylation d'un composé de formule:

$$R^1$$
 $N$ 
 $R^2$ 
 $N$ 
 $R^3$ 

dans laquelle:

15

20

25

30

35

40

45

50

55

R1 et R2 sont choisis, indépendamment l'un de l'autre, le groupe comprenant un atome d'hydrogène, un radical alkyle en C1 à C8, à condition que lorsque R1 est un atome d'hydrogène, alors R2 ne peut être un atome d'hydrogène et que lorsque R1 est un radical alkyle en C1 à C8, alors R2 ne peut pas être un radical alkyle en C1 à C8, un radical alkyle ramifié en C₃ à C₈, cycloalkyle en C₃ à C₇, cycloalkylalkyle en C₄ à C₁₀, aralkyle en C7 à C14, 2-, 3- ou 4-pyridinyle, 2-thiényle, 2-furanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome. un groupe OH, un radical alcoxy en C1 à C4, alkyle en C1 à C4, alkyle ramifié en C3 à C₈, CH₃S(O)_r, NO₂, CF₃ ou NR⁷R⁸; ou

R1 et R2 peuvent former ensemble un groupe:

dans lequel:

ī. est O, O(CH2)m+1O, ou (CH2)m, m étant un nombre de 0 à 4;  $\mathbb{R}^3$ 

est un atome d'hydrogène, un radical alkyle en C1 à C6, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH₂, CH₂O ou CF₃; ou un groupe protecteur convenable tel qu'un groupe silvle ou trilvle; et est O ou S,

avec un composé de formule:

dans laquelle:

5

10

15

20

25

30

35

40

45

50

55

M est un halogénure ou un tosylate;

A est un radical alkyle en  $C_2$  à  $C_{10}$ , alkyle ramifié en  $C_3$  à  $C_{10}$ , alkényle en  $C_3$  à  $C_{10}$ , ou

alkynyle en C₃ à C₁₀;

fe est un atome d'hydrogène, un radical alkyle en C₁ à C₈, alkyle ramifié en C₃ à C₈,
cycloalkyle en C₂ à C₇, alkynyle ou alkényle en C₃ à C₈, phányle éventuellement substitué
par 1 à 3 groupes choisis parmi alcoxy ou alkyle en C₁ à C₄, les atomes de fluor, brome,
chlore, les groupes NH₂, OH, CN, CO₂H, CF₃, NO₂, carboalcoxy en C₁ à C₄, NR' R⁶ ou
NCOR'; pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi
alcoxy ou alkyle en C₁ à C₄, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN,
CO₂H, CF₃, NO₂, carboalcoxy en C₄ à C₄, NR' R⁶ ou NCOR';

Y est O, S ou H₂; et

Z est NHR⁴, OR⁴ ou R⁴, pour conduire à un composé de formule (I):

dans laquelle:

oans aqueuie:

R' et R² sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en C₁ à C₅, alkyle ramifé en C₅ à C₅, cycloalkylelyle en C₅ à C₇, cycloalkylelyle en C₆ à C₁₀, aralkyle en C₇ à C₁₁, 2-2, 3- ou 4-pyridinyle, 2-thiényle, 2-turanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, groupe OH, radical alcoxy en C₁ à C₄, alkyle en C₅ à C₄, alkyle mifé en C₅ à C₅, cHs/C0, No₇, C₇-5 ou NF? R²- ou

R1 et R2 peuvent former ensemble un groupe:

dans lequel:

### EP 0 372 445 B1

- est O, O(CH2)m+1O, ou (CH2)m, m étant un nombre de 0 à 4;  $R^3$ est un atome d'hydrogène, un radical alkyle en C1 à C6, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH3, CH3O ou R4 est un radical alkyle linéaire en C1 à C8 éventuellement substitué par un atome de fluor; un radical alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7, cycloalkylalkyle en C4 à C10, aralkyle en C7 à C14, dans lequel le radical aryle est éventuellement substitué par un à trois groupes choisis parmi les radicaux alcoxy ou alkyle en C1 à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO2H, CF3, NO2, carboalcoxy en C1 à C4, NR7R8 ou NCOR7; les radicaux alkynyle ou alkényle en C3 à C6, perfluoroalkyle en C1 à C3, phényle éventuellement substitué par un groupe choisi parmi les radicaux alcoxy ou alkyle en C1 à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO2H, CF3, NO2, les radicaux carboalcoxy en C1 à C4, NR7R8 ou NCOR7; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C1 à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO2H, CF3, NO2, carboalcoxy en C1 à C4, NR7R8 ou NCOR7; les radicaux 2-, 3- ou 4-pyridinyle, pyrimidinyle ou biphényle; R5 est un atome d'hydrogène ou un radical alkyle en C1 à C6 ou benzyle; B6 est un atome d'hydrogène, un radical alkyle en C1 à C8, alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7, alkynyle ou alkényle en C3 à C8, phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C1 à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO2H, CF3, NO2, carboalcoxy en C1 à C4. NR7R8 ou NCOR7; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en C1 à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO2H, CF3, NO2, carboalcoxy en C1 à C4, NR7R8 ou NCOR7;
  - R⁷ et R⁸ sont, indépendamment l'un de l'autre, choisis parmi l'atome d'hydrogène ou les radicaux alkyles en C₁ à C₄;
  - X est S(O)_r, O, NR⁵, CH₂;

5

10

15

20

25

55

- 30 A est un radical alkyle en C₂ à C₁₀, alkyle ramifié en C₃ à C₁₀, alkényle en C₃ à C₁₀, ou alkynyle en C₃ à C₁₀;
  - Y est O, S ou H₂;
  - Z est NHR⁴, OR⁴ ou R⁴;
  - r est un nombre de 0 à 2.
- 35 et formant éventuellement un sel pharmaceutiquement acceptable en dérivant.
  - Un procédé selon la revendication 13, comprenant en outre l'élimination de tout groupe protecteur sur R³.
- 40 15. Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un réactif de Lawesson ou un pentasulfure diphosphoreux, pour conduire à un composé de formule (I) dans laquelle Y est S.
- 16. Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un agent réducteur tel que l'hydrure d'aluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y est H₂.
- 17. Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle X est S, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans lequel r est égal à 1, soit la sulfone SO₂, dans laquelle r est égal à 2.
  - 18. Un procédé selon la revendication 13, comprenant en outre la réaction d'un composé de formule (I) dans laquelle R³ est un atome d'hydrogène, avec un agent d'alkylation convenable tel qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R³ est un radical alkyle en C: à C. allvle ou benzyle.

### Revendications pour l'Etat contractant suivant : ES

### Un procédé de préparation d'un composé de formule (I):

R₂ N X-A-N-R

dans laquelle: R1 et R2

5

10

15

20

25

30

35

40

45

50

56

**P**3

R⁴

sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en C₁ à C₈, à condition que lorsque R¹ est un atome d'hydrogène, alors R² ne peut être un atome d'hydrogène et que lorsque R¹ est un radical alkyle en C₁ à C₈, alors R² ne peut pas être un radical alkyle en C₁ à C₈, un radical alkyle ramifié en C₈ à C₈, cycloalkyle en C₈ à C₇, cycloalkylalkyle en C₈ à C₁₀, aralkyle en C₉ à C₁₀, cycloalkyle en C₈ à C₁₀, aralkyle cycloalkyle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en C₁ à C₈, alkyle on C₁ à C₈, alkyle ramifié en C₈ à C₈, Chs(O), NO₂, CF₉ ou NR² R³; ou

R1 et R2 peuvent former ensemble un groupe:

dans lequel:

est O, O(CH2)m+1O, ou (CH2)m, m étant un nombre de 0 à 4;

est un atome d'hydrogène, un radical alkyle en C₁ à C₆, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH₂, CH₂O ou CF₈;

est un radical alkyle linifaire on C; à C_e éventuellement substitué par un atome de fluor, un radical alkyle ramifie en C; à C; cyclasklye en C; à C; else atomes de fluor, brome, chlore, les groupes NH;. OH, CN, CO;H, CFs, NO;, carboalcoxy en C; à CA, NRT'R' ou NCOR'; les radicaux alkynyle ou alkényle en C; à C, perfluorablyle en C; à Cs, pérfluorablyle en C; à Cs, les atomes de fluor, brome, chlore, les groupes NH;, OH, CN, CO;H, CFs, NO;, les radicaux alkynyle ou chlore, les groupes NH; oh, CN, CO;H, CS, NO; les radicaux carboalcoxy en C; à Cs, NRT'R' ou NCOR'; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à Groupes Chies par lies radicaux alcoyo vu alkyle en C; à Cs, les atomes de fluor,

brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₃, NO₂, carboalcoxy en  $C_1$  à  $C_4$ , NR⁷R⁸ ou NCOR⁷; les radicaux 2-, 3- ou 4-pyridinyle, pyrimidinyle ou biphényle;

R⁵ est un atome d'hydrogène ou un radical alkyle en C₁ à C₆ ou benzyle:

R⁶ est un atome d'hydrogène, un radical allyle en C, à C_a, allyle 'ramifié en C, à C_a, cycloallyle en C_a à C₇, allynyle ou allényle en C, à C, phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux atoxy ou alkyle en C, à C, les atomes de fluor, brome, chlore, les groupes NH₅, DH, CN, CO₂H, CF₅, NO₂, carboal-coxy en C, à C, nPf² en un COff; les radicaux pentallurorphényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi les radicaux atoxy ou alkyle en C, à Ca, les atomes de fluor, brome, chlore, les roupes NH₅, OH, CN, CO₂H, CF

NO₂, carboalcoxy en C₁ à C₄, NR⁷R⁸ ou NCOR⁷;

R⁷ et R⁸ sont choisis, indépendamment l'un de l'autre, parmi l'atome d'hydrogène ou les radicaux alkyles en C₁ à C₄:

X est S(O)_r, O, NR⁵, CH₂;


75 A est un radical alkyle en C₂ à C₁₀, alkyle ramifié en C₃ à C₁₀, alkényle en C₃ à C₁₀, ou alkynyle en C₃ à C₁₀:

Y est O, S ou H₂;

Z est NHR⁴, OR⁴ ou R⁴; r est un nombre de 0 à 2.

20 ou un sel pharmaceutiquement acceptable en dérivant; comprenant les étapes de:

- réaction d'un composé de formule:



30 dans laquelle:

avec

25

40

45

50

55

R1, R2, X, A et R6 sont tels que définis ci-dessus; et

R3 est également tel que défini ci-dessus, ou est un groupe protecteur convenable tel qu'un groupe silvle ou trilvle.

35 i) un isocyanate de formule:

 $B^4-N=C=O$ 

dans laquelle R⁴ est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y représente O et Z est NHR⁴; ou

ii) un isothiocyanate de formule:

R4-N=C=S

dans laquelle R⁴ est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (I) décrite ci-dessus, dans laquelle Y est S et Z est NHR⁴; ou

iii) un chloroformiate de formule:

$$R^4$$
-0-C  $C_1$ 

dans laquelle R⁴ est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (l) décrite ci-dessus, dans laquelle Y représente O et Z est OR⁴; ou iv) un chlorure d'acide de formule:

5

10

15

20

25

30

35

45

55




ou un autre acide carboxylique activé, dans laquelle R¹ est tel que défini ci-dessus, pour conduire à un composé représenté par la formule (f) décrite ci-dessus, dans laquelle Y représente O et Z est R⁴.

### 2. Un procédé selon la revendication 1, dans lequel:

R¹ et R² sont choisis, indépendamment l'un de l'autre, parmi les radicaux alkyles en C, à C₃, à condition que lorsque R¹ est un radical alkyle en C, à C₆, R² ne puisse pas être un radical alkyle en C₁ à C₆, cycloalkyle en C₇ à C₉, cycloalkyle en C₈ à C₁, cycloalkyle en C₈ à C₁, azalkyle en C₇ à C₁₄, 2., 3 ou 4-pyridinyle, 2-thényle, 2-turanyle, phényle éventuellement substitué par 1 ou 2 groupes choisis parmi F, Cl. Br, OH, alcoxy en C; à C₄, alkyle en C; à C₄, alkyle ramifié en C₃ à C₈, CH₃S(O), NO₂, CF₅ ou NR⁷(R³) ou encore

R1 et R2 peuvent former ensemble un groupe:



dans lequel:

L est O, O(CH₂)_{m+1}O, ou (CH₂)_m, m étant un nombre de 0 à 4.

## 40 3. Un procédé selon la revendication 2, dans lequel:

R3 est un atome d'hydrogène, un groupe CH3, ou un groupe phényle;

R⁶ est un atome d'hydrogène, un radical alkyle en C, à Ca, alkyle ramifié en C, à Ca, cycloalkyle en Ca à Cr, phényle éventuellement substitué par 1 à 3 groupes choisis parmi CH₃, CH₃O, F, Br, CI, NH₂, OH, CN, CO₂H, CF₃ ou dialkyl-(C, à C₃)-amino; ou benzyle éventuellement substitué par 1 à 3 groupes choisis parmi CH₃, CH₃O, F, Br, CI, NH₂, OH, CN, CO₃H, CF₃ ou dialkyl-(C; à C₃)-amino;

X est S(O)_r, CH₂;

A est un radical alkyle en C₂-C₁₀, ou alkyle ramifié en C₄- C₉.

# 50 4. Un procédé selon la revendication 3, dans lequel:

R¹ et R² sont choisis, indépendamment l'un de l'autre, parmi les radicaux alkyle en C₁ à C₂, alkyle ramifié en C₂ à C₂, cycloakyle, en C₂ à C₂, cycloakyle en C₂ à C₂, cycloakyle, en C₂, cycloak

R¹ et R² peuvent former ensemble un groupe:

dans lequel: 15

5

10

25

30

35

40

45

50

55

est 0 ou OCH2O:

**R**3 est un atome d'hydrogène;

R⁴ est un radical alkyle en C1 à C8, alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7,

cycloalkylalkyle en C4 à C10, aralkyle en C7 à C14, phényle substitué par 1 à 3 groupes 20 choisis parmi CHa, F, CI, CHaO, CN, ou benzyle éventuellement substitué par 1 à 3

groupes choisis parmi CH3, CH3O, F, CI ou CN;

R6 est un radical alkyle en C1 à C8 ou phényle éventuellement substitué par 1 à 3 groupes

choisis parmi CH3, CH3O, F, CI ou CN;

Α est un radical alkyle en C4 à C9;

х est S(O).: est O. H₂.

Un procédé selon les revendications 1 à 4, dans lequel les composés sont choisis parmi ceux appartenant à la liste comprenant:

N'-(2.4-difluorophényl)-N-[5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl)-N-heptylurée;

N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]-N-heptylurée;

N-butyl-N'-(2,4-difluorophényl)-N-[8-(4,5-diphényl-1H-imidazol-2-ylthio)octyl]urée;

N'-(2.4-diméthoxyphényl)-N-[5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée:

N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-méthylurée;

N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-propylurée;

N-[5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl]-N'-(3-fluorophényl)-N-heptylurée:

N'-(2,4-difluorophényl)-N-[5-[(4,5-diphényl-1H-imidazol-2-yl)sulfonyl)pentyl]-N-heptylurée; N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptyl-N'-(1-méthyléthyl)urée;

N-[5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-2.4-difluoro-N-heptylbenzèneacétamide:

N'-cyclohexyl-N-[5-(4.5-diphényl-1H-imidazol-2-vlthio)pentyl]-N-heptylurée:

N'-(2,4-difluorophényl)-N-[5-([4,5-diphényl-1H-imidazol-2-yl)sulfinyl]pentyl]-N-heptylurée; N-[5-(4.5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylbutanamide:

N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;

N-[5-[4,5-bis(1-méthyléthyl)-1H-imidazol-2-ylthio]pentyl]-N-heptylcyclohexaneacétamide; N-[5-[4,5-bis(2-méthoxyphényl)-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-heptylurée;

Phényl-[5-(4,5-diphényl-1H-imidazol-2-vlthio)pentyl]heptylcarbamate:

N-[5-[4.5-bis[4-(diméthylamino)phényl]-1H-imidazol-2-ylthio]pentyl]-N'-(2,4-difluorophényl)-N-

heptylurée:

N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N'-octyl-N-phénylurée;

N-[5-[4.5-bis(4-méthoxyphényl)-1H-imidazol-2-vlthio]pentyl]-2.4-difluoro-Nheptylbenzèneacétamide:

Phényl-[5-[(4.5-bis-(4-diméthylamino)phényl)-1H-imidazol-2-ylthio]pentyl]-heptylcarbamate:

N-[5-(4,5-dicyclohexyl-1H-imidazol-2-ylthio)pentyl]-N'-(2,4-difluorophényl)-N-heptylurée.

Un procédé selon la revendication 1, comprenant en outre l'élimination de tout groupe protecteur sur R3 pour conduire à un composé de formule (I) dans laquelle R3 est H.

- 7. Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est 0, avec un réactif de Lawesson ou un pentasulfure diphosphoreux, pour conduire à un composé de formule (II dans laquelle Y est S.
- Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est 0, avec un agent réducteur tet que l'hydrure d'aluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y set It-b.
- 9. Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans la laquelle X est 5, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans lequel r est égal à 1, soit la sultone SO₂, dans laquelle r est égal à 1.
  - 10. Un procédé selon la revendication 1, comprenant en outre la réaction d'un composé de formule (I) dans laquelle R³ est un atome d'hydrogène, avec un agent d'alkylation convenable tel qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R³ est un radical alkyle en C; à C; allyle ou benzyle.
  - 11. Un procédé comprenant les étapes d'alkylation d'un composé de formule:

dans laquelle:

15

20

25

30

35

an

45

50

55

R¹ et R² sont choisis, indépendamment l'un de l'asure, le groupe comprenant un atome d'hydrogène, un radical alkyle en C₁ à C₆, à condition que lorsque R¹ est un atome d'hydrogène, alors R² ne peut êire un atome d'hydrogène et que lorsque R¹ est un radical alkyle en C₁ à C₆, alors R² ne peut pas être un radical alkyle en C₁ à C₆, un radical alkyle ramifé en C₆ à C₆, cycloalkyle en C₇ à C₇ cycloalkylalkyle en C₇ à C₈, alors R² ne peut pas aralkyle en C₇ à C₁₄, 2, 3- ou 4-pyridinyle, 2-thiényle, 2-thuranyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, un groupe OH, un radical alcoxy en C₁ à C₄, alkyle en C₁ à C₄, alkyle ramifié en C₅ à C₈, CHSS(O). NO₂, CE₈ ou NR² R²; ou

R1 et R2 peuvent former ensemble un groupe:

dans lequel:

L est O, O(CH₂)_{m+1}O, ou (CH₂)_m, m étant un nombre de 0 à 4;

### EP 0 372 445 B1

R³ est un atome d'hydrogène, un radical alkyle en C1 à C6, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH3, CH3O ou CF₃; ou un groupe protecteur convenable tel qu'un groupe silvle ou trilvle; et х

est O ou S.

avec un composé de formule:

5

10

15

20

25

30

35

40

45

50

55

dans laquelle:

М est un halogénure ou un tosylate;

est un radical alkyle en C2 à C10, alkyle ramifié en C3 à C10, alkényle en C3 à C10, ou alkynyle en C3 à C10;

R6 est un atome d'hydrogène, un radical alkyle en C1 à C8, alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7, alkynyle ou alkényle en C3 à C8, phényle éventuellement substitué par 1 à 3 groupes choisis parmi alcoxy ou alkyle en C1 à C4, les atomes de fluor, brome, chlore, les groupes NH2, OH, CN, CO2H, CF3, NO2, carboalcoxy en C1 à C4, NR7R8 ou NCOR7; pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisi parmi alcoxy ou alkyle en C₁ à C₄, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO2H, CF3, NO2, carboalcoxy en C1 à C4, NR7R8 ou NCOR7;

est O, S ou H2; et

est NHR4, OR4 ou R4,

pour conduire à un composé de formule (I):

dans laquelle:

R1 et R2 sont choisis, indépendamment l'un de l'autre, dans le groupe comprenant un atome d'hydrogène, un radical alkyle en C₁ à C8, alkyle ramifié en C3 à C8, cycloalkyle en C3 à C7, cycloalkylalkyle en C4 à C10, aralkyle en C7 à C14, 2-, 3- ou 4-pyridinyle, 2thiényle, 2-furanyle, phényle éventuellement substitué par 1 à 3 groupes sélectionnés parmi: atomes de fluor, chlore, brome, groupe OH, radical alcoxy en C1 à C4, alkyle en C₁ à C₄, alkyle ramifié en C₃ à C₈, CH₃S(O), NO₂, CF₃ ou NR⁷R⁸; ou

R1 et R2 peuvent former ensemble un groupe:

15 dans lequel:

R⁴

R⁵

R6

х

5

10

20

25

30

35

40

45

50

est O, O(CH2)m+1O, ou (CH2)m, m étant un nombre de 0 à 4;

R³ est un atome d'hydrogène, un radical alkyle en C₁ à C₅, allyle, benzyle ou phényle éventuellement substitué par un atome de fluor, de chlore, un groupe CH₃, CH₃O ou

eventuellement substitue par un atome de fluor, de chlore, un groupe CH₃, CH₃O ou CF₃;

est un radical alkyle linéaire en C₁ à C₈ éventuellement substitué par un atome de fluor; un radical alkyle ramifie en C₈ à C₈, cycloalkyle en C₂ à C₇, cycloalkylalkyle en C₇ à C₁₀, cycloalkylalkyle en C₇ à C₁₄, dans lequel le radical aryle est éventuellement substitué par un à trois groupes choisis parmi les radicaux alcoxy ou alkyle en C₁ à C₁, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₈, NO₂, carboalcoxy en C₁ à C₄, NR² R³ ou NCOR²; les radicaux alkynyle ou alkényle en C₃ à C₅, perfluyor éventuellement substitué par un groupe choisi parmi les radicaux alcoxy ou alkyle en C₁ à C₄, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₈, NO₂, les radicaux carboalcoxy en C. à C₄, NR² R³ ou NCOR²; les radicaux pentafluorophényle, benzyle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en C₁ à C₄, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₈, NO₂, earboalcoxy en C; à C₄, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₈, NO₂, carboalcoxy en C; à C₄.

NR⁷ R⁸ ou NCOR⁷; les radicaux 2-, 3- ou 4-pyridinyle, pyrimidinyle ou biphényle; est un atome d'hydrogène ou un radical alkyle en C₁ à C₆ ou benzyle

est un atome d'hydrogène, un radical alkyle en  $C_1$  à  $C_4$ , alkyle ramilié en  $C_2$  à  $C_5$ , phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_3$  à  $C_6$ , phényle éventuellement substitué par 1 à 3 groupes choisis parmi les radicaux alcoxy ou alkyle en  $C_1$  à  $C_4$ , les atomes de fluor, brome, chlore, les groupes NH $_2$ ,  $C_1$ ,  $C_1$ ,  $C_2$ ,  $C_3$ ,  $C_4$ ,  $C_4$ ,  $C_5$ ,  $C_6$ , C

tuellement substituté par 1 à 3 groupes choisi parmi les radicaux alcoxy ou alkyle en C₁ à C₄, les atomes de fluor, brome, chlore, les groupes NH₂, OH, CN, CO₂H, CF₃, NO₂, carboalcoxy en C₁ à C₄, NR⁷R³ ou NCOR⁷;

R⁷ et R⁸ sont, indépendamment l'un de l'autre, choisis parmi l'atome d'hydrogène ou les radicaux alkyles en C₁ à C₄;

est S(O), O, NR⁵, CH₂;

A est un radical alkyle en C₂ à C₁₀, alkyle ramifié en C₃ à C₁₀, alkényle en C₃ à C₁₀, ou alkynyle en C₃ à G₁₀:

Y est O, S ou H₂;

Z est NHR⁴, OR⁴ ou R⁴;

est un nombre de 0 à 2,

et formant éventuellement un sel pharmaceutiquement acceptable en dérivant.

12. procédé selon la revendication 11, comprenant en outre l'élimination de tout groupe protecteur sur R3.

13. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est O, avec un réactif de Lawesson ou un pentasulture diphosphoreux, pour conduire à un composé de formule (I) dans laquelle Y est S.

### EP 0 372 445 B1

- 14. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle Y est 0, avec un agent réducteur tel que l'hydrure d'alluminium lithium ou du borohydrure de sodium, pour conduire à un composé de formule (I) dans laquelle Y est H₂.
- 5 15. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle X est S, avec un agent d'oxydation convenable pour obtenir soit le sulfoxyde SO, dans leucuel r est égal à 1, soit la sulfons SO, dans laquelle r est égal à 1, soit la sulfons SO, dans laquelle r est égal à 1, soit la sulfons SO, dans laquelle r est égal à 1, soit la sulfons SO.
  - 16. Un procédé selon la revendication 11, comprenant en outre la réaction d'un composé de formule (I) dans laquelle R³ est un atome d'hydrogène, avec un agent d'alkylation convenable let qu'un halogénure d'alkyle, pour conduire à l'obtention d'un composé de formule (I) dans laquelle R³ est un radical alkyle en C; à C_s, allyle ou benzyle.

17. Un procédé de préparation d'une composition pharmaceutique consistant à mélanger une quantité efficace du point de vue thérapeutique d'un composé préparé selon l'une quelconque des revendications 1 à 16, et un support pharmaceutiquement acceptable.